Development of methods for detection and eradication of mouse parvovirus from a laboratory mouse colony by Filipovska-Naumovska, Emilija
 
 
Development of methods for detection 
and eradication of mouse parvovirus 
from a laboratory mouse colony 
 
 
 
 
 
Emilija Filipovska-Naumovska 
 
 
 
This thesis is presented for the degree of Doctor of 
Philosophy at Murdoch University 
 
2007 
 
 
  Declaration 
 
 
 
 
 
 
 
 
 
 
 
 
I declare that this is my own account of my research and contains work 
that has not been submitted for a degree at any tertiary institution 
 
 
 
 
 
 
 
………………………………. 
 
Emilija Filipovska-Naumovska 
 
 
 
 
 
 
   
Abstract 
 
The mouse parvovirus designated MPV can infect laboratory mice and affect the humoral 
and cellular immune response of infected mice, reducing their value for biomedical and 
medical research.  The development and maintenance of MPV-free mouse colonies for 
biomedical research is therefore essential and requires routine monitoring of the infection 
status of mice, using serological surveillance procedures.  
Recent experience in the Animal Resources Centre (ARC), a major supplier of mice to the 
medical research community in Australia, was that MPV infection was present but was 
not detectable with the serological tests that were then in routine use.   
This thesis reports the development of a polymerase chain reaction (PCR) assay for the 
detection of the MPV in the ARC mouse colonies, the genetic characteristics of the strain 
of MPV detected, the development of a recombinant virus protein that provided a suitable 
antigen for enzyme-linked immunosorbent assay (ELISA) and a Western immunoblot 
(WIB) assay for the detection of MPV antibodies, and use of these various assays to 
determine aspects of the epidemiology and pathogenicity of the infection that were critical 
to the eradication of virus infection and future immunological surveillance to ensure the 
absence of infection.   
The recombinant protein produced as an antigen was a biotinylated fusion protein, a 
truncated capsid protein of the strain of MPV detected in the ARC, and was produced 
using the Pinpoint
TM vector and with expression in Escherichia coli.  The protein was 
produced as an insoluble intracellular product within inclusion bodies and was solubilised 
using urea and purified. The purified protein was utilised as an antigen for ELISA and the 
WIB assays to detect virus antibody in infected mice.  
The outbreak of MPV infection in the ARC was used as an unique opportunity for 
assessment of the seroprevalence of MPV-1 infection in a large laboratory mouse colony 
and to utilise this data to determine the sampling size needed to reliably detect MPV-1 
infection within such large laboratory mouse colonies.  An overall seroprevalence of 
16.5% was detected using the developed serological tests, but considerable variation in 
prevalence was detected in different mouse strains. 
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The response to MPV infection of 4 different but common strains of mice was determined 
as a basis for developing appropriate surveillance procedures and the selection of 
appropriate sentinel animals. The effect of infection of these strains at different ages was 
also investigated. Virus replication was detected in tissues of all the mice strains infected 
(outbred ARC(s) and inbred C57BL/6JArc, BALB/c and BALB/c-Foxn1
nu/Arc) as 
juveniles and adults, with the exception of C57BL/6JArc inoculated as adults. However, 
while seroconversion in mice inoculated as juveniles and adults was detected in ARC(s) 
and C57BL/6JArc mice, it was not detected in BALB/c mice. The high rate of 
seroconversion to MPV, the early and prolonged development of an immune response, 
and the lack of age differences in their susceptibility indicated that ARC(s) mice would 
provide reliable sentinels for the detection of MPV.   
The genomic nucleotide sequence of the ARC strain, excluding the terminal palindromic 
regions and the predicted amino acid sequences of the non-structural and structural 
proteins was determined.  This strain was very similar (98-99% nucleotide identity) to the 
previously described MPV strains MPV-1a, MPV-1b and MPV -1c. The similarity 
suggested there were unlikely to be significant antigenic differences in the proteins of the 
ARC strain and those strains of MPV reported previously. 
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Chapter 1.  General introduction 
 
Mouse parvovirus type 1 (MPV-1) is a recently recognized rodent parvovirus but 
now one of the most common infectious agents found in laboratory mouse colonies. 
While it does not produce overt clinical disease in mice (Smith et al., 1993; Jacoby 
et al., 1996) it is able to alter cellular growth kinetics and the immunological 
response of infected mice (Mc Kisic et al., 1993) and has been demonstrated to 
interfere with research involving in vitro T-cell mediated responses such as the 
rejection of tumour and skin grafts (Mc Kisic et al., 1993 and 1996). 
The presence of MPV-1 in laboratory mice is of major concern as infections are 
generally asymptomatic and impossible to recognise clinically. The detection of 
antibody has been the primary diagnostic method and the enzyme-linked 
immunosorbent assay (ELISA) has been commonly used for the serological 
evaluations (Riley et al., 1996; Jacoby et al., 1996).  
The recognition in 2001, that the Animal Resources Centre (ARC), a major supplier 
of mice to the medical research community in Australia, had MPV-1 infection that 
was not detectable serologically by the then commercially available serological tests, 
an immunofluorescence assay (IFA) based on antigens of the antigenically cross-
reactive Minute virus of mice (MVM) parvovirus and ELISA based on recombinant 
non-structural proteins of MPV-1, created a dilemma.  It was not possible to monitor 
the success of any eradication program without suitable means of detection of the 
virus, and methods of routine immunosurveillance.   
The lack of cytopathogenicity of the virus in any known cell culture system required 
a molecular biological approach to the detection of the virus, and polymerase chain 
reaction (PCR) technology was chosen and a suitable PCR was developed and 
optimised (Chapter 3). This enabled the detection of virus in lymphoid tissues 
(spleen and lymph nodes) of infected mice and also in faeces.  Molecular biological 
approaches were used to produce a suitable MPV-1 specific capsid protein with 
which it was possible to develop specific and sensitive ELISA and Western 
immunoblotting (WIB) procedures. 
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It was deemed of critical importance that this infection be eradicated and as a 
consequence, it was necessary to firstly characterise the virus and then develop 
methods of detection based on the use of PCR technology and serological techniques 
for the detection of infection.  These techniques were required for future attempts by 
the ARC to eradicate the infection.  
As a background to the studies that were undertaken and reported in this thesis, the 
literature describing general characteristics of the parvovirus group and in particular 
the murine parvoviruses was reviewed.  This review is provided in Chapter 2. 
Studies undertaken to develop methods of detection of the Australian strain of MPV 
detected in the ARC are described in Chapter 3.  The techniques developed included 
a PCR-based assay for the detection of the virus, and an ELISA and WIB procedure 
for the detection of antibody. The serological procedures required the production and 
purification of a recombinant capsid protein of the Australian strain of MPV that was 
used as the antigen for both procedures.  
Chapter 4 reports a seroprevalence study of the virus in the ARC before the initiation 
of the eradication program. The information from this study was used to determine 
the sampling size needed for confident detection of virus in a large laboratory mouse 
colony.  During the course of these studies it was noted that there was considerable 
variation in seroprevalence depending on the mouse strain sampled, so an 
investigation was undertaken of virus infection in 4 common mouse strains in the 
ARC, with particular attention to the duration of virus infection and the antibody 
response.  The investigation and the results obtained are presented in Chapter 5 and 
utilised the techniques developed and described in Chapter 3.  This information on 
strain variation was invaluable in the interpretation of serological data during routine 
immunosurveillance.  
The genomic nucleotide sequence analysis and the predicted amino acid sequences 
of the MPV-1 strain detected in the ARC was determined and compared with strains 
of MPV-1 reported previously, and this is reported in Chapter 6. 
A general discussion of the results obtained and how they were successfully used 
during a program to eradicate MPV-1 from the ARC is presented in Chapter 7. 
2 
Chapter 2. Review of the literature  
 
As a background to the thesis, the literature describing general characteristics of the 
parvovirus group and in particular the murine parvoviruses with emphasis on 
existing methods of diagnosis and control of the murine parvoviruses was reviewed.   
 
2.1 General characteristics of parvoviruses 
Morphology and structure of parvoviruses 
In all, more than 50 parvoviruses have been identified and 41 of them have been 
recognised as individual species within the family Parvoviridae (Lukashov and 
Goudsmit, 2001).  They were only discovered in the 1960s and are among the 
smallest and structurally simplest of the DNA animal viruses (Kilham and Oliver, 
1959). They are unique among all known viruses in having a linear single-stranded 
DNA (ssDNA) genome of approximately 5,000 nucleotides in size, encapsidated 
within a non-enveloped simple icosahedral protein coat with a diameter of 18-26 nm 
(Pintel et al., 1983; Baldauf et al., 1997) as depicted in the electron micrograph 
shown in Figure 2.1.  The ratio of protein to DNA is about 1:1, and essential lipids, 
carbohydrates, RNA, cellular and virally coded enzymes have not been detected 
(Yang et al., 1995).  The protein coat is comprised of about 60 polypeptides, each 
with a quadrilateral “kite”-shape, giving the capsid the appearance of having small 
surface projections and a rough appearance (Pintel et al., 1983; Baldauf et al., 1997).  
 
 
 
Figure 2.1. Electron micrograph of parvovirus particles. From http://virology-
online.com/viruses/Parvoviruses.htm. 
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Structure of the parvovirus genome 
Most parvoviruses have a similar genetic organisation (Bando et al., 1987); the left 
half of the genome encodes 2 regulatory proteins or non-structural (NS) proteins 
(NS1 and NS2), and the right half encodes 3 capsid proteins, or structural proteins 
(VP1, VP2, and VP3), shown schematically in Figure 2.2. Both ends of the linear 
ssDNA molecule are folded back to form short double-stranded hairpin-like 
(palindromic) structures (Rhode and Klaassen, 1982; Cotmore and Tattersall, 1987).  
With the exception of the adeno-associated viruses (AAV) (Srivastava et al., 1983), 
the human B19 virus (Astell and Blundell, 1989), and the densoviruses (Rhode and 
Klaassen, 1982; Bando et al., 1987), the right (3’) terminal sequence of the 
parvoviruses is distinct from that at the left (5’) terminus both in size and in 
sequence.  The right hairpin-like structure serves as a primer for the synthesis of a 
complementary strand.   
 
Structural proteins 
 
5’  3’ 
Non-structural proteins 
5’ palindrome 
(200+ bases) 
3’ palindrome 
(100+ bases) 
Figure 2.2 Characteristic structure and coding-assignments of the genome of the 
Parvoviridae. The palindromic termini at both the right and left ends play an essential role
origins of replication of the viral genome. The non-structural proteins encoded by the left h
of the genome are required for viral gene expression and replication. Structural proteins 
encoded by the right half of the genome determine the viral host range and tissue tropism. 
Adapted from Ozawa
 as 
alf 
 et al.,(1987). 
 
 
 
Differentiation of parvoviruses from other ssDNA viruses 
Other viruses exist that also contain ssDNA genome and these share some 
characteristics of the parvoviruses but have additional features that enable them to be 
distinguished taxonomically.   
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The viruses with ssDNA genome include the "bacteriophages" (Inoviridae, 
Microviridae), those that infect mammals and birds (Circoviridae, Parvoviridae), 
and those that infect plants (Nanovirus, Geminiviridae).  Although they all have 
ssDNA, their genomes differ in whether they are linear or circular and in the number 
of components their genomes include: those with a single linear genome 
(Parvoviridae), those with a single circular genome (Microviridae, Inoviridae, 
Circoviridae, some Geminiviridae), those with a circular 2-component genome 
(some Geminiviridae) and those with a circular multicomponent (>3) genome 
(nanoviruses), (Murphy, 1995) as shown in Figure 2.3. 
 
 
 
Figure 2.3. Viruses containing a single-stranded DNA genome.  Source: 
http://tolweb.org/Single-stranded_DNA_Viruses/21829 (derived from Tree of Life Web 
Project, 2005). 
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The genomes of all ssDNA viruses are all relatively small: Circoviridae about 3 kb, 
Parvoviridae 4-5 kb, Geminiviridae about 2.7-5.4 kb, Microviridae about 4.5 kb and 
Inoviridae and Nanovirus about 5-6 kb (Brentlinger et al., 2002; Murphy, 1995).  
Replication of all of the ssDNA viruses requires formation of a replicative form 
double-stranded DNA (RF dsDNA) intermediate, formed by the host cell DNA 
polymerases presumably in an attempt to "repair" the ssDNA. Parvoviruses differ in 
that that they possess a unique strategy for replicating their genomes, which uses 
internal or self-complementarity of genome ends to get around the problem of how 
to replicate a linear DNA genome (Astell et al., 1985).  In the infected cell, the 
ssDNA is converted to a dsDNA RF by cell polymerases, which then serves as a 
template for the formation of more copies of the virion ssDNA (Berns, 1996).  A 
comparison of the strategy of ssDNA replication in the Circoviridae and 
Parvoviridae is summarised in Figure 2.4. 
(A)
(B) (C)
(A)
(B) (C)
 
Figure 2.4. Information flow during ssDNA replication of the circular genome of the 
Circoviridae and linear genome of the Parvoviridae. (A) A virus-specific process is required 
both to nick the dsDNA RF and to sequester newly-formed genomic ssDNA into assembling 
particles. (B) Circoviruses replicate by a "rolling circle" model: nicking of one strand of the 
DNA RF allows use of an exposed 3'-terminus as a primer, which results in elongation of the 
"primer" strand, and displacement of the other. (C) In the case of Parvoviridae (AAV DNA 
replication) the nicking of the dsDNA RF is done by a non-structural protein and the 
sequestering of the newly formed genomic ssDNA into assembling particles is done by a 
coat protein. A B C D and A’B’C’D’ are inverted palindromic terminal repeats. From 
http://microbiology.columbia.edu/Micro_Files/virology/DNA%20Replication%2010-7-
05.pdf. 
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Physicochemical properties of rodent parvoviruses 
The simple structure of the parvoviruses, the absence of a lipid envelope and the 
small DNA genome are thought to account for their stability and remarkable 
resistance to environmental conditions such as heat, low temperature, varied pH, 
desiccation, chemical disinfectants and ultraviolet (UV) radiation (Harris et al., 
1974). The resistance of the viruses makes them difficult to eradicate and control 
(Fassolitis et al., 1985; Yang et al., 1995). 
Thermal stability  
Parvoviruses resist inactivation by high temperatures, although there is some 
variation between species.  Rodent parvoviruses survive at up to 80°C for 2 h and 
40°C for up to 60 days (Kilham and Oliver, 1959; Fassolitis et al., 1985; Tattersall 
and Cotmore, 1986).  Definite loss of infectivity at 37°C was shown to occur only 
after 180 days, and they had a half-life of 30 min at 60°C (Hoggan et al., 1966). 
Greater susceptibility to heat treatment has been demonstrated by Harris et al. (1974) 
for minute virus of mice (MVM) that had a half-life of 15 min at 60°C.  Unlike other 
parvoviruses, over 90% of MVM infectivity was lost within 3 h at temperatures of 
35°C and above (Fassolitis et al., 1985). 
Rodent parvoviruses are stable at low temperatures but different parvoviruses show 
different stability at low temperatures.  Feline panleukopenia virus did not lose 
infectivity when stored at 4°C for over 13 months (Poole, 1972) and H-1 virus did 
not lose infectivity after storage at refrigerator temperature (4°C) for over 6 years 
(Toolan and Ledinko, 1968).  In contrast, MVM was less stable, losing 4.3 log10 of 
viral infectivity over a 10-week period when stored at 4ºC (Poole, 1972) and 99% of 
MVM infectivity was lost after storage at 4ºC for 10 weeks (Toolan and Ledinko, 
1968), although MVM remained stable on storage in liquid nitrogen (Harris et al., 
1974).  
pH stability  
Rodent parvoviruses can resist a wide range of pH (pH 2-9) (Yang et al., 1995).  
Crawford (1966) observed that the MVM haemagglutinating activity was not 
affected at pH 7.0 to 8.5, and Greene (1965) demonstrated that the haemagglutinin of 
Toolan’s H-1 virus was stable at pH 2.0.  On the other hand, a study by Harris et al. 
(1974) has shown that 99% of the infectivity of MVM was lost after exposure of the 
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virus to pH 2.0 for 24 h, although a very small percentage of residual infectivity 
could still be detected after 7 days of the acid treatment.  However, it is not known 
whether or not the haemagglutinin of parvoviruses is correlated with infectivity 
(Crawford, 1966).  
Resistance to desiccation 
Rat virus (RV) survived and remained infective after they were dried on a plastic 
surface for 3-5 weeks, the duration of survival depending on the initial virus 
concentration of virus in the virus preparation tested (Yang et al., 1995; Jacoby et 
al., 1996). 
Resistance to chemical disinfectants  
Once shed in the environment, MVM was shown to be exceptionally resistant to 
denaturant disinfectants such as alcohols, phenolic and quaternary ammonium 
compounds that readily inactivate enveloped viruses (Harris et al., 1974; Yang et al., 
1995). Parker et al. (1970 b) reported that chloroform treatment had no effect on 
induction of MVM-specific fluorescence in infected cells, although the concentration 
of chloroform used and the details of treatment were not reported.  
Resistance to UV radiation 
Harris et al. (1974) observed different sensitivity among parvoviruses to a same dose 
of UV irradiation. MVM was found to be less stable to UV than has been reported 
for other parvoviruses. Although they found that the majority of MVM appeared 
inactivated by UV, a small “resistant population” remained, demonstrating that UV 
radiation is not an efficient method of complete inactivation of this virus. The 
survival of the “resistant population” was hypothesised to be either a resistant mutant 
viral population or related to formation of aggregates of virus particles or virus and 
cellular components, which limit complete destruction of the virus (Wallis and 
Melnick, 1967; Harris et al., 1974).  
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2.2 Classification of parvoviruses 
Classification based on the virus host range 
Current classification methods are based on the virus host range (vertebrates versus 
invertebrates) (Berns et al., 1995) and dependence on help from other viruses for 
replication (Cotmore and Tattersall, 1987). Additionally, parvoviruses are classified 
based on the nature of the distinct terminal sequence of the genome and the selection 
of the DNA strands for encapsidation (Pattison, 1990; van Regenmortel et al., 2000).   
Based on virus host range, the family Parvoviridae contains 6 genera divided 
between 2 subfamilies: the Parvovirinae that infect vertebrates, and the 
Densovirinae that infect arthropods (Berns et al., 1995), illustrated in Table 2.1. The 
known rodent parvoviruses are members of the family Parvoviridae, subfamily 
Parvovirinae and genus Parvovirus. The Parvovirinae have a wide distribution 
among warm-blooded animals, and have been recovered from a wide range of 
vertebrate host species, shown in Table 2.2. 
 
Table 2.1. Classification of parvoviruses based on virus host range.  Reproduced from van 
Regenmortel et al. (2000). 
 
Subfamily  Genus  Type species  Host organism 
Parvovirinae Parvovirus  Autonomous parvoviruses  Vertebrates 
 Erythrovirus  B19 virus  Vertebrates 
 Dependovirus  Adeno-associated viruses  Vertebrates 
Densovirinae Densovirus  Junonia coenia densovirus  Invertebrates 
 Iteravirus  Bombyx mori densovirus  Invertebrates 
 Contravirus  Aedes aegypti densovirus  Invertebrates 
 
 
Classification on the basis of dependency on other viruses for replication  
Viruses in the genera Parvovirus and Erythrovirus include most of the parvoviruses 
and are autonomous, meaning they are capable of replication in cells without the 
assistance of other viruses (Cotmore and Tattersall, 1987). However, their replication 
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is dependent upon cellular factors that are transiently expressed in host cells during 
cell division (Jacoby et al., 1979; Spalholz and Tattersall, 1983).   
 
 
Table 2.2. Species of the 3 genera of Parvovirinae.  Reproduced from Berns (1996). 
 
Parvovirus Erythrovirus  Dependovirus 
Minute virus of mice 
Mouse parvovirus  
Canine parvovirus   
Aleutian mink disease virus  
Chicken parvovirus 
Bovine parvovirus  
Feline panleukopenia virus 
Feline parvovirus 
Goose parvovirus 
Canine minute virus   
HB parvovirus  
Porcine parvovirus 
H-1 parvovirus  
RA-1 virus 
Kilham rat virus 
Racoon parvovirus 
Lapine parvovirus  
RT parvovirus  
LuIII virus 
Mink enteritis virus 
Tumour virus X   
B19 virus (human) 
V9 (human) 
Rhesus parvovirus 
Pig-tailed macaque 
parvovirus 
Adeno-associated virus types 1-5 
Avian adeno-associated virus 
Bovine adeno-associated virus  
Canine adeno-associated virus 
Equine adeno-associated virus    
Ovine adeno-associated virus 
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Viruses in the genus Dependovirus, also known as adeno-associated viruses (AAV), 
are replication-defective. The AAV are unique among animal viruses in that, except 
under special conditions, they require co-infection with an unrelated helper virus 
either adenovirus or a herpes virus for productive infection and are not themselves 
pathogenic (Cotmore and Tattersall, 1987).  There are at least 8 known AAV, mostly 
infecting primates, and including at least 4 insect parvoviruses (Tattersall and 
Cotmore, 1986).  
Classification on the basis of terminal sequence characteristics 
Terminal sequence characteristics of the genome of parvoviruses have also been 
used for classification. Based on the similarities and differences between the terminal 
hairpin sequences of the genome of AAV and autonomous parvoviruses respectively, 
this unique characteristic offers an additional foundation for accurate classification 
of parvoviruses as defective or autonomous.  While AAV possess identical 5’ and 3’ 
terminal hairpin sequences, autonomous parvoviruses terminate with non-identical 5’ 
and 3’ hairpin sequences (Berns et al., 1979; Bates et al., 1984).  
Classification on the basis of selection of DNA strands for encapsidation 
In the late 1970s when it was thought that all members of autonomous parvoviruses 
encapsidated a unique minus-strand DNA and AAV separately encapsidated equal 
amounts of plus and minus DNA strands, the strand specificity of viral DNA 
encapsidation had been an additional basis for classification of parvoviruses as 
defective or autonomous (Bachmann et al., 1979).  It has since been confirmed that 
Kilham rat virus (KRV), H-1 virus and MVM encapsidate a unique minus DNA 
strand complementary to the mRNA (Bates et al., 1984,) whereas LuIII, an 
autonomous parvovirus closely related to the rodent parvoviruses, encapsidates equal 
amounts of complementary DNA strands when propagated in the same host cell type 
(Berns and Hauswirth, 1978).  
The finding that different members of autonomous parvoviruses encapsidate ssDNA 
of different polarity did not make it a useful characteristic for differentiation between 
dependoviruses and the autonomous parvoviruses as initially thought. It rather 
suggested that selection of strands for encapsidation, when propagated in the same 
host cell type, was a virus-coded rather than host-controlled event (Bates et al., 
1984).  
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Possible reclassification of parvoviruses  
In addition to the virus host range and helper virus requirement, it has been 
suggested that additional characteristics, including the genomic locations of 
transcriptional promoters, splice sites, signals for polyadenylation and organisation 
of the terminal genomic sequences indicate that methods for the classification of 
parvoviruses should be revised (Ledinko et al., 1969; Berns et al.,1979; Bates et al., 
1984).  
In spite of the distinctions between the 3 genera of the Parvovirinae subfamily, 
Parvovirus, Erythrovirus and Dependovirus, described above, there are also 
significant similarities between the members in relation to their genome structure, 
organisation and expression (Berns, 1996).  Berns (1996) considered possible 
reclassification and regrouping because (i) there are significant similarities in 
genome organisation of the viruses of the current genera of Parvoviridae family 
(Berns, 1996), (ii) AAV do not always require a helper co-infection for a productive 
infection to occur (Bantel-Schaal and zur Hausen, 1988) and (iii) the replication of 
some autonomous parvoviruses had been reported to be greatly enhanced in human 
cells by adenovirus co-infection (Ledinko et al., 1969).  
These observations prompted the suggestion that the original hypothesis of a host-
dependent evolution of parvoviruses (Bando et al., 1987) may have limited value 
within and among the genera (Parrish and Truyen, 2000).That the current 
classification of viruses within Parvovirinae (van Regenmortel et al., 2000) does not 
always reflect their evolutionary relationships was indicated by Lukashov and 
Goudsmit (2001). Sequence information on parvoviruses generated using 
phylogenetic methods available at the time revealed several discrepancies in the 
evolutionary relationships on parvoviruses. Lukashov and Goudsmit (2001) found 
that avian parvoviruses currently classified as members of the Parvovirus genus, had 
an evolutionary link to AAV rather than to any autonomous parvoviruses.  
Moreover, the genome sequences that are available of 4 strains of MVM were 
considered to be derived from a single species, while the available genome 
sequences of 3 strains of mouse parvovirus (MPV) were considered to represent 
different species MPV-1a, -b, and -c even though the genetic heterogeneity in MVM 
is much higher that in MPV-1. MVM strains are derived from a single species while 
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the more closely genetically related MPV represent different species (Lukashov and 
Goudsmit, 2001).  
Analysis has provided evidence for both host-dependent and host-independent 
evolution in the history of parvoviruses. For instance, the 2 human parvoviruses B19 
and V9 that are in one phylogenetic group matched exactly the relationships among 
their hosts. On the other hand, B19 and V9 were found to have a greater 
evolutionary relationship to simian parvoviruses rather than to each other (Lukashov 
and Goudsmit, 2001).  
Lukashov and Goudsmit (2001) indicated that the absence of host-specific 
clustering of rodent parvoviruses suggests the occurrence of cross-species 
transmissions among rodents. Additionally, the functional difference between the 2 
open reading frames within the parvovirus genome was suggested to indicate 
selection pressure on these 2 genomic regions, which differ among distinct lineages.  
Based on this observation, they considered MPV to be a recombinant between 
MVM and LuIII-related viruses. Chapman and Rossmann (1993) hypothesised that 
MPV originated by a recombination event between LuIII and MVM to generate a 
hybrid virus.  They considered that the differences found in the nucleotide (nt) and 
coding sequences of LuIII and MPV exceed those found between parvoviruses.  In 
contrast, Parrish (1990) and Parrish et al. (1991) noted that the occurrence of 
antigenic changes in the autonomous canine parvovirus occurred as a result of 
mutation causing multiple individual nt changes, rather than by recombination 
events. 
 
2.3 Parvovirus species   
Human  
The human B19 virus is the only member of Parvoviridae pathogenic to humans 
(Chipman et al., 1996).  Most adults (85 to 90%) have been exposed to B19. Like 
most autonomous parvoviruses, B19 reduces the number of circulating lymphocytes, 
which can lead to panleukopenia and fatal aplastic crisis in the haemolytically 
compromised individuals.  B19 is the cause of erythema infectiosum, also known as 
‘fifth disease’ (Anderson and Torok, 1989).  With the exception of aplastic crises, 
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and those with haemolytic anaemia and non-immune hydrops of the infected foetus 
many B19 infections result in no or only mild illness (Kurtzman et al., 1989).   
LuIII virus was isolated from human cells. Although it was shown that it can grow 
only in human cells, its origin is not known (Siegl and Gautschi, 1973, 1976).  The 
studies on sequence homology strongly suggest that it is closely related to the rodent 
parvoviruses (Banerjee et al., 1983). 
Domestic animals  
There are several autonomously replicating parvovirus species causing important 
diseases in domestic animals, including the antigenically related feline 
panleukopenia virus (Truyen and Parrish, 1992), canine parvovirus (Truyen, 2000) 
and mink enteritis virus (Uttenthal et al., 1990, 1999), Aleutian mink disease (Zellen 
and Tapscott, 2002) and porcine parvovirus (Mengeling et al., 2000).  
Rodent parvoviruses 
Rodent parvoviruses were first isolated from cell culture stocks in the 1960s (Kilham 
and Oliver, 1959). Since then, an ever-increasing number of serologically distinct 
viruses have been isolated and characterised from rodent (hamsters, rats and mice) 
colonies, and others has been identified in cell culture stocks originating from rodent 
species (Parrish et al., 1988).   
Rat virus (RV) was the first parvovirus isolate discovered as a contaminant in a 
transplantable neoplasm (Kilham and Oliver, 1959).  The association of this virus 
with mitotically active cells was an early indication of the predilection of 
parvoviruses for replication in mitotically active cells (Jacoby et al., 1979).  
Rat parvovirus (RPV) was discovered during an experimental study of RV infection 
and isolated by exploiting the predilection of parvoviruses for tumour cells (Jacoby 
and Ball-Goodrich, 1995). Originally designated Rat orphan parvovirus, it was 
characterised and renamed RPV by Ball-Goodrich et al. (1998).  
H-1 virus is similar but antigenically distinct virus from RPV detected in a human 
tumour cell line (Hep-1) that had been passaged in laboratory rats (Toolan et al., 
1960). It can be propagated in either rodent or human cells (Siegl and Gautschi, 
1978).  
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Hamster parvovirus (HaPV) was isolated from a colony of Syrian hamsters that 
experienced high morbidity and mortality in sucklings and weanlings (Gibson et al., 
1983). It was subsequently isolated by propagation in explant cultures and induced 
clinical disease in hamsters inoculated as neonates (Besselsen et al., 1996).  
Murine parvoviruses 
There are 2 important murine parvoviruses, Minute virus of mice (MVM) and Mouse 
parvovirus (MPV-1). 
MVM  
MVM is the best-characterised murine parvovirus. There are 2 allotropic strains of 
MVM, MVMp, the prototype strain and MVMi, the immunosuppressive strain, and 
there are 2 additional recently isolated MVM strains, MVM-Cutter (MVMc) and 
MVMm (Crawford, 1966; Bonnard et al., 1976; Besselsen et al., 1996; Naugler et 
al., 2001). MVMp and MVMi are serologically indistinguishable, but possess 
different molecular mechanism of the virus tropism. MVMp, the fibrotropic 
determinant, was isolated from a contaminated stock of mouse adenovirus by 
Crawford (1966). After adaptation to cell culture and plaque cloning, this prototypic 
isolate was designated MVMp by Tattersall and Bratton (1983). MVMi, the 
lymphotropic determinant, was isolated in 1976 from a transplantable mouse T-cell 
lymphoma EL-4 by Bonnard et al. (1976). This virus inhibited a variety of 
lymphocyte functions in vitro (such as inhibition of antigen-induced proliferation 
and the generation of cytotoxic T-cells in mixed lymphocyte cultures), and was 
designated MVMi by Engers et al. (1981). 
Although MVMi and MVMp are 97% identical at the nucleotide (nt) level, with 16 
primarily single based nt changes scattered throughout the genomes (Gardiner and 
Tattersall, 1988), they differ in 4 important characteristics.  First, the 
immunosuppressive properties are exhibited by MVMi only (Segovia et al., 1991).  
Second, replication takes part in different host cells: MVMp infects fibroblasts, 
whereas MVMi infects lymphocytes (Tattersall and Bratton, 1983; Astell et al., 
1986; Brownstein et al., 1992).  Third, their pathobiology differs: MVMi causes a 
lethal infection in perinatal mice of susceptible strains (Kimsey et al., 1986; 
Brownstein et al., 1991), while MVMp infection is asymptomatic (Kimsey et al., 
1986). Brownstein et al. (1991) have found that the lethal effects of MVMi results 
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from its tropism for capillary endothelium, while the failure of MVMp to replicate in 
capillary endothelium was found to be the basis of its avirulence. Fourth, the 
pathogenesis of the infections they cause differ: both MVMi and MVMp target small 
intestine and lymphoid tissue in susceptible mice, but MVMi replicates preferentially 
in the kidney (Jacoby and Ball-Goodrich, 1995). Brownstein et al. (1991) found that 
the genotype of the host also plays an important role in the pathogenesis of MVM 
infection. 
MVMc was isolated during the 1980s as a contaminant of BHK-21 cells that were 
being used to produce a recombinant protein at a commercial laboratory (Besselsen 
et al., 1996). The most recent MVM strain, isolated from clinically ill NOD-μ chain 
knockout mice (growth retardation, reduced fecundity and premature death) was 
designated MVMm (Naugler et al., 2001). The nt sequence identities (96%) 
indicated that MVMm was most similar to MVMc. 
MPV-1 
The origin of MPV-1 is unknown, but retrospective testing of stored sera has 
indicated that MPV-1 has been present in mouse colonies for nearly 30 years, and 
that it was responsible for about 80% of natural parvovirus infections in mice in the 
1970s (Jacoby et al., 1996).  Ball-Goodrich and Johnson (1994) concluded that MPV 
could not have been identified earlier because the confirmatory assay for 
parvoviruses was the MVM haemagglutination-inhibition (HAI) test, which 
measures reactivity to VP capsid antigens.  The levels of amino acid identity in the 
VP1 and VP2 capsid proteins of the 2 viruses, particularly in regions thought to be 
surface epitopes of the virion, causes a lack of cross-reactivity between MPV-1 and 
MVM by HAI (Chapman and Rossmann, 1993).  
Early indications of the possible presence of MPV-1 in mouse colonies were the 
observations by workers at several diagnostic laboratories that some mouse sera 
reacted with MVM antigen in IFA but not with HAI assays using the same MVM 
antigen or highly purified MVM virions (Jacoby et al., 1996). A candidate 
parvovirus that was lymphocyte-tropic and had adverse effects on in vitro immune 
responses was subsequently isolated by McKisic et al. (1993).  The virus grew 
lytically in a CD8+ T-cell clone designated L3 and inhibited the proliferation of 
cloned T-cells stimulated with antigen or interleukin 2 (IL-2), (McKisic et al., 1993).   
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In the early 1990s, the viruses that could not be grown successfully in cell cultures 
that otherwise supported replication of MVM or RV was referred to as “orphan” 
viruses because there was only a vague understanding of their biologic significance 
for rodents (Smith et al., 1993).  The first of these parvoviruses was isolated when a 
loss of function and/or viability was noticed when clonal murine T-cell lines were 
co-cultured with splenic feeder cells containing the virus (McKisic et al., 1993). The 
new virus identified using serologic techniques and Southern blot analysis produced 
a lytic infection of cloned L3 cytotoxic T-cells but was unable to produce productive 
infection in BHK21 or EL-4 (G) cells. It was subsequently characterised and 
renamed MPV-1 by Ball-Goodrich and Johnson (1994). Initial genomic sequence 
analysis indicated that MPV-1 was most closely related genetically to MVM and 
LuIII with approximately 88% nt sequence similarity (Ball-Goodrich and Johnson, 
1994).  
Three strains of a single serotype of MPV-1 have now been reported: MPV-1a, 
MPV-1b and MPV-1c (Besselsen et al., 1996). MPV-1a was isolated from cultures 
of L3 cytolytic T-lymphocytes and splenocytes (McKisic et al., 1993). This isolate 
was adapted to grow in CTLL-2 cytolytic T-lymphocytes and subsequent sequencing 
showed that several mutations had occurred during adaptation of the virus to the 
CTLL-2 cells. The adapted virus was designated MPV-1b (Ball Goodrich and 
Johnson, 1994; Besselsen et al., 1996). MPV-1c was identified from a naturally 
infected mouse and it has several nt differences from the MPV-1a and MPV-1b 
(Besselsen et al., 1996).  
Novel murine parvoviruses, MPV-2 and MPV-3, were detected in naturally infected 
laboratory mice (Besselsen et al., 2006). These strains were revealed by numerous nt 
mis-matches within the primers and probe, which were observed when amplicons 
from MPV/HaPV-specific polymerase chain reaction (PCR) sequences were aligned 
with MPV and HaPV.  
 
2.4 Murine parvovirus genome 
As it is the best characterised autonomous parvovirus, MVM serves as a model virus 
for the study of the genetics, function and replication of murine parvoviruses and 
also other parvoviruses.  The MVM genome contains 2 large open reading frames 
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(ORFs) that do not overlap, and several smaller ORFs (Astell et al., 1986). The 
physical map of MVM, with ORF 3 extending in the left half of the genome and the 
ORF 1 extending in the right half of the genome is shown in Figure 2.6(A).  
The MVM genome encodes 2 overlapping transcription units which produce 3 major 
spliced cytoplasmic transcripts (mRNA species): R1, 4.8 Kb; R2, 3.3 Kb; R3, 3.0 Kb 
(Pintel et al., 1983).  Transcription proceeds from left to right and starts at 2 
promoters that are located upstream from each of the large ORFs, P4 and P38; 
transcripts R1 and R2 are synthesised using P4, while the R3 transcript utilise P38 
(Pintel et al., 1983). The early promoter P4 regulates the expression of the 2 non-
structural proteins NS1 and NS2 and the late promoter P38 regulates the expression 
of the 2 capsid proteins VP1 and VP2 (Cotmore et al., 1983). All transcripts 
terminate at the right end of the genome. The viral genome of MVM presented in a 
3’ to 5’ orientation with the 3 major cytoplasmic transcripts R1, R2 and R3 is shown 
in Figure 2.5(B). 
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Figure 2.5 Genomic organisation of MVM gene products and genetic and transcription map 
of the MVM genome. (A) The presence of the 2 major ORF (ORF 1 and ORF 3) and a 
smaller ORF 2 are illustrated on the genomic map. (B) P4 and P38 indicate the 2 promoters 
located upstream from each of the 2 ORFs. R1, R2 and R3 indicate the 3 mRNA species 
produced by MVM. R1 arises from the P4 promoter at genome map unit 4 and encodes the 
83 kDa non-structural NS1 protein. R2 also arises from the P4 promoter, but a large intron 
between nt514 and 1989 is spliced out of the primary transcript. R2 generates the 23-25 kDa 
smaller non-structural protein NS2. R3 arises from the P38 promoter and encodes the 2 
structural viral proteins, the 83 kDa VP1 and the 64 kDa VP2.  (A) is reproduced from 
Naeger et al. (1990) and (B) from Cotmore and Tattersal (1986). 
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The coding region of MVM genome is bracketed by short imperfect palindromic 
sequences (telomeres) at the right and left termini (Astell et al., 1983 b). These 
sequences initiate amplification of the RF when they are folded back and serve as 
primers for strand displacement synthesis during rolling circle replication and 
formation of dimeric replicative form DNA (RF DNA) (Willwand et al., 1998).  
While AAV, human B19 and the densoviruses contain the same sequence at both 
termini (Berns, 1990), the right and left-terminal palindromic sequences differ in 
sequence and size.  The left terminal palindrome of 206 nt contains 2 sequences in 
equimolar amounts, one of which is the inverted complement of the other (Astell et 
al., 1985).  It can form a hairpin, the stem of which is entirely
 base-paired except for 
3 consecutive unpaired nt which form a
 bubble. This structure is well conserved 
among different
 parvoviruses (Costello et al., 1995).  The right terminal palindrome 
on MVM consists of a unique 115 nt sequence, 104 nt of which are base-paired 
(Astell et al., 1983 a). The schematic illustration of the structures at the right and left 
ends of the parental virion strand DNA (V-strand DNA), monomer RF DNA (mRF 
DNA) (extended) and monomer RF DNA (joined) are illustrated in Figure 2.6, while 
the structural features at the MVM genomic termini and the nt sequence organisation 
of the right and left hairpins of MVM are shown in Figure 2.7.   
19 
 
 
Figure 2.6 Schematic illustrations of the structural features at the right and left ends of the V 
strand DNA, monomer RF DNA (extended) and monomer RF DNA (joined) of MVM DNA. 
A and B: unique or heterogeneous nt sequence organization of the 3’and 5’hairpins, 
respectively, of V-strand DNA. C and D: nt sequence heterogeneity of the right and left 
terminal regions of monomer RF DNA (extended form) and the sequence orientation at the 
right-end RF. Both V DNA and mRF DNA contain the same unique right-end sequence. E 
and D: the structure of the right loop which covalently links V and C strands of m RF. The 
asymmetry at the right end is limited to the AAG bubble. V strand represents the parental 
virion strand, C strand the complementary DNA strand and RF the replicative form. 
Reproduced from Astell et al. (1985). 
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Figure 2.7. Nucleotide sequences at the right and left terminus of MVM virion DNA, 
illustrated in their hairpin confirmation. The right- and left-termini of the single-stranded 
MVM genome contain palindromic sequences which adopt a “hairpin” configuration. (A) 
The unique right-hairpin structure contains 115 nucleotides, 104 of which are base-paired. 
right-end and have essentially identical sequences among rodent parvoviruses, MPV-1 
included. (B) The heterogeneous left-hairpin structure contains 206 nucleotides. It possesses 
2 nt sequences that are the inverted complement of each other, designated “Flip” and “Flop”. 
In both sequence orientations, 200 of the 206 nucleotides are capable of base-paring to form 
a stable duplex structure. Reproduced from Astell et al. (1983 a). 
 
 
2.5 Rodent parvovirus non-structural proteins  
Two non-structural proteins, NS1 and NS2, are produced prior to the structural 
(capsid) protein during MVM infection (Cotmore et al., 1983).  NS1 and NS2 differ 
in size and subcellular distribution (Cotmore and Tattersall, 1990). The NS1 and 
NS2 polypeptides of several rodent parvoviruses (MVM, H-1 and LuIII) share a 
common amino-terminal region of approximately 84 amino acids encoded by the 
single ORF located between nt 225 and 534 in the viral genome; the ORF located 
between nt1110 and 1638 is expressed only in the NS1 protein, and the sequence 
encoded in a small alternative ORF located between nt 2075 and 2291 is expressed 
exclusively in NS2 (Cotmore and Tattersall, 1986). The NS1 is the product of the R1 
viral transcript, while NS2 is a product of the R2 transcript (Cotmore and Tattersall, 
1986; Morgan and Ward, 1986).   
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NS1 protein  
MVM NS1 has been characterised as an 83 kDa stable phosphoprotein; although 
NS1 exhibits a mainly nuclear localisation during natural MVM infection (Cotmore 
and Tattersall, 1986), 30 to 40% of wild-type MVM NS1 is retained in the cytoplasm 
of infected cells (Nuesch and Tattersall, 1993).  To perform its distinct activities in a 
timely coordinated manner, it was suggested that NS1 was regulated by 
posttranslational modifications, probably phosphorylation, which was thought to be 
for the role of NS1 in DNA replication (Naeger et al., 1990).  This multifunctional 
protein is involved in many processes necessary for virus replication (Cotmore and 
Tattersall, 1995; Nuesch et al., 1995), shown in Figure 2.8. Early studies of 
parvoviruses determined that the NS1 of both dependoviruses and the autonomous 
parvoviruses have a similar function.   
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Figure 2.8. Linear representation of the amino acid sequence and functional regions of MVM 
NS1 necessary for virus replication. NS1 exhibits ATPase and helicase activities, sequence-
specific DNA binding properties and is required for viral DNA replication and transactivation 
of the P4 and P38 promoters. Reproduced from Hirt (2000). 
 
 
The role of NS1 in viral DNA replication and transactivation of the P4 and P38 
promoters 
The key role of NS1 in MVM DNA replication was initially established through the 
use of temperature-sensitive mutations in the NS1 gene (Littlefield, 1964) and 
subsequently confirmed by Pujol et al. (1997).  NS1 is translocated into the nucleus 
(Yang et al., 2002) where it protects the RF DNA from left-to-right exonuclease 
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activity and therefore protects viral DNA from degradation after excision (Rhode 
and Paradiso, 1989). 
NS1 is able to either activate or inhibit gene expression from heterologous promoters 
(Legendre and Rommelaere, 1992; Faisst et al., 1993; Vanacker et al., 1993).  The 
transcription-regulating domains of NS1 are confined to the carboxy-terminal 
portions of the protein and can be dissociated from its replicative function (Legendre 
and Rommelaere, 1992). 
NS1 upregulates transcription from both viral P4 and P38 promoters (Rhode, 1985; 
Doering et al., 1988, 1990; Hanson and Rhode, 1991; Cotmore and Tattersall, 1986, 
1995). It strongly and efficiently induces the viral P38 promoter late in infection 
(Rhode and Richard, 1987; Doering et al., 1990) probably due to interaction with 
cellular transcription factors rather than the binding with the viral DNA (Krauskopf 
et al., 1990).  It binds, in an ATP-dependent manner, to the P38 region that mediates 
the NS1 transactivation response in cis (Christensen et al., 1995).  It also controls 
transcription in trans from both the P4 and P38 promoters, which drive the 
expression of non-structural and capsid proteins, respectively (Cotmore and 
Tattersall, 1987; Doering et al., 1988, 1990; Vanacker et al., 1996). NS1 can also 
suppress transcription from a number of cellular and heterologous viral promoters 
(Legendre and Rommelaere, 1992; Rhode and Richard, 1987).  A study has shown 
that the terminal regions of the MVM NS1 are involved in promoter trans inhibition 
(Legendre and Rommelaere, 1992).  Laurent et al. (2001) have indicated that the 
transcription-regulating function of NS1, using NS1-mediated trans-inhibition of the 
CMV promoter as a target for the NS1-dependent trans-inhibition, is likely to require 
NS1 homo-oligomerisation. 
NS1 endonuclease activity 
The endonuclease activity of NS1 for the excision and replication of the cloned 
genome of LuIII was demonstrated by Tattersall and Ward (1976) and Rhode and 
Paradiso (1989); the enzymatic domain responsible for the site-specific endonuclease 
(nicking) activity was in the amino-terminal half of the molecule (Koonin and Ilyina, 
1993; Nuesch et al., 1995; Hickman et al., 2004); this has been confirmed both in 
vivo (Cotmore and Tattersall, 1992) and in vitro (Cotmore et al., 1992).  The central 
role of NS1 in the replication of MVM DNA has also been demonstrated (Tattersall 
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and Ward, 1976; Astell et al., 1983 b, 1985; Rhode and Paradiso, 1989; Cotmore and 
Tattersall, 1989; Skiadopoulos and Faust, 1993). NS1 introduces nicks into the left 
end of the genome in the vicinity of the hairpin structure (Tattersall and Ward, 1976; 
Baldauf et al., 1997).  Although the exact mechanism remains to be defined, it was 
postulated (Cotmore and Tattersall, 1989; Skiadopoulos and Faust, 1993) that the 
covalent association of NS1 with the 5 left ends of viral DNA occurred 
predominantly through the adenine residue at nt 5170.  The left-end hairpin of MVM 
is insensitive to the nicking activity of NS1 (Baldauf et al., 1997). 
Host cellular accessory proteins are also required for site- and strand-specific nicking 
of both the left-and right-end MVM origins of replication: parvovirus initiation 
factor (PIF) for the NS1 nickase activity (Christensen et al., 1997) and high mobility 
proteins for activation of the viral protein at the right-end origin (Cotmore and 
Tattersall, 1988).  Christensen and Tattersall (2002) showed that NS1 and PIF bind 
to the left-end minimal replication origin of MVM, forming a ternary complex.  In 
this complex,
 NS1 is activated to nick one DNA strand and in the process becomes 
covalently
 attached to the 5' end of the nick and provides
 a left OH site for priming 
the DNA synthesis.  Within the terminal hairpin structure there is a mismatched 
“bubble” between the binding sites for PIF and NS1, in which a triplet left end-
GAA-right end on one strand opposes a dinucleotide left end-GA-right end.  Under 
physiological conditions, nicking of NS1 in concert with PIF occurred only at origins 
containing the dinucleotide bubble sequences, whereas a trinucleotide between the 
NS1 and PIF binding sites abolished the reaction (Christensen et al., 1997). 
NS1 helicase activity 
The NS1 protein also has DNA helicase activity, associated with the carboxy-
terminal half, which is one of a group of viral enzymes with an evolutionary 
relationship to a family of cellular ATPases (Gorbalenya et al., 1990; Christensen 
and Tattersall, 2002).  It is involved in the separation of the 2 strands of the dsRF 
during DNA replication (Tattersall and Ward, 1976; Wilson et al., 1991; Nuesch et 
al., 1992). Baldauf et al. (1997) found that NS1 has a stimulatory effect over the 
production of the dsRF from monomeric right-end extended molecules during the 
replication of the MVM genome.  They attributed this activity of NS1 to the helicase 
activity of the viral product (Wilson et al., 1991).  NS1 promotes the initiation of 
dsRF formation by allowing the extended right-end telomere to fold back into a 
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rabbit-eared structure, and/or by facilitation of the elongation of the newly 
synthesised strand by enabling the replication complex to displace the parental viral 
strand.  To be fully functional in DNA metabolism, NS1 requires self-association in 
order to fulfil its helicase function and to support viral replication (Wilson et al., 
1991; Pujol et al., 1997). Christensen and Tattersall (2002)
 showed that the DNA 
helicase activity of the parvovirus
 initiator protein NS1 was highly directional, 
binding to the
 single strand at a recessed 5 left end and displacing the other
 strand 
while progressing in a right-to-left direction on the bound
 strand. 
Cytotoxicity of NS1 protein 
NS1 seems to be the major effector of parvovirus-induced cytotoxicity although the 
mechanism is not understood.  Although it is not clear why, MVM preferentially 
lyses transformed rather than non-transformed cells (Chen et al., 1989).  Cells 
transformed by oncogenic viruses or cellular oncogenes display an increased 
permissiveness for parvovirus replication, and cells infected with MVM are arrested 
in the S-phase of the cell cycle because of inhibition of DNA replication in the cell 
(Faisst et al., 1989; Salome et al., 1990).  The ability of NS1 to modify the 
expression of cellular genes, to phosphorylate some cellular proteins and inhibit 
cellular transformation, has been speculated to contribute to NS1-dependent 
cytotoxicity (Branderburger et al., 1990; Legendre and Rommelaere, 1992; Vanacker 
and Rommelaere, 1995). Legendre and Rommelaere (1992) showed that it is the 
terminal regions of the NS1 protein of the MVM that are involved in cytotoxicity. 
NS2 protein  
NS2 is the predominant virus-encoded non-structural phosphoprotein detected early 
in the S-phase of infected cells.  It is a labile protein with a short half-life of about 90 
min (Cotmore et al., 1983; Clemens et al., 1990; Cotmore and Tattersall, 1990; 
Miller and Pintel, 2001). R2 mRNA is spliced between nt 514 and 1990, which 
results in NS2 shifting into ORF2 (Astell et al., 1986).  Because of its small size, 23-
25 kDa, NS2 can enter and exit the nuclear membrane by passive diffusion, since the 
cut-off size for facilitated transport versus diffusion across the nuclear pore complex 
is considered to be 40 to 50 kDa (Dingwall and Laskey, 1986). The NS2 protein of 
MVM is degraded by a proteasome in a cellular proteasome-virus interaction (Miller 
and Pintel, 2002).  
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NS2 is present in 3 isoforms designated NS2-P, NS2-Y and NS2-L, all with a 
molecular mass in a range of 23-25 kDa.  All 3 isoforms share the first 85 amino 
acids with NS1 (Cotmore and Tattersall, 1986, 1987) but they differ in the carboxy-
terminal regions as a result of alternative splicing of a precursor mRNA (Morgan and 
Ward, 1986; Cotmore and Tattersall, 1990). It is not known whether these isoforms 
have different or redundant functions, but NS2 exists in phosphorylated and non-
phosphorylated forms which seem to have different locations and therefore possibly 
different functions.  Phosphorylated forms of NS2 are confined to the cytoplasm of 
infected cells (A9 cells) (Cotmore and Tattersall, 1990; Li and Rhode, 1991), while 
the majority of nuclear NS2 is not phosphorylated (Fornerod et al., 1997).  
Studies by Brownstein et al. (1992) and Bodendorf et al. (1999) have led to the 
identification of NS2-interacting host cell proteins: nuclear export factor Crm1 
(chromosome region maintenance factor), and the signalling 14-3-3 protein.  These 
complexes may play a role in NS2 function and/or regulation.  Crm1, a mainly 
nuclear protein, is associated with the non-phosphorylated form of NS2 in the nuclei 
of infected cells (Fornerod et al., 1997).  The 14-3-3 host cell signalling protein 
interacts only with phosphorylated NS2 (Bodendorf et al., 1997, 1999).  Although it 
is not known that phosphorylation pattern confers a distinct function on NS2 or plays 
a regulatory role, those proteins are considered as host participants in the regulation 
and/or functioning of NS2.  
The role of NS2 in viral DNA replication 
Naeger et al. (1990) generated a series of mutations in the MVMp strain designed to 
solely affect NS2.  These experiments revealed that NS2 participates in viral DNA 
replication and is required for efficient virus production in murine A9 fibroblasts.  
The requirement for NS2 was shown to be cell type-specific and significantly more 
pronounced in murine A9 fibroblasts than in certain other cells.  Their studies also 
showed that different cells in culture support wild type murine parvovirus production 
to different extents. NS2 is required for efficient virus production and viral 
replication in cells from the natural host species but not from heterologous species 
(Cotmore et al., 1997).  
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The role of NS2 in capsid assembly 
Parvovirus capsid formation is a multi-step process, which is still not fully 
understood.  In MVM infections in mouse cells, it was  shown that NS2 is not 
needed for synthesis of the viral capsid proteins and their subsequent migration to 
the nucleus but it is needed for the generation of progeny ssDNA and capsid 
assembly (Eichwald et al., 2002).  In the absence of NS2, VP1 and VP2 proteins are 
not efficiently assembled into MVM capsids (Cotmore et al., 1997).   
The role of NS2 protein in the export of assembled capsids from the nucleus  
The interaction of both the phosphorylated forms of NS2 with the signalling protein 
14-3-3 and the non-phosphorylated forms of NS2 with the nuclear export factor 
Crm1 was shown to be important in 2 functions: the transport of NS2 from the 
nucleus to the cytoplasm of infected cells, and the proper localisation of NS2 within 
a host cell (Bodendorf et al., 1999; Fornerod et al., 1997; Ullman et al., 1997; 
Ohshima et al., 1999). Miller and Pintel (2002) have also shown the importance of 
the interaction between NS2 and the nuclear export protein Crm1 in MVM infection, 
which is involved in export of assembled capsids from the nucleus of the infected 
cells.  They have postulated that NS2 interacts directly with full virions to facilitate 
their exit through a Crm1-mediated pathway and that the NS2-Crm1 interaction 
influences the nuclear location of a kinase or phosphatase for this regulation. Having 
found that a defect in the progeny ssDNA production in NS2-Crm1 mutants was a 
direct result of the block in the export of full MVM virions from the nucleus to the 
cytoplasm of the host cell, Miller and Pintel (2002) have confirmed that NS2 has 
also multiple functions and is required for the early and late steps of MVM infection.  
The need to interact with the nuclear export receptor Crm1 for their active export out 
of the nuclei of infected cells was also confirmed by Eichwald et al. (2002).  
Additionally, it was found that the phosphorylation of the amino terminus of VP2 is 
also critical for viral exit. The viral NS2 proteins were shown to contribute to the 
regulation of VP2 phosphorylation, which was shown to take place in the cytoplasm 
prior to the migration of VP complexes into the nucleus and to require the NS2 
mediated intracellular delocalisation of a kinase, phosphatase, or associated 
regulating factor/s (Maroto et al., 2000).  Eichwald et al. (2002) found that either 
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cytoplasmic NS2 or NS2 transport through the nuclear envelope is required to 
facilitate the release of infectious MVM particles. 
The role of NS2 protein in the enhancement of cell killing  
NS2 proteins were found to enhance NS1-associated parvovirus-induced cell killing 
in some but not all cell lines tested (Branderburger et al., 1990; Caillet-Fauquet et 
al., 1990).  There is some evidence that NS2 may have a direct cytotoxic effect 
(Branderburger et al., 1990, Clemens et al., 1990). 
Homology between MPV-1 and MVM NS1 and NS2 proteins 
Serological studies by McKisic et al. (1993) and molecular analysis by Ball-
Goodrich and Johnson (1994) have indicated that MPV-1 is antigenically and 
genetically distinct from MVMi and MVMp.  However, MPV-1 does resemble 
MVM in many basic characteristics, including the nature of the replication 
intermediates, their genome size, and their non-structural proteins.   
Genetic analysis of MPV-1 indicates that regions encoding the NS proteins are 
similar to those of MVM, a finding that accounts for cross reactivity between the 
viruses in generic serological tests (Ball-Goodrich and Johnson, 1994).  MVMi NS1 
has a closer relationship to MPV-1 than to MVMp (Ball-Goodrich and Johnson, 
1994), perhaps correlated with the more efficient replication of MVMi in vivo and 
MPV-1 replicating more efficiently than MVMp.  The amino acid sequence of the 
NS1 proteins of MVMi and of MPV-1 are highly conserved, with 99.3% similarity, 
while the similarity of the sequence in the 2 allotropic variants of MVM, MVMi and 
MVMp is 97.8%.The amino acid sequence similarity and identity of NS1 between 
MPV-1 and other rodent parvoviruses is listed in Table 2.3 (Ball-Goodrich and 
Johnson, 1994). 
 
2.6 Rodent parvovirus virion proteins  
The capsid or virion proteins (VP) of parvoviruses are generated from the right end 
of the genome under the control of the P38 promoter (Berns, 1996), (Figure 2.9). The 
VP determines tissue tropism and the host range of the virus and differ substantially 
between parvovirus types (Gardiner and Tattersall, 1988). Up to 3 capsid proteins 
may be produced in the autonomous parvoviruses, VP-1, VP-2, and VP-3, which 
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have approximate molecular weights of 80,000 to 86,000 (VP-1), 64,000 to 75,000 
(VP-2) and 60,000 to 62,000 (VP-3) for different species, and they account for 60% 
to 80 % of the virion mass (Berns, 1996).  
 
Table 2.3.Amino acid sequence comparison of NS1 between MPV and other rodent 
parvoviruses. From Ball-Goodrich and Johnson (1994). 
 
Virus strain  MPV 
  % similarity  % identity 
MPV 100  100 
MVMi 99.9  99.3 
MVMp 98.5  97.6 
LuIII 95.7  93.1 
H-1 95.4 91.4 
 
 
 
 
Figure 2.9. Capsid proteins generated from the right end of AAV genome. The capsid 
proteins determine tissue tropism and the host range of the virus, and differ substantially 
from one parvovirus type to the next. VP1, 83 kDa, has extra 150-230 amino acids than VP2 
at the N-terminal end, and it is a minor component of mature capsid. The major capsid 
protein VP2, 64 kDa, is capable of virion formation and DNA packaging by itself and is 
essential for virus infectivity.  From 
http://www.tulane.edu/~dmsander/WWW/335/Parvoviruses.html. 
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In MVMp, the capsid is composed of 60 protein subunits, 90% of which consist of 
VP2 and 10% of which consist of VP1 (Tattersall and Ward, 1976).  MVMp VP1 
(83 kDa) and VP2 (64 kDa) share most of their sequence (Tattersall, 1978) but VP1 
differs from VP2 in that that it has a unique N-terminal end of some extra 150-230 
amino acids and it is a minor component of mature capsids (Chapman and Rossman, 
1993).  The major capsid protein, VP2, is by itself capable of virion formation and 
DNA packaging, but VP1 is essential for parvovirus infectivity presumably due to 
the function(s) of its unique N-terminal region (Tullis et al., 1993; Maxwell et al., 
1995).  VP1 and VP2 of MVM are synthesised in the cytoplasm of infected cells, 
where they cooperatively interact before migrating to the nucleus.  In the nucleus, 
VP1- and VP2-containing complexes are assembled into icosahedral virions which 
are able to package ssDNA (Cotmore and Tattersall, 1995; Vanacker et al., 1996) 
and are released from the infected cells (Richards et al., 1977; Singer and Rhode, 
1978; Siegl, 1984).  
It was suggested that the N-terminal region of VP1, rich in basic amino acids, is 
involved in the intracellular trafficking of the infecting virion and specifically in 
delivery of the viral genome to the host cell nucleus; this suggestion was based on 
the finding that nuclear delivery could be inhibited by mutagenesis of specific amino 
acid residues in this sequence (Vihinen-Ranta et al., 2002).  More extensive 
mutagenesis studies with MVM confirmed the role of this sequence of VP1 in 
nuclear delivery.  Lombardo et al. (2000, 2002) have elucidated the cooperative 
effects between the VP1 N-terminal sequence and the VP2 C terminus, named 
nuclear localisation motif, important for the viral assembly in the nucleus and for the 
onset of infection.  Phosphorylation of the VP2 N-terminus plays an important role 
in the parvovirus life cycle (Maroto et al., 2000).  The virion proteins are not 
glycosylated, are rich in acidic amino acids, and are poorly soluble in aqueous 
solution (Johnson, 1983). 
Some additional modification of VP2 may occur during replication.  In complete 
virions, the N terminus of some VP2 molecules becomes exposed at the particle 
surface and is further cleaved during release and/or subsequent uptake of infectious 
particles into the host cells, leading to the appearance of VP3 (60 kDa) (Tattersal and 
Shatkin, 1977; Agbandje-Mckenna et al., 1998).  During the replication process, as 
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well as in DNA containing particles, most VP2 molecules are cleaved by removal of 
some amino acids from the N terminus (Agbandje-McKenna et al., 1998).   
Comparison of VP1 and VP2 proteins in MPV-1 and MVM 
Significant differences between MPV-1 and MVM are found in the genes encoding 
the virion proteins, which accounts for the antigenic specificity and differences 
between these viruses.  Most diversity between MPV and MVM is at or near 
positions determined to be surface amino acids (Ball-Goodrich and Johnson, 1994).  
The similarity in the deduced amino acid sequences of the capsid proteins of MVMi 
and MPV-1a is 77.0%, far lower than the 98.4% similarity of the capsid regions of 
MVMi and MVMp. The VP1 amino acid sequence of MPV and LuIII has 85.6% 
similarity, higher between MPV and either MVM serotype (Ball-Goodrich and 
Johnson, 1994).  The percentage similarity of VP1 between MPV, MVMi, MVMp 
and LuIII is shown in Table 2.4. A summary of the properties of parvovirus 
structural and non-structural proteins is given in Table 2.5. 
 
 
Table 2.4.  Amino acid sequence similarities between VP1 of MPV, MVMi, MVMp 
and LuIII. From Ball-Goodrich and Johnson (1994). 
 
Virus strain  MPV  
  % similarity  % identity 
MPV 100  100 
MVMi 86.7  77.0 
MVMp 86.8  77.4 
LuIII 91.2  85.6 
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Table 2.5. Summary of structural and non-structural proteins of murine parvoviruses. 
From Ball-Goodrich and Johnson (1994). 
 
Characteristic Structural  proteins Non-structural  proteins 
Biological properties 
 
Components of the capsid of 
the virus particle 
 
Not components of the virus 
particle but present in virus 
infected cells where they 
bind DNA 
Antigenic characteristics 
 
Capsid proteins are the 
serotype determinant 
antigens 
Highly conserved among 
serotypes and allow 
parvovirus antibodies to 
cross-react 
Immunogenicity  Stimulate a rapid and strong 
immune response 
The host immune response 
may be slower to develop 
 
 
2.7  Murine parvovirus replication 
Although murine parvoviruses are capable of autonomous replication in susceptible 
cells, replication of these viruses is dependent on the cellular functions expressed 
transiently during the late S-phase of the host cell cycle.  This cellular dependency is 
because the small amount of DNA contained in the murine parvoviruses does not 
carry sufficient genetic information and the viral genes do not code for polymerases 
to direct its own replication.  As a result, murine parvoviruses have predilection for 
the nuclei of rapidly dividing cells, which are in the process of replicating their own 
DNA (Cotmore and Tattersall, 1987).  
Although murine parvoviruses can infect resting cells, they are unable to induce 
them to enter the S-phase and therefore they have to wait for the next S-phase in 
order to synthesise new DNA (Rhode, 1973; Tattersall et al., 1973; Hirt, 2000).  In 
extracts of cells infected with MVM, synthesis of the viral DNA coincides with the 
display of the cellular helper function during the late S phase. Some of the helper 
functions are thought to be mediated by direct interaction of cellular factors with the 
viral genome and/or regulatory proteins NS1 and NS2 (van Hille et al., 1989).  
However, which step in the viral replication cycle is controlled by the cellular helper 
function remains unanswered (Siegl and Gautschi, 1976). The steps involved in 
parvovirus DNA replication are shown in Figure 2.10. 
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1 Receptor binding and entry
2 Translocation to the nucleus
3 Synthesis of dsDNA
4 NS expression
5 VP expression
6 Genome 
replication
7 Capsid assembly
8 Cell lysis and 
release
 
Figure 2.10. Summary of the steps involved in parvovirus DNA replication. (1) Parvovirus 
binding and internalisation, (2) translocation to the nucleus, (3) synthesis of dsDNA, (4) NS 
protein expression, (5) virion protein expression, (6) genome replication, (7) capsid 
assembly, (8) lysis of  infected cells and release of the parvovirus virions. From 
http://www.tulane.edu/~dmsander/WWW/335/Parvoviruses.html. 
 
 
Attachment and internalisation 
Studies in vitro of the 2 MVM types, MVMp and MVMi, suggest that there are 
intracellular specificity factors that determine whether the parvoviruses replicate: 
when virus was added to cells, it was bound and taken up irrespective of whether the 
cells were permissive or not Tattersall and Spalholz (1983). This is in agreement 
with the findings reported for MVMi where the permissivity of fibroblasts was 
changed by conferring on the MVMi the capacity to grow in fibroblasts, achieved by 
substitution (by mutation) of only 2 amino acids in the coat protein (Ball-Goodrich 
and Tattersall, 1992). 
Several groups have postulated that a productive infection begins with the binding of 
the virion to an undefined cell surface receptor(s), and that a common uptake 
principle involves receptor mediated endocytosis (Ros et al., 2002). Different cell 
surface attachment proteins for parvoviruses have been reported: sialic acid moieties 
were proposed as receptor(s) for MVM (Cotmore and Tattersall, 1987) and 
transferrin receptors for canine and feline parvoviruses (Parker et al., 2001). Bantel-
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Schaal et al. (2002) suggested that after animal viruses bind to receptors at the 
surface of a host cell, their entry into the interior of the cell is initiated by direct 
fusion of the virus with the cell surface or by receptor-mediated endocytosis via 
clathrin-coated pits and vesicles and via small non-coated vesicles.  Details of the 
mechanism of entry of parvoviruses is still unclear; however, sequence analyses of 
the VP1 of parvoviruses have revealed phospholipase A2 motifs, not known to exist 
in other viruses, which might be connected with parvovirus entry and infectivity 
(Zadori et al., 2001).  In AAV type 5, Bantel-Schaal et al. (2002) suggested that 
there are 2 types of binding sites on HeLa cells: one, at the apical cell surface, which 
appears to be restricted in number and becomes transiently exhausted during 
internalisation and recycling; a second, on lateral surfaces, which may provide a high 
binding capacity receptor allowing binding and uptake of large amounts of AAV5 
over an extended period of time. The nature of the binding sites used by AAV2 is 
still unknown (Hansen et al., 2001).  
Translocation to the nucleus  
Once the virus is internalised, the viral particle must uncoat and release the genomic 
DNA.  Studies of MVMp infection of EL4 lymphocytes have shown that after the 
internalisation, MVMp is released to the cytosol and migrates towards the cell 
nucleus (Previssani et al., 1997), wherein several steps of the replication cycle occur, 
including viral DNA amplification, capsid assembly and viral ssDNA packaging.  
Ros et al. (2002) postulated that the uncoating takes place during the free cytosolic 
transport of the virus to the nucleus and/or inside the nucleus.  Ros et al. (2002) have 
suggested that MVMp is not directly released to the cytosol but passes through 
several endosomal compartments before it is released.  Studies by Tullis et al. (1993) 
have indicated that there are nuclear localisation signals present in the regions 
encoding VP1 and VP2 that are essential for the transport of the intact or partially 
uncoated capsids to the nucleus.  
Synthesis of a double-stranded replicative form (dsRF) DNA  
The genomic ssDNA released from the virions is converted into a dsRF, detected 
during studies of MVM (Dobson and Helleiner, 1973). The palindromic termini of 
the MVM genome interact with the synthetic machinery of the host cell using 
cellular proteins and a pleiotropic virally coded NS1 protein to establish a type of 
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unidirectional single strand synthesis (Tattersall and Ward, 1976; Baldauf et al., 
1997) followed by the amplification of dsRF (Cotmore and Tattersall, 1995).  
Replication initially proceeds rightwards from the left hydroxyl terminus of the 
hairpin stem.  All known DNA polymerases require a primer to start the synthesis of 
a polynucleotide chain, and in the case of the autonomously replicating parvoviruses, 
MVM and MPV-1 included, the right hairpin region serves as the primer (Astell et 
al., 1985).  This allows a host cell polymerase to add nucleotides to the right 
hydroxyl end, and synthesise a complementary copy of the viral genome until the 
growing strand reaches the folded back left terminus at the right end, resulting in a 
covalently closed DNA RF (cRF) (Baldauf et al., 1997). Since it is one continuous 
strand, it renatures spontaneously after denaturation (Tattersall et al., 1973). The 
process has been named “rolling hairpin” replication because instead of progressing 
continuously around a circular template, the replication fork is flipped back and 
forward along the linear genome by sequential synthesis and rearrangement of the 
palindromic viral termini. 
Further processing involves the opening of the cRF at its right end by the NS1, 
which attaches covalently to the newly generated 5 left end at the nick site via a 
phosphor-tyrosine bond (Cotmore and Tattersall, 1988), followed by displacement 
and copying of the right end hairpin giving rise to an extended molecule designated 
5’ (eRF) (Cotmore and Tattersall, 1988, 1989; Willwand et al., 1998; Cotmore et al., 
1992, 1993).  NS1 protects the RF DNA from left-to-right exonuclease activity and 
therefore protects the viral sequence from progressive degradation after excision 
(Rhode and Paradiso, 1989).  Host cell accessory proteins are required for the site- 
and strand-specific nicking of both the left- and right-end MVM origins, including 
PIF for the NS1 nickase activity (Christensen et al., 1997) and high mobility proteins 
for activation of the viral protein at the right-end origin (Cotmore and Tattersall, 
1998).  
Astell et al. (1985) established that the sequences of the right termini of all the RF 
DNA molecules in the replication pool were in one orientation, identical to that of 
the parental viral genome, whereas the left termini of the virion DNA contained 2 
sequences. They also determined that the left end of the monomer RF was 18 base 
pairs (bp) longer than expected, and they concluded that the V-strand of DNA in the 
RF molecule contained 18 nt that are not present in the V-strand DNA extracted 
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from virus particles.  They, therefore proposed a modified rolling hairpin model for 
the replication of autonomous parvovirus DNA, which they claimed was consistent 
with all the sequence and biochemical data available at the time (Figure 2.11).   
 
 
Figure 2.11. Modified rolling model for autonomous parvovirus DNA replication. Step1, the 
incoming V strand is extended by a DNA host polymerase; Step 2, the left hairpin is 
displaced, Step 3, a rabbit-eared structure is formed; Step 4, the dimer RF is produced as a 
result of the displacement synthesis; Step 5, the site-specific nick is introduced and extension 
of the V-strand occurs in a left-right direction; Step 6, the right palindrome is displaced and 
folded up into a hairpin configuration, the site-specific nick remains covalently attached to 
the left end of the nicked DNA, after the second nick opposite the hairpin, the nickase 
reseals a complete 3’ hairpin and V-strand synthesis occurs by repeated displacement of V 
strands on a C-strand template; Steps 7 and 8, the sequence orientation at right end of V 
strands is retained, whereas hairpin transfer results in 2 sequence orientations at the left end. 
The 2 sequences at the left end are related in that one is the inverted complement of the 
other. V strand represents the parental virion strand, C strand the complementary DNA 
strand. From Astell et al. (1985). 3’ refers to the right half of the genome and 5’ refers to the 
left half of the genome.  
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Synthesis and encapsidation of the progeny ssDNA  
Generation of MVM progeny ssDNA is related to the availability of assembled 
MVM capsids, and the progeny virus ssDNA is synthesised during encapsidation of 
the DNA (Cotmore and Tattersall, 1995, 1996).  To produce progeny DNA, NS1 
nicks at the 5’end of the viral genome and stays covalently linked to it (Cotmore and 
Tattersall, 1988; Nuesch et al., 1995).  The resulting 3’ end at the nick site serves as 
a primer.  The DNA polymerase then copies the strand opposite to the nick, 
displacing from the template the strand to be packaged.  The 5’ end then is expected 
to be recognised by capsid proteins that progressively wrap the 3’ and not the 5’ end 
of the DNA (Willwand and Hirt, 1993). In vitro resolution of the dimer bridge of 
MVM genome supports the modified rolling hairpin model for MVM replication. 
The processes where the viral NS1 protein is required to generate progeny mRF 
molecules followed by extension leading to higher-order concatemers is summarised 
in Figure 2.12 (Brunstein and Astell, 1997).  
 
 
 
Figure 2.12. The roles of NS1 in resolving of the dimer bridge during MVM replication 
cycle. Step 1, monomeric genome is extended from the base-paired 3’ terminus; Step 2, 
displacing and extending the left hairpin structure (mRF); Step3, the extended hairpin 
termini undergo rearrangement to self-associate; Step 4, affording a primer for further 
extension to a dimer-length molecule (dRF); Step 5, further rounds of terminal 
rearrangement as in step 4 and extension to higher-order concatemers, or asymmetric 
resolution by site-specific nicking by NS1 (shaded arrows) and ligation to generate the forms 
in steps 6a and 6b; Step 6a, this form is identical to the form in step 3 and may be used to 
continue the cycle; Step 6b, this form serves as a template to generate viral progeny by site-
specific nicking by NS1 (shaded arrow) and Step 7, hairpin transfer; Step 8, encapsidation of 
the upper progeny strand. The cycle continues as a mature genome (step 1) allows the lower 
strand to regenerate.  From Brunstein and Astell (1997). 
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After VP1 and VP2 self-associate, the viral genomic DNA is packed into the 
preformed capsids where the 5’ oligonucleotide sequence of ~ 24 nucleotides 
remains located on the external surface of the mature virion (Willwand and Hirt, 
1993). Therefore, more than 99.5% of the packaged ssDNA within the viral particles 
is protected from the external environment by capsid proteins, except for the 24 
nucleotides of the NS1 that project through the capsid structure and remain 
accessible to proteases and nucleases in the external medium. 
Murine parvoviruses package a single negative-sense copy of the linear ssDNA 
(Bates et al., 1984; Cotmore and Tattersall, 2005). The replication origins rather than 
sense-specific packaging signals seem to determine the polarity of strands selected 
for encapsidation. Chimeric virus was generated by fusing 95% of the MVM 
sequence with the right-hand terminus of LuIII (Cotmore and Tattersall, 2005) and it 
appeared to package >40% positive-sense DNA. On the other hand, MVM 
encapsidated predominantly negative-sense ssDNA and LuIII encapsidated strands 
of both polarities (Berns and Hauswirth, 1978). It was therefore speculated by 
Cotmore and Tattersall (2005) that the proportion of single strand negative-and 
positive-sense DNA displaced from the duplex replication intermediates during the 
packaging phase of viral DNA amplification is determined by the 2 telomeric 
origins.  They hypothesised that the displaced strands and replicating DNA 
complexes appear to serve as equivalent candidates for encapsidation, as suggested 
by the hairpin model proposed by Chen et al. (1989). 
Exit of virions from the nucleus   
What facilitates the exit of the formed virions from the nucleus is poorly understood. 
Electron microscopic studies have detected virus particles within the cytoplasm in 
the vicinity of nuclear pores at late phases of infection, suggesting that nuclear exit 
of progeny virions might result from an active transport process (Marato et al., 
2004). Additionally, the presence of virus in the cytoplasm has indicated the 
possibility of passive release of progeny virions from a degenerating nucleus (Siegl, 
1984).  
Marato et al. (2000) have shown that phosphorylation of the amino-terminus of VP2 
is critical for viral exit.  Miller and Pintel (2002) concluded that the NS2-Crm1 
interaction perhaps influences the nuclear location of a kinase or phosphatase, which 
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is then important for the critical modification of VP2.  Miller and Pintel (2002) 
hypothesised that NS2 is involved in egress of assembled capsids from the nucleus, 
probably by NS2 interaction directly with full virions through the Crm1 nuclear 
export factor-mediated pathway but were unable to demonstrate a direct interaction 
between NS2 and assembled capsids. They suggested that the NS2-Crm1 interaction 
might be important for the regulation of a cellular protein that is required for the 
nuclear export of the virus.  
Release of virions from infected cells 
The mechanism by which MVM particles are released from infected cells remains 
enigmatic.  Initially, mature DNA release was considered as a lytic process, resulting 
from the degeneration of both the nucleus and the cytoplasm, leading to the 
disruption of the plasma membrane and release of newly formed virions (Richards et 
al, 1977; Singer and Rhode, 1978; Jacoby et al., 1979; Jacoby et al., 1996). 
However, Miller and Pintel (2002) have indicated that parvoviruses can exit from 
cells prior to cell lysis, at least at early times of infection. Cotmore and Tattersall 
(1989) have demonstrated persistence of 2 forms of ssDNA of a mature virion that 
are released from the infected host cell into the surrounding medium (original parent 
cell), designated as S1 protein associated and S2 protein free. 
Replication kinetics 
As the kinetics of parvovirus replication in general depend on the host cell entering 
S-phase, virus production in cell cultures is normally not synchronous, and detailed 
kinetic analysis has been difficult.  With LuIII, it was shown that the parental ssDNA 
was converted into a dsDNA within 60 min after infection (Siegl and Gautschi, 
1976).  Viral transcription and translation result in the production of NS proteins and 
once produced, NS then up-regulates the synthesis of the NS and VP proteins, and a 
burst of viral genomic DNA replication occurs a short time later (Rhode, 1985; 
Doering et al., 1988, 1990; Hanson and Rhode, 1991). Ros et al. (2002) tried to 
elucidate the kinetics of MVM DNA replication by blocking specific cellular 
functions with various chemicals, and demonstrated that cytoplasmic trafficking of 
MVMp takes 7-8 h to be completed, and is followed by the interaction with cellular 
proteasomes (a multicatalytic proteinase complex implicated in the degradation of 
most cellular proteins) (Myung et al., 2001; Ros et al., 2002).  Nuclear accumulation 
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of viral DNA was detected 18 h post-infection, at about the time progeny virus was 
detected (Ros et al., 2002).  VP1 and VP2 self associate to form capsids, and viral 
genomic DNA is packed into these preformed capsids (Willwand and Hirt, 1993).  
 
2.8 Murine parvovirus infection in vivo 
Both MVM and MPV-1 are commonly detected in contemporary laboratory mouse 
colonies and there are clear differences between the pathogenesis of infection of 
mice with either variant of MVM (MVMi and MVMp) and MPV-1 (MPV-1a, MPV-
1b and MPV-1c (McKisic et al., 1993, Smith et al., 1993, Ball-Goodrich and 
Johnson, 1994, Jacoby and Ball-Goodrich, 1995).   
While MVMi is highly virulent and often lethal, MPV-1 appears to be non-
pathogenic even for neonatal and immunocompromised mice (Smith at al., 1993).  
MVMi replication is more widespread in immunodeficient mice (Segovia et al., 
2003). Infant mice are more permissive hosts for MVM infection than are adults, 
whereas adult mice are as susceptible as neonates to MPV-1 infection (Brownstein et 
al. 1992; Smith et al., 1993).  In situ hybridisation has confirmed the small intestine 
as a site of viral entry and early replication, but respiratory infection was also 
thought to be possible (Segovia et al., 1995).  MVM infection is thought to be acute 
and self-limiting, regardless of the age of the mice infected (Smith and Paturzo, 
1988), whereas MPV-1 infection can persist after seroconversion and viral DNA is 
detectable in lymphoid tissues for at last 9 weeks after infection (Jacoby et al., 
1995).  The persistence of MPV-1 in tissues that normally respond to a variety of 
antigenic stimuli could result in inappropriate immune response against the virus 
itself and/or other antigens (Jacoby et al., 1995; McKisic et al., 1996).  
Pathogenesis of MPV infection 
The route of entry for all natural murine and rat parvovirus infections is oral (Jacoby 
et al., 1988; Gaertner et al., 1993) although parenteral inoculation of parvovirus-
contaminated biological materials is another important entry route (Shek and 
Gaertner, 2002). Primary replication is in the digestive tract, and virus can be 
detected in small intestinal cells within 3 days of infection (Smith et al. 1993).  The 
primary site of MPV-1 replication appears to be the intestinal mucosa, following 
which and in the first week after infection the virus is disseminated to lymph nodes 
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(Jacoby et al., 1995; Shek et al., 1998).  In immunocompetent mice, besides 
replication in the small intestine and lymphoid organs, MPV-1 replication occurs in 
the pancreas (of neonatal mice) and liver and may persist for several weeks (Baker, 
1998).  
Initial studies indicated that passively or maternally acquired immunity can protect 
against MPV-1 infection but immunity to MVM variants may not confer cross-
immunity to MPV (Hansen et al., 1999). Based on initial transmission studies, MPV-
1 is thought to be transmitted primarily by faecal excretion and ingestion of 
contaminated material. Therefore, exposure to infected mice, their soiled cages, or 
contaminated personnel, surfaces or equipment that have been in contact with 
infectious mice are most important for transmission from animal-to-animal (Jacoby 
and Ball-Goodrich, 1995). There is no information available on vertical transmission 
with MPV-1. 
MPV-1 results in subclinical infection, which means that the infected animals do not 
show any outward signs of illness. Instead, the virus localises to epithelial tissue and 
silently begins to modulate immune response and alter growth patterns of rapidly 
dividing cells (McKisic et al., 1998; Jacoby et al., 2000). 
MPV-1 result in an apparently sub-clinical infection, which means the infected mice 
do not show overt signs of illness (Jacoby et al., 1979).  Infection is asymptomatic 
even in neonatal, infant and severely immunocompromised mice (Smith et al., 
1993). There is no pathology or histological lesions after experimental infection, 
despite the potential cytolysis that might occur during parvovirus replication (Smith 
et al., 1993; Jacoby et al., 1995; Ball-Goodrich et al., 1998).  
Under appropriate circumstances, infection can persist within individual animals, 
and thereby persist within in a population of animals (Gaertner et al., 1993).  
Persistent lymphocyte-tropic infection in adult mice by MPV-1 adds to concerns 
about potential adverse influences of murine parvovirus infections on immune 
function.  In this context, MPV-1 was shown to inhibit the proliferation of cloned T-
cells in vitro (McKisic et al., 1993). It has been suggested that infection may 
modulate the growth pattern of rapidly dividing cells (Redig, 2002). 
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Mouse strain variation and specificity of MPV-1 
Mouse strain variation in the susceptibility to MPV-1 has been reported depending 
on use of various assays (rNS1 ELISA, MVM ELISA, MPV IFA, MVM IFA, MPV 
HAI and MVM HAI), evaluated for their ability to detect virus-specific antibodies or 
viral DNA as well as on use of different antigens and a dose of the antigen 
(Besselsen et al., 2000): seroconversion was not detected in C57BL/6 mice; 
seroconversion was observed in all C3H mice, in some but not all BALB/c, ICR, and 
DBA/2 mice. That mice with a BALB/c background generate a poor antibody 
response to MPV has been confirmed by Khan et al. (2005). They have shown that 
BALB/cJ failed to generate antibodies against MPV-1 after a range of routes of 
infection including intranasal, exposure to contaminated bedding and gastric lavage. 
Only those mice inoculated by the intraperitoneal route alone produced MPV-1 
infection, detected by ELISA kits purchased from Charles River Laboratories that 
incorporated a recombinant structural protein VP2 (rVP2) from Research Animal 
Diagnostic Laboratory, University of Missouri (Livingston et al., 2002). However, 
more than one dose intraperitoneally was required to produce detectable MPV-1 
infection in this mouse strain. Inoculation of C57BL/6J has shown that this mouse 
strain generates an antibody response more readily than BALB/cJ mice (Khan et al., 
2005). C57BL/6J mouse strain was reported to rarely seroconvert to MPV 
(Besselsen et al., 2000).  
A predilection for lymphoid tissues in both adult and infant laboratory and wild mice 
is a characteristic of acute and persistent MPV-1 infection (Jacoby et al., 1996).  
During acute infection of immunocompetent adult mice, virus is dispersed in the 
lymph node but during persistent infection virus apparently localises in germinal 
centres. McKisic et al. (1996) have shown that MPV-1 infection of adult BALB/c 
mice accelerates tumour allograft rejection. They have also shown, based on in vivo 
experiments with adult BALB/c mice primed with ovalbumin and infected with 
MPV-1, that the spleen and popliteal lymph node cells had reduced proliferation 
responses, whereas the proliferative capacity of mesenteric lymph node cells from 
these mice was increased (McKisic et al., 1996). 
MPV-1 did not appear to inhibit the generation of cytotoxic T-cells in primary mixed 
lymphocyte cultures (McKisic et al., 1993). MPV-1 also diminished the proliferation 
rate of lymphocytes from spleen and popliteal lymph nodes, but augmented the 
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proliferative response of cells from mesenteric lymph nodes (McKisic et al., 1996; 
Jacoby et al., 1996).  
Host immunity to murine parvoviruses 
The onset of host immunity is marked by seroconversion but the relative importance 
of humoral versus cellular immunity in the host defences against murine 
parvoviruses has not been resolved.  A role for cell-mediated immunity in host 
defences against parvoviruses is implied from mononuclear cell infiltrations 
observed in parvovirus infections of rats (Gaertner et al., 1993) but functional 
evidence for cell-mediated immunity in parvovirus infection of mice has not been 
reported. In situ hybridisation studies have not demonstrated any mononuclear cell 
response during MPV-1 infection (Jacoby et al., 1995) but while this may indicate 
that cellular immunity plays a relatively minor role in infections, it also could 
indicate that MPV-1 suppresses or eliminates T-cells that would nominally respond 
to infection.  Preferential depletion of such T-cells also may facilitate persistent 
infection by compromising antiviral immune surveillance. It appears that preferential 
production of particular lymphokines in mouse models affects the outcome of the 
immune response to certain micro-organisms, resulting in resistance or susceptibility 
to disease (Heinzel et al., 1989).  
 
2.9 Diagnosis of parvovirus infections  
Although numerous techniques can potentially be used to detect parvovirus 
infections in animals and contaminated biological materials, serological (Jacoby et 
al., 1996) and PCR assays (Besselsen et al., 1995 a, 1995 b) are currently the most 
commonly used detection methods.  
Since parvovirus infections are generally asymptomatic, serological evaluations for 
presence of anti-parvovirus serum antibodies have provided valuable diagnostic 
methods (Riley et al., 1996; Jacoby et al., 1996).  Serological procedures do have 
limitations: they provide an indirect measure of past exposure to given parvovirus, 
but fail to identify an acutely parvovirus infected animal and do not give information 
regarding the current infection status of an animal before certain time post infection; 
they can only be used to test immunocompetent animals.  Common methods used 
include enzyme-linked immunosorbent assays (ELISA), indirect fluorescent 
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antibody assays (IFA), and haemagglutination-inhibition assays (HAI) (Smith et al., 
1993; Besselsen et al., 2000; Besselsen and Livingston, 2001). 
PCR assays can detect viral nucleic acid and differentiate between virus types if 
primers are designed to detect the appropriate type-specific regions of parvovirus 
DNA, thus PCR is providing information about the current infection status of 
animals.  Laboratories may also use PCR assays to test for environmental 
contamination as an aid in the detection of parvovirus-contaminated equipment and 
as a method of assessing the effectiveness of decontamination efforts after a 
parvovirus outbreak (Besselsen et al., 1995 a, 1995 b).  
Serological methods of diagnosis 
Results of serologic tests performed to monitor laboratory mice for murine 
parvovirus infections are dramatically more accurate now than in the 1970s when 
serologic testing was largely limited to complement fixation and HAI tests (Smith et 
al., 1982).  The improvements in methodology have revealed an unexpectedly high 
prevalence of infection with novel murine parvoviruses that were previously 
unknown.  For example, many sera from mice that had sustained infection with 
MPV-1 yielded uninterpretable results in the MVM ELISA tests, but were clearly 
positive when tested retrospectively by ELISA that used a recombinant VP MPV-1 
and by IFA using MPV-infected cells (Shek, 2003). 
Until the early 1980’s, the HAI was the principal serological method by which 
mouse and rat colonies were screened for antibodies to the 3 then known parvovirus 
serotypes: MVM and the rat viruses KRV and H-1 virus (Smith et al., 1982).  The 
HAI was considered a specific test, since it detected only the interaction of 
antibodies directed against a specific conformational epitope, the parvovirus 
haemagglutinin, which is distinct for each parvovirus species (Tattersall and 
Cotmore, 1986). The switch by many laboratories to more generic and sensitive 
solid-phase immunoassays, including the ELISA and the IFA, coincided with 
serological evidence suggesting the existence of additional novel parvovirus 
serotypes in both mice and rats (Smith et al., 1993).  
The ELISA has been preferred by larger laboratories due to its high throughput 
capability, with the IFA and HAI assays being considered more labour intensive 
(Smith et al., 1982).  Sensitivity varies and the ELISA and IFA are considered more 
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sensitive than HAI. Specificity also varies and the IFA will detect antibodies against 
both group-reactive and strain-specific protein antigens (Tattersall and Cotmore, 
1986) and therefore do not distinguish infection between different parvoviruses in 
rats and mice.  Although a study by Shek (2003) indicated that IFA was even more 
specific than ELISA, an ELISA using purified virions as antigen was considered to 
distinguish strains of parvoviruses, whereas an ELISA using infected cells as antigen 
could not because of the high degree of homology among non-structural 
polypeptides that are expressed in infected cells (Tattersall and Cotmore, 1986; 
Cotmore and Tattersall, 1987).  
Most laboratories screen sera with an ELISA or IFA assay to take advantage of the 
increased sensitivity of these assays, and then perform confirmatory testing, some 
with the HAI assay and some with IFA, to ensure the result is truly specific for the 
targeted parvovirus and therefore elucidate the true infection status of the animal 
(McMaster et al., 1981; Compton and Riley, 2001). However, a study by Smith et al. 
(1993) found that rodent colonies that had consistently been parvovirus negative by 
HAI were seropositive by IFA. 
Genus-specific and species-specific assays for the detection of murine parvoviruses 
have been developed with fluorogenic nuclease PCR technology (Kendall et al., 
2000; Redig and Besselsen, 2001; Besselsen et al., 2006). 
Murine parvovirus antigens 
For serological testing, especially for the detection of MPV-1, the choice of 
parvovirus antigen is critical.  The source of the diagnostic antigen used for 
serological tests has varied considerably among testing laboratories, ranging from 
whole virus to recombinant NS1 (rNS1) (Riley et al., 1996) and recombinant VP2 
(rVP2) proteins (Livingston et al., 2002). 
Whole virus antigens derived from cell-culture-propagated murine parvoviruses have 
been available for many years.  Cell-culture-propagated MVM as an antigen for IFA 
has been available since 1983 (Smith, 1983).  An ELISA that utilises cell culture-
propagated MVM as antigen has been available for detection of MPV-1 infection 
since 1986 (Kraft and Meyer, 1986).  IFA and HAI assays that use cell-culture-
propagated MPV antigens have been available since 1993 (Smith et al., 1993).  
45 
A considerable advance has been the use of rNS and rVP MVM and MPV-1 
antigens. ELISAs that use baculovirus-expressed rNS1, baculovirus-expressed rVP1 
MVM (Riley et al., 1996) and MPV (Livingston et al., 2002), and ELISA that uses 
E. coli strain BL21 MPV VP2 (Ball-Goodrich et al., 2002) as antigen are now 
available.   
Methods used for the production of MVM and MPV-1 antigens 
For several decades, MVM antigens have been generated by infecting susceptible 
cell lines (A92L, BHK-21, and NB324K) as it replicates well in cell culture and 
produces highly concentrated antigen preparations (McMaster et al., 1981). This 
antigen has worked well for the detection of MVM by ELISA, IFA and HAI formats 
and has also been used for serodiagnosis of MPV infections (Smith et al., 1982; 
Kraft and Meyer, 1986). The MVM antigen displayed cross-reactivity with 
antibodies directed against MPV-1 and it was used to provide evidence for the 
existence of MPV-1 even prior to the initial isolation pf MPV-1 in the early 1990s 
(McKisic et al., 1993). This cross-reactivity was primarily due to the antigenic 
similarities of the NS proteins of MPV-1 and MVM and reflected the high degree of 
homology among the NS proteins of the rodents of the rodent parvoviruses 
(Chapman and Rossmann, 1993). However, the serodiagnosis of MPV infections 
using MVM antigen-based assays has not always been effective and has several 
disadvantages (discussed below). 
A potential improvement in the development of MPV-1 antigens occurred when 
MPV-1b was successfully propagated in CTLL-2 murine cytotoxic T-cells, and this 
propagated virus was used as antigen to detect anti-MPV-1 antibodies (Besselsen et 
al., 2000).  However, high titre stocks of MPV-1 were extremely difficult and 
expensive to obtain in this system and largely precluded the use of cell culture-
derived MPV-1 antigens for routine ELISA (Smith et al., 1993). 
The method used to prepare MVM antigens from virus-infected cell cultures 
(Besselsen et al., 2000) impacted on the sensitivity in ELISA and IFA assays and 
their ability to detect MPV-1. It was suggested that this was because cell culture 
preparations used to prepare ELISA antigen were allowed to go to complete 
cytopathic effect (CPE), while IFA antigen preparations were harvested after only a 
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few days to keep the cells intact so that antibody localisation (nuclear and/or 
cytoplasmic) could be visualised.   
Studies have shown that any ELISA that used whole-virus preparations of MVM as 
an antigen lacked specificity in detecting antibodies to then novel orphan rodent 
parvovirus species then designated mouse orphan parvovirus (but now designated 
MPV-1) because of the antigenic cross-reactivity between them.  MVM prepared 
from cell cultures required secondary testing with MVM- or MPV-1-specific HAI 
assays to elucidate the true infection status of the animal (McMaster et al., 1981). 
Recombinant MVM and MPV-1 NS protein antigens 
To standardise the amount of NS protein in MVM ELISA antigen preparations and 
to develop a sensitive serologic assay that could be useful to identify rodents with 
any of the murine parvovirus species, recombinant protein technology was applied.  
When NS1 was cloned into a baculovirus expression system and used as ELISA 
antigen (Riley et al., 1996), the antigen prepared provided significantly improved 
sensitivity in detection of MPV-1 antibodies, relative to whole parvovirus antigens. 
The rNS1 ELISA provided 93% sensitivity in detecting MPV-1-positive serum 
samples, whereas the whole virus MVM ELISA had only 26.4% sensitivity. 
Unfortunately, although rNS1 MVM ELISA could identify rodents infected with any 
parvovirus species, the antigen lacked specificity. NS proteins are highly conserved 
among all rodent parvoviruses and therefore there is a possibility that a parvovirus 
distinct from MVM was causing the infection (Riley et al., 1996).   
Another problem with the NS protein antigen was the inability of rNS1 MVM 
ELISA to detect anti-MPV-1 antibodies in adult mice (Besselsen, 2000).  Mice 
experimentally inoculated with MPV-1 after 12 weeks of age developed anti-VP 
antibodies more so than anti NS1 antibodies (Besselsen et al., 2000).  Besselsen et 
al. (2000) suggested that NS proteins, including NS1, were not present in the 
parvovirus virion and were produced more transiently upon infection; an 
undetectable anti-NS1 humoral immune response could result from a non-productive 
parvovirus infection or from a productive infection that produces an insufficient 
amount of NS1 to induce an immune response.  
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Recombinant MPV-1 and MVM VP proteins 
As a result of the problems associated with using MVM rNS1 antigen to detect 
seroconversion to MPV-1, recombinant structural proteins have been trialled.  
ELISA assays that utilise baculovirus-expressed MVM and MPV rVP2 (Livingston 
et al., 2002) and bacterial expressed (E. coli strain BL21) MPV VP2 (Ball-Goodrich 
et al., 2002) as antigens have recently been developed. As indicated by the 
preliminary data in both naturally and experimentally infected mice, these antigens 
have not only overcome the problems of generating cell culture propagated MPV-1 
antigen but significantly improved both the sensitivity and specificity of MPV-1 
antibody detection relative to results using the NS1 ELISA (Livingston et al., 2002).  
When compared directly in a commercial laboratory, bacterial-expressed MPV VP2 
ELISA had higher sensitivity (90.3% versus 65%) than and similar specificity 
(98.3% versus 99.6%) to the MVM rNS1 ELISA (Ball-Goodrich et al., 2002). The 
baculovirus-expressed rVP2 MPV-1 was more sensitive and specific than MVM 
rNS1 ELISA in detecting MPV-1-infected mice. Similarly, an ELISA utilising a 
baculovirus-expressed MVM rVP2 antigen has been developed and also displayed 
improved sensitivity as compared to the NS1 ELISA for detecting mice naturally and 
experimentally infected with MVM. The 2 serological assays described seemed to 
provide rapid and accurate methods for screening research mouse colonies for MVM 
and MPV-1 infections (Livingston et al., 2002).   
A potential advantage of screening for MPV-1 antibodies using the rVP2 ELISA was 
that the major capsid VP2 protein can be presented to the immune system upon 
exposure to the virus or during viral replication.  It might be expected that mice 
would seroconvert more quickly to the VP2 protein than to the NS1 protein, and be 
more advantageous in screening for recent MPV-1 infection and infection of mice 
infected as adults (Besselsen et al., 2000).  
Baculovirus-expressed rVP2 proteins including those of MVM and MPV-1 self-
assemble into virus-like particles (VLP).  Their morphological similarity to empty 
parvovirus capsids with conformational epitopes presented on their exterior was 
thought to enhance the sensitivity and specificities of the MVM and MPV-1 ELISA 
over those that would be attained with unassembled MVM rVP2 or MPV rVP2 
proteins as antigens (Livingston et al., 2002).  While the formation of VLP may 
contribute to the high sensitivities of the MVM and MPV-1 ELISA, the formation of 
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MVM and MPV-1 VLP from MPV-1 and MVM rVP2 seems to be associated with a 
decrease in the specificities of the WIB assays that utilise these antigens.  Western 
immunoblots with the baculovirus-expressed MVM and MPV-1 rVP2 revealed 
evidence of a strong cross-reaction of sera from MPV-1-infected mice with MVM 
rVP2 proteins, which was not seen within the ELISA (Livingston et al, 2002).  The 
hypothesis for this observation (Livingston et al., 2002) was that the MVM rVP2 and 
MPV-1 rVP2 VLP behave antigenically like whole virions and anti-VP antibodies 
were able to associate only with antigenic epitopes present on the exterior of the 
VPL.  When the VLP were subjected to denaturing during SDS-PAGE and Western 
immunoblotting procedures, this possibly exposed cross-reactive epitopes. 
Polymerase chain reaction (PCR) for diagnosis 
PCR represents a rapid, specific, and sensitive assay that is less labour-intensive, less 
expensive to perform and has a faster turnaround time than most serological assays.  
Although they have many advantages, there are also several critical aspects to 
success that need to be considered, including (1) where in the animal is the virus 
replicating and which tissue should be selected for assay, (2) how to prevent false 
positive results due to contamination, and (3) the prevention of false negative results 
due to the presence of PCR inhibitors in the samples assayed.  Prevention of false 
positive results secondary to contamination with DNA template or PCR product 
requires appropriate decontamination of instruments with bleach between collection 
of tissues, excellent bench top laboratory technique, and separate areas for DNA 
isolation, PCR set up, and PCR product analysis (Walter et al., 2004).  
Given the limitations of serological methods for detecting rodent parvovirus 
infections, Besselsen et al. (1995 b) developed a series of PCR assays that enabled 
rapid detection and differentiation of rodent parvoviruses.  All PCR primer sets were 
designed on the basis of DNA sequence comparisons of the rodent parvoviruses for 
which sequence data were available, with genus specific assays based on the 
conserved NS genes (Besselsen et al., 1995 b) and species-specific assays that target 
heterologous regions in the viral capsid (VP1/VP2) genes are highly variable among 
rodent parvoviruses and useful to identify which species is present (Besselsen, 
1998).  It is evident however, that careful selection of the region of the genomes used 
for primer design is essential.  A genus-specific PCR assay developed by Taylor and 
Copley (1993) to detect KRV infection in rats was unable to distinguish between 
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KRV and H-1 as the primers utilised were based upon the DNA sequence at the 3’ 
terminus of the parvovirus genome, a region that is conserved within the rodent 
parvoviruses.   
Besselsen et al. (1995 a) developed a PCR assay specific for detection of the newly 
identified parvoviruses MOPV, HOPV and LuIII.  It was able to distinguish these 
viruses from the prototypic rodent parvoviruses MVM, H-1 and KRV by using an 
oligonucleotide primer set designed on the bases of the DNA sequence at the 
conserved 5’ terminus of the parvovirus genome. 
Since both MVM and MPV-1 can be detected in the enteric tract, display 
lymphotropism and MPV persistence in the mesenteric lymph nodes was observed 
for at least 9 weeks, intestines, spleen, and lymph nodes are considered the best 
tissues from mice for PCR analysis, although results from the small intestine 
appeared to be inconsistent (Jacoby and Ball-Goodrich, 1995). 
 
2.10 Effect of murine parvovirus infection on immune function   
The effects of murine parvoviruses on research are attributable to their predilection 
for mitotically active cells (McKisic et al., 1996). Distorted immunological and 
biological responses are found whereas they depend on cell proliferation, particularly 
in the areas of immunology, transplantation, and oncology (McKisic et al., 1993).  
Murine parvoviruses can also interfere with research progress by contaminating cell 
cultures and tissues of mouse origin (Nicklas et al., 1993).  
Host immunomodulation by MPV-1 
Data from investigations of the pathogenesis of MPV-1 in several strains and ages of 
mice have collectively indicated that MPV-1 infection significantly and persistently 
affects the immunological response (McKisic et al., 1996). The immunomodulatory 
effects are dependent on genetic factors unique to different mouse strains and also 
differ among different lymphoid tissues within the same mouse strain.  For example, 
MPV-1 potentiates and accelerates rejection of allogeneic and syngeneic skin grafts 
in BALB/c mice by altering the T-cell dependent immune response, while infected 
C3H/HeSn and C57BL/6 mice do not reject syngeneic skin grafts (McKisic et al., 
1993, 1996, 1998). 
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The immunosuppressive properties of MPV-1 have been characterised by (i) reduced 
cytokine and antigen induced T-cell proliferation in vitro, without affecting cell 
viability, suggesting that infection need not to be lytic to alter effector functions 
(McKisic et al., 1996), (ii) poor growth of CD8+, CD4+, and g/d T-cell clones 
((McKisic et al., 1993), (iii) inhibition of proliferative responses of CD8+ and CD4+ 
(particularly Th0 and Th1) T-cell clones in response to IL-2 or antigen in vitro 
(McKisic et al., 1993) and (iv) induction of interferon production (McKisic et al., 
1993). 
Tumour suppression associated with MPV-1 
Parvoviruses including murine parvoviruses have generally been found to be tumour-
suppressive in cases where the relationships between parvoviruses and cancer, 
tumour or transformed cells have been studied.  Tumour suppression by MPV-1 has 
been demonstrated for hybridoma and sarcoma cells and was postulated to occur 
either as a consequence of increased lytic viral infection of susceptible tumour cells, 
a consequence of increased replication of virus in the mitotically active cells in the 
tumour, or by enhancement of immunity to tumour cells (McKisic et al., 1993, 
1996). 
 
2.11 Control of murine parvovirus infections in laboratory mouse 
colonies 
Serological evidence strongly suggests that MPV-1 causes natural infection in mice 
(Smith et al., 1993; Jacoby and Ball-Goodrich, 1995) and as mice are widely used 
for biomedical research and as MPV-1 affects the immune function including 
augmentation or suppression of the humoral and cellular immune responses of the 
MPV-1 infected mice (McMaster et al., 1981; McKisic et al., 1993; McKisic et al., 
1996; McKisic et al., 1998), the availability of MPV-1-free mice for use in research 
is essential (Jacoby and Lindsey, 1998). As a result of frequent parvovirus-associated 
complications of research, there has been immense pressure from the research 
community to develop parvovirus-free colonies. 
Retrospective serological surveys have indicated that MPV-1 infection circulated in 
mouse colonies in the USA for at least 30 years before it was recognised.  In the 
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early 1970s, even though only 7% of tested sera contained antibody against the 
MVM antigen then used in serological assays, the prevalence of MPV-1 infection 
possibly approached 40% (Jacoby et al., 1996).   
There are several reasons for the discovery of MPV-1.  First, it can be attributed to a 
change from virus-specific assays such as HAI, which utilised purified virions as a 
substrate and detected surface structural proteins, to those that use infected cells as 
an antigen substrate, and even more recently to those that use recombinant NS or VP 
proteins.  In colonies where known rodent parvoviruses had been eliminated, this 
resulted in the recognition of seroconversion to other viruses that share antigenically 
cross-reactive NS proteins with those of the known parvoviruses (MVM, RV and 
Toolan H-1 virus).  Second, they were detected during research involving 
transplantable neoplasms, in tissue cultures or other derivatives of biological 
material obtained from mice with inapparent infections.  Third, they were recognised 
or suspected to occur due to the increased microbiologically pristine environment of 
rodents that led to recognition of agents of lesser pathogenicity than MVM 
(Besselsen et al., 1996). 
The key for control of any pathogen is effective detection and therefore effective 
monitoring programs; if these do not exist then detection is difficult especially when 
the pathogen does not cause any overt clinical disease.  Regular health monitoring, 
serological surveillance and maintenance under strict barrier protocols are essential.  
Also important is knowledge of the pathogenesis and epidemiological characteristics 
of the infection so that appropriate diagnostic tests can be applied (Livingston and 
Riley, 2003). Prevention and control of MPV-1 infection is made difficult by the 
persistence of MPV-1 in mice, its potential for provoking immune dysfunction, and 
the resistance of murine parvoviruses to environmental inactivation.   
Routine monitoring for virus exposure has been accomplished by serologically 
testing serum samples for MPV-1-specific antibodies.  Serology is used because 
antibodies are persistent and assays for their detection are rapid, sensitive and 
specific when performed properly.  Early serologic tests, such as HAI, have been 
supplanted by ELISA and IFA, which are extremely sensitive and depending on the 
antigen used, more or less specific, and both performance and processing of results 
can be automated.  IFA assays are the most commonly used secondary serological 
tests for samples positive for MPV-1 by ELISA.  PCR usually is reserved for 
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confirming serological test results and also for testing for environmental 
contamination and to assess effectiveness of decontamination efforts after an MPV-1 
outbreak (Livingston and Riley, 2003). 
As no diagnostic test is normally 100% sensitive or 100% specific, and there is 
always a chance of obtaining a false-negative or false-positive test result, 
confirmation of unexpected or unusual test results should always precede their use in 
making major colony management decisions (Livingston and Riley, 2003).  Options 
for confirmatory testing include repeating the same test or doing a suitable 
alternative test on the same sample or a new sample derived from the same animal, 
or conducting the same or different tests on samples collected from cohort animals.  
For example, if a serum sample tests positive for MPV-1 by ELISA, confirmation of 
the result by retesting the sample using alternative serological assays such as WIB or 
IFA tests was recommended by Livingston and Riley (2003).  Confirmation by non-
serological methods, such as PCR, is also possible. 
Monitoring protocols may utilise specific-pathogen-free (SPF) immunocompetent 
mice as sentinels, which are amenable to serological tests and act as sensors to 
document the MPV-1 status of a given mouse colony.  Sampling is set up to detect 
the agent in sentinel mice that have been exposed either via direct contact or through 
soiled bedding.  After exposure, these sentinel mice are sacrificed and their sera are 
tested by conventional immunoassays.  If the agent is detected in the sample group, 
even in a single individual, the inference can be made that the larger group, 
represented by the sample, is contaminated as well.  Of equal importance is the 
inability to detect MPV-1 under circumstances controlled for adequacy of the sample 
and detection technology (Weisbroth et al., 1998).  
Several factors need to be considered in MPV surveillance monitoring programs: the 
time of sample collection after infection, the interval between testing, and the strain 
of the sentinel mice (Barthold, 1998). An antibody response to MPV-1 is not 
detectable for at least 10 days following the initial exposure and differences in the 
susceptibility and response of different mouse strains to MPV-1 are known 
(Besselsen et al., 2000). 
The source of MPV-1 infection in a rodent facility can often be difficult to determine 
(Barthold, 1998). Pullium et al. (2004) suggested that commercially bred mice 
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intended for use as sentinels may arrive at animal facilities already infected with 
MPV-1, and introduction is most likely through the introduction of such animals. 
However, Shek et al. (2005) suggested that large-scale rodent production methods 
make it unlikely that vendor barrier rooms will have persistent low-prevalence 
parvovirus infection; they reported that MPV-1 infection in Charles River 
Laboratory barrier rooms rapidly reached a high prevalence and that such 
contaminations were detected quickly. 
Even with the use of best practises, animals readily become colonised with microbial 
forms by virtue of human contact (Jacoby and Lindsey, 1997).  As advised by Reuter 
and Dysko (2003), prevention of infection therefore requires the rigorous use of 
several barrier entry procedures: personnel entering mouse rooms must wear a 
disposable gown, hair net, surgical-type mask, shoe covers and gloves, and must 
change such garb if moving from room-to-room; mice should only be handled in a 
biosafety cabinet with gloved hands kept moist with disinfectant; animal transfers 
either between institutions, room-to-room or building-to-building need to be 
restricted; movement of animals to small groups of cages and sampling surplus or 
culled animals, especially retired breeders is another approach to infection control 
and elimination; environmental decontamination must be considered, and chemical 
disinfection of suspect animal rooms and heat sterilisation of caging and other 
housing equipment are prudent steps.  
Once infected, eradication is necessary.  If mice are not easily replaced from clean 
sources, the persistence of virus in the absence of transplacental transmission favours 
rederivation as a relatively rapid option to obtain uninfected stock.  Re-derivation of 
mice is usually done by using caesarean delivery and fostering to specific-pathogen-
free females (Weistbroth et al., 1998). Alternatively, if new stock is introduced into a 
facility, animals are typically held in quarantine and mixed with sentinels for a 
minimum of 10 days, during which time exposure of the sentinels to potential MPV-
1 infection through direct contact or dirty bedding transfer will occur (Reuter and 
Dysko, 2003).  
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2.12 Prevalence and detection of MPV-1 infections in Australia 
The prevalence of rodent parvovirus infections was always considered low in 
Australia, but moderate to high in the rest of the word in both mice (MVM, MPV-1 
infections) and rats (KRV, RPV, and Toolan’s H1 infection). MPV-1 was identified 
in the mouse stocks in the Animal Resources Centre (ARC) for the first time in 
February, 2001.  Despite an active serological testing program using the 
commercially available MVM rNS-1 antigen of USA origin in an ELISA, MPV-1 
infection was detected only when the Centre serendipitously tested a few faecal 
samples for MPV-1 infection by PCR (Dr David Pass, personal communication).  
The reason why there was no detectable serological response to the rNS1 antigen, 
despite the PCR evidence for infection, was not known. With hindsight, however, 
there had been suggestions that MPV-1 could be present as there were anecdotal 
reports from clients in the preceding 3 years of inconsistencies in immunologically-
based research using ARC-derived mice that might suggest MPV infection. 
 
2.13 Mouse strains maintained at the Animal Resources Centre used 
in this research 
Details of the husbandry methods and quality control programme utilized by the 
Animal Resources Centre are available at www.arc.wa.gov.au. The nomenclature 
used is that utilised by the Animal Resources Centre (www.arc.wa.gov.au). 
Outbred Swiss ARC(s)  
This strain is maintained as an outbred population. The colony was originally bred 
from CD1 stock from Charles River Breeding Laboratories, Kingston NY. 
Hsd:NIH 
This strain is maintained as an outbred population. 
C57BL/6JArc 
The population of mice used in this study was bred from mice received from the 
Jackson Laboratory in 1998.  
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BALB/cArc 
This strain was originally obtained from the Animal Breeding Unit, University of 
Western Australia in 1981 and has been maintained as a closed inbred colony. 
BALB/cArc-Foxn1
nu/+ (inbred athymic nude) 
This strain has been maintained at the ARC as a closed colony since 1987. It is 
maintained by mating homozygous males to heterozygous females.   
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Chapter 3. Development of a recombinant MPV-1 fusion 
protein for use as an antigen in ELISA and Western 
immunoblotting  
 
Summary 
A recombinant biotyinylated AD protein based on a truncated VP1 protein of an 
Australian strain of MPV-1 was produced using the PinPoint
TM vector and an 
Escherichia coli expression system.  The protein was produced as an insoluble 
intracellular product within inclusion bodies, and was solubilised using urea. The 
protein was successfully utilised as an antigen for ELISA and Western immunoblots. 
High background levels of reactivity were successfully reduced by use of dried skim 
milk powder as a blocking agent.  
 
Introduction 
Mouse parvovirus type 1 (MPV-1) is known to naturally infect laboratory mice and 
is among the most prevalent infectious agents found in contemporary laboratory 
mouse colonies (Smith et al., 1993). Since MPV-1 infection does not result in overt 
clinical signs, serology is the primary diagnostic method with the enzyme-linked 
immunosorbent assay (ELISA) most commonly used for the serologic evaluation 
(Riley et al., 1996; Livingston et al., 2002). 
An MPV-1 outbreak within the Animal Resources Centre (ARC) in 2001 was not 
initially recognised despite an active serological testing program using the 
commercially available recombinant non-structural MVM (rNS1 MVM) antigen 
sourced from the USA, but MPV-1 was detected by NS1 MPV-1 specific PCR when 
mice were serendipitously tested. The objective of the studies in this Chapter was to 
produce an antigen and use it to develop a specific and sensitive ELISA assay that 
could reliably identify MPV-1 infection within laboratory mouse colonies. The 
production and purification of a recombinant allotropic determinant (AD) region 
capsid VP1 protein antigen of an Australian strain of MPV-1, and use of the protein 
as an antigen in ELISA and Western immunoblotting (WIB) assays, to detect and 
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confirm MPV-1 antibody in sera of naturally and experimentally infected mice is 
reported.  
 
Materials and methods 
Source of MPV-1 DNA 
The MPV-1 DNA used was recovered from spleens of naturally infected outbred 
mice (Hsd:NIH) from the ARC. Mice were killed using carbon dioxide and spleens 
obtained using standard aseptic micro-isolation techniques in a class-II biological 
safety cabinet.  To prevent DNA contamination, instruments were soaked in ethanol 
and flamed between collections. After collection, spleens were stored separately in 
sterile 1.5 ml microcentrifuge tubes (Sarstedt) at -20ºC.  
DNA was extracted from faeces using a QIA amp DNA stool minikit (QIAGEN) 
according to the manufacturer’s instructions with the exception that the amount of 
the sample and reagents used was scaled down to half of that recommended. The 
extracted DNA was stored in 1.5 sterile tubes at -20ºC until needed. 
DNA was extracted from spleen and lymph node using a DNEasy tissue extraction 
kit (QIAGEN) according to the manufacturer’s instructions.  The extracted DNA was 
stored in 1.5 ml sterile tubes at -20ºC until needed. 
Construction of recombinant MPV-1a VP1 capsid proteins 
Oligonucleotide primers 
A series of oligonucleotide primers was designed to amplify the whole VP1 gene and 
7 fragments within the VP1 open reading frame as illustrated in Figure 3.1. This led 
to the production of 9 recombinant proteins, 4 encoded from non-overlapping and 5 
from overlapping fragments of the VP1 gene, as shown in Table 3.1. The purified 
VP1 plasmid diluted at 1:100 dilution served as a template. The primer sequences 
were selected on the basis of the sequence of MPV-1a available from Genbank, 
accession number MPU-12469. Oligonucleotide primers, listed in Table 3.2, were 
designed using Primer Designer software (Education and Scientific Software) 
checked by the Amplifier program (Macintosh edition) and synthesised by Proligo. 
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Figure 3.1. Schematic illustration of VP1 gene and VP1 gene fragments of MPV-1a. A, size 
of the clone sequence in nucleotides. B, VP1 gene showing the position of the VP1 clone and 
the fusion sites with The PinPoint
TM Xa-1 T-vector: 2271 indicates the VP1 nt binding to t
PinPoint
he 
TM vector sequencing primer and 4561 the VP1 nt binding with the SP6 promoter 
sequencing primer within the plasmid. Arrows indicate the series of pairs of oligonucleotide 
primers used to generate fragments within the VP1 gene sequence. Numbers 1-7 represent the 
number of VP1 fragments, which subsequent individual and combined amplification resulted 
in production of 9 recombinant truncated VP1 proteins. AD represents the 3 overlapping 
fragments 4+5+6 of the VP1 gene, which amplification and expression resulted in the rAD 
VP1 protein. 
 
 
Table 3.1. Designation of the VP1 gene fragments and predicted recombinant truncated 
proteins obtained by individual and combined fragment amplification. 
 
VP1 
fragments  
1 
 
2 
 
3 
 
3 + 4 
 
4 + 5 
 
5 + 6 
 
6 + 7 
 
7 
 
4 + 5 + 6 
 
Recombinant 
truncated 
proteins 
A B C D E F G H AD 
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Table 3.2. Primers used to amplify VP1 gene fragments.  All primers were designed based 
on the reported sequence of MPV-1a (Genbank MPU-12469). 
 
Product 
amplified (bp) 
Primer pair  Primer sequence  Position 
in MPV-
1a 
VP1 (2310)  VP1_2271F 
VP1_4581R 
5’-gAA CTT ggA CTA Agg TAC g-3’ 
5’-gAA AgA Aag AAC Atg gTT gg-3’ 
2271 
4581 
A   (396) 
 
VP1_2401F 
VP1_2797R     
5’-Agg TTg ggT ACC TCC Agg-3’  
5’-TTA TgT CTg AgT TCT TTg CTg Tg-3’         
2401 
2797 
B   (402)  VP2_2797F  
VP2_3199R 
5’- AAT gAg TgA Tgg CgC CgA-3’ 
5’-TTA gTT gTT ACA AAT AAA TTg CCA 
AT-3’  
2797 
3199 
C    (306)  VP2_3199F 
VP2_3505R 
5’-CAT gAG TCA TgT gAA TCT ACA-3’ 
5’-TTA CAT TgT gTC AAC AAT gCT TC-3’ 
3199 
3505 
D   (519)  VP2_3199F  
VP2_3718R     
5’-CAT gAG TCA TgT gAA TCT ACA-3’  
5’-TTA TAA AgT AgC ATT TTC gTT gTC-3’ 
3199 
3718 
E   (423)  AD_3505F   
VP2_3928R     
5’-ggC TAA TgC CAg Cgg gCT g-3’  
5’-TTA TgT gTA TCT TAg gCT gCC A-3’          
3505 
3928 
F   (423)  VP2_3718F  
AD _4158R     
5’-AgT AAC TAg Agg TgA CAg AT-3’ 
5’-CAg TTA gTg gTC CAT AgC-3’                      
3718 
4158 
G   (636)  VP2_3928F 
VP2_4561R     
5’-ATA TgA CAA ACA ACA Tgg TCA A-3’ 
5’-TTA gTA AgT ATT TCT AgC AAC a-3’        
3928 
4561 
H   (423)  VP2_4141F  
VP2_4561R     
5’-CTA Tgg ACC ACT AAC TgC TT-3’   
5’-TTA gTA AgT ATT TCT AgC AAC A-3’       
4141 
4561 
AD  (653)  AD _3505F  
AD _4158R     
5’-ggC TAA TgC CAg Cgg gCT g-3’   
5’-CAg TTA gTg gTC CAT AgC-3’                      
3505 
4158 
 
 
PCR amplification of MPV-1aVP1 fragments 
All reactions were performed in a 20 μl volume in an automated Thermal Cycler 
(Bio-Rad) using 200 μl flat-top PCR tubes (Sarstedt). All PCR reagents were 
purchased from Invitrogen. Each reaction contained 1 μl of the extracted DNA eluate 
as a template, 0.916 U Platinum Taq DNA Polymerase, 0.2mM of each dNTP 
(dATP, dCTP, dGTP, dTTP), 10X PCR buffer, 1.5 mM MgCl2, 20 pmol/μl of each 
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oligonucleotide primer and ultra-pure water to provide the final volume of 20 μl.  
Aerosol-resistant pipette tips were used for all preparation and handling of PCR 
reagents and DNA samples. The thermal cycling conditions used to amplify the PCR 
products are shown in Table 3.3.  
 
 
Table 3.3. Thermal cycling conditions used to amplify the VP1 region and the VP1 
fragments of MPV-1a. 
 
Cycles  Amplified regions   
  VP1  Fragments of VP1 
  1  95ºC for 2.5 min  94ºC for 3 min 
  95ºC for 0.5 min  94ºC for 0.3 min 
30  54ºC for 0.5 min  54ºC for 0.3 min 
  72ºC for 2 min  72ºC for 0.3 min 
  1  72ºC for 5 min  72ºC for 7 min 
 
Agarose gel electrophoresis of the PCR products 
The PCR products were electrophoretically separated in a 1.2% (w/v) electrophoresis 
grade agarose (Progen) containing ethidium bromide (Invitrogen) at 80 V for 
approximately 1 h using TAE buffer (1mM EDTA, 40 mM Tris-acetate, pH 8.0).  
Controls included a MPV-negative DNA sample and water as a template. 1 kb plus 
DNA molecular weight markers (Life Sciences) were run on each gel to facilitate 
determination of the sizes of the reaction products.  The gels were visualised by UV 
light using a UVP transilluminator (Bio-Rad). 
DNA recovery and purification from the dissolved gel slices  
To recover and purify the amplified PCR products, the bands of interest were excised 
in a minimal volume of agarose using a clean scalpel and purified using the Wizard 
PCR Purification System (Promega) in accordance with the manufacturer’s protocol.  
Competent E. coli JM109  
High efficiency competent E. coli JM109 (Promega) are endonuclease (endA) 
deficient, which greatly improves the yield and quality of isolated plasmid DNA; 
recombinant (recA) deficient, which improves insert stability; β-galactosidase 
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activity deficient, due to deletions in both genomic and episomal copies of the lacZ 
gene, which does not allow blue-white screening for recombinant plasmids; and have 
hsdR mutation, which prevents the cleavage of cloned DNA by the EcoK 
endonuclease system. The cells were stored at –70°C.  
PinPoint™ Xa-1 T-vector  
The PinPoint
TM Xa-1 T-vector System (Promega) provides a means to clone, express 
PCR products and purify fusion proteins that are biotinylated in vitro (Technical 
Bulletin No. 234, Promega). The vector is approximately 3.35 kb in length and 
carries a multiple cloning region for construction of fusion proteins and restriction 
sites downstream of the coding region for the biotinylated segment (Figure 3.2). The 
single 3’ T-overhangs at the insertion sites of the vector are stated to improve the 
efficiency of ligation of a PCR product into the plasmid (Technical Bulletin No. 234, 
Promega). 
 
Figure 3.2. PinPoint
TM Xa-1 T-Vector. The vector circle map included the following 
reference points: tac promoter 3202-3282; biotin purification tag coding region 1-386; 
Factor Xa protease recognition site 379-390; multiple cloning region 387-441; PinPoint
TM 
Vector sequencing primer binding site 325-343; SP6 promoter sequencing primer binding 
site 451-468; T7 RNA polymerase promoter 2796-2815; biotinylated lysine codon 262-264; 
β-lactamase (Ampr) coding region 919-1778 (derived from Technical Bulletin No. 234, 
Promega).   
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Ligation of the PinPoint
TM Xa-1 T-vector and PCR products 
Ligation of the PCR products into the PinPoint
TM Xa-1 vector was performed as 
specified by the manufacturer.  The ligation reactions were conducted in 1.5 ml 
sterile microcentrifuge tubes incubated overnight in a 15ºC water bath. The 
concentration of each DNA product was visually estimated by comparing the 
intensity and the area of each product to the 80 ng 1.65 Kb band of the 1 kb plus 
DNA marker (Life Sciences). To obtain optimal ligation, an approximate 4.5:1 molar 
ratio of the PCR products to the PinPoint
TM Xa-1 vector was used. The appropriate 
amount of PCR products (inserts) that should be included in the ligation reaction was 
determined using procedure recommended by the manufacturer: 
 
ng of vector x kb size of insert 
-------------------------------------   X  insert:vector molar ratio = ng of insert 
kb size of vector  
 
Transformation of E. coli JM109 with ligated PCR-PinPoint
TM Xa-1 vector  
The protocol used for transformation was as recommended by the manufacturer. 
Briefly, tubes containing the ligation products were centrifuged for 5 seconds in a 
microcentrifuge to collect the contents at the bottom of the tubes. A 2 μl volume of 
each ligation product was added to a tube with 50 μl of High Efficiency E. coli 
JM109. The tubes were gently flicked to mix the contents and immediately placed on 
ice for 30 min before the cells underwent heat-shock transformation for 45 seconds 
at 42°C. The transformed cells were then placed on ice for 2 min.  A volume of 950 
μl of SOC medium [2% (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2 (w/v), 20 mM glucose] was added to each sample that was 
then incubated with shaking at 37°C for 1 h.       
Selection of transformants 
To select transformants, 100 μl and 250 μl aliquots of both undiluted transformed 
cells and 1:2 dilution of the transformed cells were spread and grown on plates of LB 
agar containing ampicillin at a final concentration of 100 μg/ml. The recombinant 
clones were then selected after overnight incubation at 37°C. 
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Toothpick mini-preparations were used to produce small amounts of DNA for 
detection of clones. For each preparation, 10 single colonies of transformed E. coli 
JM109 were picked using sterile toothpicks into individual 1.5 ml sterile 
microcentrifuge tubes containing 50 μl PCR grade water. Then, a replica LB plate 
was made and each colony was transferred to a corresponding tube. The resuspended 
cells were heat treated at 90°C for 5 min with occasional vortexing to lyse the cells 
and then centrifuged (14,000 x g for 5 min). 
The plasmid DNA preparations were screened by PCR using either PinPoint
TM 
Vector sequencing primer or SP6 promoter sequencing primer and an appropriate 
oligonucleotide primer on either side of the inserts, as listed in Table 3.4. The 
content of each 20 μl reaction and the thermal cycling conditions for the primer sets 
used to amplify the 9 fragments of VP1 were the same as previously described under 
PCR amplification of MPV-1 VP1 fragments. 
 
Table 3.4. Oligonucleotide primers used to identify the clones containing the VP1 gene 
inserts in E. coli JM109. 
 
Inserts  Primer pair  Primer sequence 
A PinPointF 
VP2_3505R 
5’-CgT gAC gCg  gTg CAg  ggC g-3’ 
5’-TTA CAT TgT gTC AAC AAT gCT TC-3’                          
B PinPointF 
VP2_3928R 
5’-CgT gAC gCg  gTg CAg  ggC g-3’     
5’-TTA TgT gTA TCT TAg gCT gCC A-3’                            
C PinPointF 
VP2_4561R 
5’-CgT gAC gCg  gTg CAg  ggC g-3’    
5’-TTA gTA AgT ATT TCT AgC AAC a-3’                           
D PinPointF 
VP1_2797R    
5’-CgT gAC gCg  gTg CAg  ggC g-3’   
5’-TTA TgT CTg AgT TCT TTg CTg Tg-3’                             
E VP2_2797F   
SP6R          
5’- AAT gAg TgA Tgg CgC CgA-3’  
5’-Cg ATT Tag gTg ACA CTA Tag-3’                           
F PinPointF 
VP2_3928R          
5’-CgT gAC gCg  gTg CAg  ggC g-3’  
5’-TTA TgT gTA TCT TAg gCT gCC A-3’     
G PinPointF 
VP2_4561R 
5’-CgT gAC gCg  gTg CAg  ggC g-3’ 
5’-TTA gTA AgT ATT TCT AgC AAC a-3’                            
H PinPointF 
VP2_4561R          
5’-CgT gAC gCg  gTg CAg  ggC g-3’  
5’-TTA gTA AgT ATT TCT AgC AAC a-3’                             
AD PinPointF 
VP2_3928R           
5’-CgT gAC gCg  gTg CAg  ggC g-3’   
5’-TTA TgT gTA TCT TAg gCT gCC A-3’    
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Purification of plasmids 
Plasmids were purified with a QIAprep Spin Miniprep Kit (Promega) using the 
protocol described by the manufacturer. Briefly, a 3 ml volume of the overnight 
culture of transformed E. coli was centrifuged (5,000 x g for 10 min).  The 
supernatant was discarded and the pelleted bacterial cells resuspended in 250 μl of 
Buffer P1 (composition undisclosed) and transferred to a new 1.5 ml microcentrifuge 
tube. An additional 250 μl of Buffer P2, lysis solution (composition undisclosed) 
was added to the resuspended cells and mixed gently by inversion of the tube 4 to 6 
times. An additional 350 μl of neutralisation solution, Buffer N3 (composition 
undisclosed), was added and mixed immediately by a gentle inversion of the tube 4 
to 6 times. The solution was then centrifuged (13,000 x g for 5 min) and the resulting 
supernatant transferred to a QIAprep spin column, centrifuged (13,000 x g for 1 min) 
and the eluate discarded. The spin column was then washed with 500 μl of PB Buffer 
(composition undisclosed) to remove the trace nuclease activity of the host strain, 
washed again with 750 μl of Buffer PE (composition undisclosed) for 1 min, then the 
DNA eluted with 50 μl of Buffer EB, and clarified by centrifugation (13,000 x g for 
1 min). The purified plasmid was then stored as glycerol stock at -80ºC until 
required.  
Determination of orientation of the AD insert by restriction mapping  
The basis for determination of the orientation of the insert was determined by 
restriction endonuclease mapping and was based on the known sequence of the 
PinPoint
TM Xa-1Vector and VP1 sequence.  The endonuclease PvuII with the 
recognition sequence CAGCTG was chosen as there was one PvuII restriction site 
within the multiple cloning region of the PinPoint
TM Xa-1Vector and one PvuII 
restriction site within the AD.  After the plasmids with the in-frame ligation were 
purified, PvuII digestion was conducted.  Five μl of the plasmid were mixed with 1 
μl of NE Buffer 2, 0.5 μl of 10 units/μl of PvuII, and PCR grade water up to10 μl. 
After incubation for 1 h at 37ºC, 6X loading dye was added and the samples were 
electrophoresed in a 2% agarose gel with a 100-1,000 bp size standard marker (Life 
Sciences) using the protocol described in the above agarose gel electrophoresis of the 
PCR products section. 
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Small scale recombinant protein expression 
Freshly isolated clones of E. coli JM109 carrying the PinPoint
TM expression fusions 
were inoculated into 5 ml of Luria broth (LB) containing 100 μg/ml ampicillin and 2 
μM biotin, and incubated overnight at 37ºC with shaking.  The cultures were diluted 
1:100 by adding 50 μl to 5 ml of LB containing 100 μg/ml ampicillin and 2 μM 
biotin, incubated for 1 h at 37ºC with shaking, then expression induced by adding 
isopropyl-beta-D-thiogalactopyranoside (IPTG) (Sigma-Aldrich) to a final 
concentration of 100 μM, and further incubation for 5 h at 37ºC with shaking. 
Optimal induction times were determined for maximum expression of the AD 
recombinant protein. After induction at an A600 of ~0.4 (mid-log phase) expression 
of the recombinant AD production was evaluated for 6 h at 1 h intervals. One 
hundred μl samples of culture were transferred into 1.5 ml microcentrifuge tubes, 
centrifuged (13,000 x g for 5 min) and 50 μl of loading buffer added to each tube. 
The samples were heated at 90°C for 5 min in the presence of 10% w/v SDS and 
0.1 M 2-mercaptoethanol with occasional vortexing and 5 μl loaded onto 12.5% 
SDS-PAGE gels.  The gels were electrophoresed at a constant current of 200 V for 1 
h at room temperature or until the bromophenol blue tracking dye reached the 
bottom of the gel.  
To visualise and detect the induced biotinylated protein bands, the separated proteins 
were transferred onto a nitrocellulose membrane for WIB using the Bio-Rad semi-
dry horizontal electroblot apparatus at 15 V for 30 min at room temperature. 
Detection of recombinant proteins on the nitrocellulose membrane was performed as 
described in the Promega Technical Bulletin No.234.  Briefly, the unoccupied 
binding sites on the membrane were blocked with 0.5 % (w/v)] skim milk in TBST 
(TBS plus 1% Tween-20 [Sigma]) for 1 h at room temperature, with gentle agitation.  
The membranes were then washed 3 times with TBST, an initial quick rinse 
followed by 2 washes of 5 min each at room temperature with gentle agitation on a 
shaking platform. The blot was rinsed with TBST, then a solution consisting of 3 μl 
streptavidin-alkaline phosphatase and 15 ml of TBST was added to the membrane 
which was then incubated for 30 mins at room temperature with gentle agitation. The 
membrane was washed 3 times for 5 min each with TBST and rinsed very briefly 
with deionised water and Western Blue Stabilized Substrate for Alkaline 
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Phosphatase (Promega) was added and incubated at room temperature until purple 
bands appeared. 
In addition to the above, the expressed fusion proteins transferred to nitrocellulose 
membranes were also detected using ECL
TM WIB kit (Amersham Pharmacia 
Biotech), a light emitting non-radioactive method for detection of immobilised 
antigens. The methods used were as recommended by the manufacturer. 
Large scale protein production and purification  
Larger scale cultures for preparation of antigen were implemented by keeping the 
proportions of all components equivalent to those in the small scale cultures 
described above.  Bacterial cells were harvested by centrifugation (8,000 x g for 10 
min at 4ºC), resuspended in PBS and washed by centrifugation (8,000 x g for 10 min 
at 4ºC). The cells were then resuspended in 10 volumes of PBS and 0.1 volume of a 
lysozyme (Sigma) solution (10 mg/ml in 25mM Tris-HCl, pH8) added then stored at 
-20ºC at least overnight or until needed.  
To recover the recombinant protein, determined to be present predominantly within 
inclusion bodies within the bacterial cells, the bacterial suspension was thawed on 
ice and then sonicated by immersion of the ultrasonicator probe (Masonix Inc.) into 
the solution to about one-half the depth of the solution and then sonicating for 2 min 
on ice by using 15-second pulses with a 15 second pause between pulses. After 
sonication, the crude lysate was centrifuged (10,000 x g for 15 min at 4ºC). To 
remove contaminant proteins, the pellet was washed twice with 0.1% Triton X-100 
in PBS, and twice with 0.1% deoxycholate in PBS: all washing steps were achieved 
by centrifugation at 14,000 x g for 15 min at 4ºC), (O’Callaghan et al., 1998). The 
washed inclusion bodies were then solubilised by suspending them in extraction 
buffer (50 mM Tris-HCl [pH 7.5], 8 M urea, 1 mM dithiothreitol [Promega], 1 mM 
phenylmethyl sulfonyl fluoride [PMSF; Promega]) for 60 min at room temperature. 
The solubilised proteins were then diluted approximately 10-fold with extraction 
buffer so the final protein concentration was approximately 0.1 mg/ml, and dialysed 
overnight against a 100-fold volume of wash buffer (50 mM Tris-HCl, pH 7.5; 200 
mM NaCl).  The final dialysate was clarified by centrifugation (14,000 rpm for 30 
min at 4ºC). The concentration of the solubilised protein was determined by using 
Bio-Rad protein acidic dye binding assay as recommended by the manufacturer.  
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Indirect ELISA for identification of MPV-1 specific IgG in mice 
An optimal method for the indirect ELISA was determined as follows.  ELISA plates 
(Maxisorb; NUNC) were coated with 50 μl per well of 5 μg/ml streptavidin 
(Promega) in ultrapure PCR grade water (Fisher Biotec) uncovered overnight at 
37ºC. Fifty μl of Blocking buffer (1.5% dry skim milk in PBST [0.05% Tween-20 in 
PBS]) was added to each well and incubated for 1 h at room temperature and the 
buffer was then discarded.  The wells were then washed 3 times with PBST.  The 
solubilised antigen (above) was diluted to 3.538 μg/μl in PBST and 50 μl added to 
each well.  The plates were covered with a lid and left for 1 h at room temperature to 
allow the protein to bind to the plates. The wells were then washed 3 times with 
PBST. 
Fifty μl of 1:20 dilution in blocking buffer of each test and appropriate control sera 
were added to duplicate wells and incubated at room temperature for 90 min.  The 
plates were then washed 3 times in PBST and 50 μl of horseradish peroxidase-
conjugated goat anti-mouse IgG secondary antibodies (ICN) diluted at 1:1,000 in 
PBST was added to each well, and the plates were incubated at room temperature for 
1 h. The plates were washed 3 times in PBST, and then 50 μl of diluted horseradish 
peroxidase substrate (Bio-Rad) was added per well and plates incubated at room 
temperature for 10 min, then the reaction was stopped by the addition of 50 μl of 2% 
oxalic acid to each well.  The absorbance at a wavelength of 405 nm (A405) for each 
well was then determined using a microplate reader (Bio-Rad). The mean A405 was 
determined from the duplicate wells. 
A standard curve was established by testing the A405 values of known MPV-1 
positive sera. A pool of MPV-1 positive mouse sera was stored in small volumes and 
kept at -80ºC until use. Serial 2-fold dilutions of an initial 1:20 dilution were 
prepared and each dilution was added in duplicate to the wells of the first 2 columns 
of an ELISA microtitre plate.  The cut-off value was derived for each microtitre plate 
based on the value of the 3 SD above the mean of 30 randomly chosen MPV-1 
negative serum samples divided by the A405 value at 1:160 dilution of the positive 
curve.  To obtain a cut-off point specific for each individual plate, the obtained value 
was multiplied by the A405 value at a 1:160 dilution. 
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The source of the standard negative sera was from WIB-negative and PCR-negative 
Swiss mice, while the initial source of the reference MPV-1 positive sera was from 
naturally MPV infected Swiss mice, positive by the above methods; subsequently, a 
pool of sera from experimentally infected mice was used. All sera were tested in 
duplicate and the mean of the 2 values was used. 
Optimizing the indirect ELISA 
Three different blocking agents (EL-Rashdy et al., 2005) were used to try and block 
the often high background A405 levels that were obtained: (1) 2.5% casein in PBST, 
(2) 0.5% to 4.5% (0.5%, 1.5%, 2.5%, 3.5%, and 4.5%) dried skim milk powder 
(DSM; Diploma Instant) in PBST and (3) 2.5% bovine serum albumin (BSA; Life 
Sciences) in PBST. These were tested with 2 MPV-1 positive, 2 sera thought to be 
providing a MPV-1 false positive reaction (ELISA positive but Western immunoblot 
and PCR negative) and 2 MPV-1 negative sera, all at 1:20 dilutions.   
The optimal concentration of each batch of antigen was optimised by testing the 
standard MPV-1 positive control against 1:2, 1:5, 1:10, 1:15, 1:20, and 1:25 dilutions 
of the rAD antigen.  
Western immunoblotting  
Recombinant AD MPV-1 protein was mixed with an equal volume of 2X sample 
solubilisation buffer, heated at 90ºC for 5 min, and separated by SDS-PAGE using a 
12.5% separating gel as described above.  The proteins were electroblotted from the 
gel to nitrocellulose membranes as described above.  The membranes were then 
clamped into a Mini-PROTEAN II multiscreen apparatus (Bio-Rad) and 600 µl of a 
1:1,000 dilution of streptavidin A (Promega) or standard positive MPV-1 control and 
1:50 dilutions of the test sera and negative sera in TBST were applied into different 
channels of the multiscreen apparatus and incubated for 1 h at 37ºC.  The 
streptavidin A was removed by vacuum aspiration and this channel was washed 3 
times with TBST. Then, 500 μl of Western Blue stabilised substrate (Bio-Rad) was 
applied to the same channel and left for 2-3 min for colour development to occur.  
The sera were then removed by vacuum aspiration, the multiscreen apparatus 
disassembled and the membrane washed 3 times with TBST.  Horseradish 
peroxidase conjugated antibody (Sigma-Aldrich) was added to the membrane at a 
1:1,000 dilution and incubated with gentle agitation for 1 h at room temperature. The 
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conjugates were decanted, the blot was washed 2 times with TBST and once with 
TBS, then chromagen reagent (3 mg of chloronaphthalene [Bio-Rad] solubilised in 1 
ml of 100% methanol, 5 ml of TBS, 2 μl of H2O2) was applied to the blot. The 
membrane was left in dark for about 3 min or until the colour developed adequately. 
The reaction was stopped by rinsing the membrane under deionised water and the 
membrane then allowed to dry. 
Western immunoblots of VP1 truncated proteins were probed with sera from one 
juvenile ARC(s) and one juvenile BALB/c mice sampled 29 days PI with the 
Australian strain of MPV and reactivity determined by an ECL detection procedure 
(Amersham Pharmacia Biotech) following the manufacturer’s instructions.  The sera 
were diluted at 1:500 and the secondary antibodies used at a 1:5,000 dilution. The 
hyper-film ECL exposure was for 5 min. 
 
Results  
Determination of conditions for maximum expression of the recombinant AD 
protein 
The growth of E. coli containing the PinPoint
TM vector and control E. coli was 
exponential up to 5 h, after which a decrease in growth rate was observed. 
Thereafter, expression of the protein with IPTG was conducted for 5 h. The results 
from the optimisation of the induction time are shown in Figure 3.3.  
Generation of VP1 PCR products and cloning into PinPoint
TM Xa-1 vector  
Nine VP1 gene fragments were generated by PCR and these were all successfully 
cloned into the PinPoint
TM vector, transfected into and replicated in E. coli JM109. 
Yields of plasmid varied from 12.8 to 64 ng/μl (Table 3.5). 
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Figure 3.3. Determination of the conditions for maximum expression of the AD recombinant 
protein. After induction at the mid-log phase, growth of E. coli JM109 and rAD production 
were evaluated at 1 h intervals for 6 h. 
 
 
Table 3.5. VP1 gene fragments generated by PCR and cloned into PinPoint
TM vector, 
concentration of plasmids obtained in E. coli JM109, and molecular weight of the expressed 
proteins.  
 
Recombinant 
proteins 
A B C D E F G H AD 
Concentration of 
plasmids (ug/μl) 
32  19.2 12.8 38.4 44.8 32  19.2 19.4 64 
Fusion proteins 
molecular weight 
(kDa)  
27.5 27.5 24.5 32.5 28.5 29.1 37.5 28.9 37.1 
 
 
The constructs with a complete in-frame AD ligation were determined by PvuII 
endonuclease digestion of the plasmid which resulted in products of the expected 
size, 171 bp and 3897 bp (Figure 3.4).  
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Figure 3.4. Confirmation of the correct AD insert orientation of the VP1 PCR fragments 
cloned into PinPoint
TM Xa-1 T-Vector, by electrophoresis of endonuclease digested plasmid 
in 1.2% agarose gels. Lanes 1 and 12, 1Kb Plus DNA ladder; lanes 3 and 6, samples with 
correct insert orientation indicated by the presence of 171 bp and 3897 bp products obtained 
after PvuII digestion of the plasmid at 400 bp cut position of the PinPoint
TM Xa-1 T-Vector 
and at 153 bp cut position of the AD insert; lanes 5, 8, 9 and 10, samples with incorrect 
insert orientation indicated by the presence of a product of 601 bp in size. 
 
 
Expression of Pinpoint
TM constructs in E. coli JM109 
When transformed into E. coli JM109 and induced, protein products of the predicted 
size were obtained from all PinPoint
TM constructs, with the exception of the 
construct containing fragment 7. Constructs containing VP1 fragments 1, 2 and 3 
produced high levels of expression of proteins A, B, and C, respectively, although 
the A protein product showed evidence of degradation.  Constructs containing VP1 
fragments 3+4, 4+5 and 6+7 resulted in moderate levels of expression of proteins D, 
E and G, respectively.  Constructs containing VP1 fragments 5+6 and 4+5+6 
resulted in expression of low levels of proteins F and AD, respectively.  
Transformation of constructs containing VP1 fragment 7 grew well in the overnight 
culture but no protein expression was detected. The analysis of the relative 
expression of each biotinylated fusion protein determined on nitrocellulose 
membranes with streptavidin-alkaline phosphatase is shown in Figure 3.5. 
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Figure 3.5. Expression of the biotinylated fusion proteins demonstrated on a nitrocellulose 
membrane using streptavidin-alkaline phosphatase detection.  Lanes 1 and 12, migration of 
the molecular weight marker (kDa); lane 2, protein A, high level of expression; lane 3, 
protein B, high level of expression; lane 4, protein C, high level of expression; lane 5, 
protein D, moderate level of expression; lane 6, untransformed E. coli as a control; lane 7, 
protein E, moderate level of expression; lane 8, protein F, low level of expression; lane 9, 
protein G, moderate level of expression; lane 10, protein H, no expression; lane 11, protein 
AD, moderate level of expression.  The 22.5 kDa bands at the bottom of all lanes is biotin 
carboxyl carrier protein (BCCP), also detected in the control preparation containing the 
untransformed E. coli as it is the endogenous protein of E. coli, assumed to be non-specific. 
 
 
Antigenicity of recombinant proteins  
The antigenicity of the proteins was examined (Figure 3.6) and reactivity between 
the immobilised antigens and MPV-1 positive sera were detected with some but not 
all proteins. No reactivity of the MPV-1-positive sera with proteins A, C and D was 
detected, protein G showed low reactivity, proteins B, F and AD showed moderate 
reactivity and protein E appeared to be highly reactive and therefore highly 
antigenic.  
Based on yield and antigenicity, proteins B, E and AD were selected as potential 
antigens for serological tests. Preliminary analysis of the yield of the B, E and AD 
proteins was 32.8 μg/μl, 34.2 μg/μl, and 35.8 μg/μl, respectively. The protein 
expression and the antigenic response to the recombinant proteins are summarised in 
Table 3.6. 
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Figure 3.6. ECL detection of the antigenic response of a MPV-1 positive ARC(s) mouse 
serum to the fusion proteins A, B, C, D, E, F, G, H and AD. Lanes 1 and 12, molecular 
markers (kDa); lane 2, protein A, not antigenic; lane 3, protein B, moderate antigenicity; 
lane 4, protein C, not antigenic; lane 5 and 6, protein D, not antigenic; lane 7, protein E, 
high antigenicity; lane 8, protein F, moderate antigenicity; lane 9, protein G, low 
antigenicity; lane 10, protein H, not expressed; lane 11, protein AD, moderate antigenicity. 
The protein present at 32 kDa was present in all samples including controls and was likely to 
be a cellular protein. 
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Table 3.6. Summary of the expression and the antigenic response to the expressed 
recombinant proteins. 
 
Recombinant 
proteins 
A B C D E F G AD 
Level of 
expression 
High High High Moderate  Moderate  Low Moderate  Low 
Antigenicity  - Moderate  - - High  Moderate  Low  Moderate 
 
 
Solubility of recombinant B, E and AD recombinant proteins  
Fusion proteins B, E and AD were detected in the bacterial cell pellet after 
expression and not the supernatant after the cells were sonicated and then 
centrifuged, indicating that the proteins were insoluble. The results from the ECL 
analysis of the solubility of the fusion proteins B and E are shown in Figure 3.7. 
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Figure 3.7. Western blot comparison of proteins B and E solubility. Proteins B and E were 
electrophoresed in a SDS-12% polyacrylamide gel and analysed by ECL after initial 
expression and again after sonication. Lane 1, migration of the molecular marker; lane 2, 
protein B, detected in the cell pellet of the total protein before the sonication; lane 3, protein 
B, not detected in the supernatant fraction after sonication; lane 4, protein B detected in the 
pellet after sonication; lane 5, protein E, detected in the cell pellet of the total protein before 
the sonication; lane 6, protein E, not detected in the supernatant fraction after sonication; 
lane 7, protein E, detected in the pellet after sonication. 
 
 
ECL detection of VP1 truncated proteins with IgG secondary antibody in 
ARC(s) and BALB/c 
To verify whether any of the VP1 truncated proteins reacted with IgG antibody 
produced by ARC(s) and BALB/c in response to infection with the local strain of 
MPV-1, WIB analysis was performed using sera from mice 29 days PI. None of the 
truncated VP1 proteins was recognised by the BALB/c sera tested, while ARC(s) 
sera recognised proteins B, E, F and AD but not proteins A, C, D, G and H (Figure 
3.8).    
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Figure 3.8. Use of ECL immunodetection to compare the reactivity of sera from MPV-1 
infected ARC(s) and BALB/c mice against the 9 Western blotted VP1 truncated proteins. 
Sera were obtained from infected mice 29 days PI and horseradish peroxidase-conjugated 
anti-IgG was used as a secondary antibody for detection. Sera from the ARC(s) mice reacted 
with the proteins B, E, F and AD but not proteins A, C, D, G and H.  No proteins were 
detected by sera from BALB/c mice. The size of the MW markers is indicated on the LHS. 
 
 
Development of ELISA  
Comparative antigenicity of recombinant proteins B, E and AD 
The antibody titre detected in the MPV-1 standard positive control was the highest 
when rAD was used as an antigen, followed by proteins B and E; the cut-off 
positive/negative A405 was calculated individually for each protein, as explained in 
Materials and Methods of this Chapter. The comparative A405 readings for the 3 
antigens calculated for the MPV-1-positive control, MPV-1 positive sera, sera 
thought to be providing a false positive MPV-1 reaction and MPV-1 negative sera 
are shown in Figure 3.9. Antibodies were detected against rAD MPV-1 in all 
positive and false MPV-1 positive sera and no antibodies were detected in the sera 
obtained from MPV-1 negative mice. Protein B detected 2 of 5 MPV-1 positive sera 
and 2 of 6 false positive sera.  All negative sera were negative by the recombinant 
protein B.  Protein E did not detect any of the positive sera and only one of 6 false 
positive sera.  
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Figure 3.9. Comparison of the 3 recombinant proteins B, E and AD as antigens in the ELISA. A 
standard curve for the calculation of the cut-off negative/positive A405 for each protein was 
established using a series of 2-fold dilutions of the standard MPV-1 positive control. Their activity 
was then determined against 6 MPV-positive and 6 MPV-negative sera and at the same time the 
antigen specificity was checked against sera thought to be providing a false positive result. The 
antigens were tested at 1:10 dilutions and the sera at 1:20 dilutions.  
 
 
Optimal antigen concentration 
The effects of different concentrations of the rAD antigen on the A405 of the MPV-1 
positive control sera are given in Figure 3.10.  Based on these results, an antigen 
concentration of 1:10 was chosen for further analysis. 
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Figure 3.10. Effect of different concentrations of the rAD antigen on the absorbance of the 
standard MPV-1 positive control serum (Std). Serial 2-fold dilutions of the standard positive 
MPV control were tested against a range of concentrations of the rAD antigen in PBST by 
indirect ELISA (1:2, 1:5, 1:10, 1:15, 1:20 and 1:25).  
 
Evaluation of blocking agents using indirect ELISA  
The A405 of the sera tested varied between the 3 blocking reagents, as shown in 
Figure 3.11. The maximum reduction in background levels of the A405 was obtained 
with 2.5% bovine serum albumin (BSA) as a blocking agent followed by 2.5% dry 
skim milk (DSM) and the lowest reduction was obtained with 2.5% casein. With the 
positive sera, the A405 was the highest with 2.5% BSA and 2.5%DSM as blocking 
agents (6-fold greater than with the negative control), and the lowest with casein (4-
fold greater than with the negative control).  A405 values with the false positive sera 
were highest when BSA used as a blocking agent, lower when casein was used, and 
lowest with DSM.  
Attempts were made to evaluate the use of various combinations of DSM, BSA and 
casein to decrease background A405 values by adding them to the ELISA diluent as 
well as using them in the initial blocking step.  The A405 with the MPV-1 false 
positive sera was consistently reduced when 2.5% DSM was used as a blocking 
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agent and it was also incorporated into the ELISA diluent; therefore, DSM was 
chosen for further ELISA optimization. The A405 varied greatly when combinations 
of 2.5% casein and 2.5% DSM were used as blocking agents and as additives to the 
diluent.  
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Figure 3.11. Effect of different blocking agents and diluents on the A405 of MPV-1-positive, false 
positive and negative mouse sera. The results shown were those when casein (2.5%), DSM 
(2.5%) and BSA (2.5%) in PBST were used to block streptavidin uncoated sites on the ELISA 
plates with 2 MPV positive sera, 2 sera thought to be providing a MPV-1 false positive reaction 
and 2 MPV negative sera (all diluted at 1:20 dilution in parallel in PBST and 2.5% 
casein/DSM/BSA in PBST). The sera were tested against rAD antigen at a 1:10 dilution. 
 
 
The results of the effect of different concentration of DSM as both a blocking agent 
and when incorporated into the diluent on the A405 of a series of 2-fold dilutions of 
the standard MPV-1 positive and the negative controls are shown in Figure 3.12. 
DSM (1.5%) reduced the non-specific binding without significantly reducing the 
specific signal obtained with 2.5% DSM, and subsequent ELISAs were performed 
using 1.5% DSM as both blocking agent and diluent.  
An example of a final MPV-1 ELISA with 2 positive sera, 2 negative sera and a 
marginally positive serum sample is shown in Figure 3.13. 
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Figure 3.12. Effect of different concentration of DSM on the A405, when it was used as a 
blocking agent and also incorporated into the ELISA diluent. A range of DSM 
concentrations (0.5-4.5%) was compared for their effect on the A405 of 2 MPV-1 positive 
mouse sera, 2 sera thought to be providing a false positive reaction and 2 MPV-1 negative 
sera. Casein (2.5%) in PBST was also used for comparative purposes.  
 
 
 
Figure 3.13.  A typical ELISA plate using a horseradish peroxidase substrate (Bio-Rad). A1, 
reference MPV-1 positive control; A2, MPV-1 positive test serum; A3-A6, MPV-1 negative 
test sera; B1,: reference MPV-1 negative control; B2-B6, MPV-1 negative test sera; C1-C6, 
MPV-1 negative test sera; D1-D2, MPV-1 negative test sera; D3, MPV-1 positive test 
serum; D4-D6, MPV-1 negative test sera.  
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Western immunoblotting 
Sera were deemed to be positive by WIB if there was reactivity with the 37 kDa rAD 
protein (Figure 3.14). A comparison of WIB results with ELISA results 
demonstrated a high level of concurrence between the 2 assays (Figure 3.14).  
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Figure 3.14. Example of WIB with ELISA MPV-1 positive and negative sera. Lane 1, 
molecular weight marker; lane 2, streptavidin-positive control; lane 3, MPV-1 ELISA 
positive sera; lanes 4 and 5, MPV ELISA negative sera; lanes 6, 7 and 8, MPV-1 ELISA 
positive sera; lane 9, no serum control.  
 
 
Discussion 
Previous ELISA testing conducted by the ARC using a commercially available 
recombinant NS1 MVM antigen of USA origin had consistently provided negative 
results, and continued to provide negative results even when there was 
overwhelming PCR evidence that the mouse colonies in the ARC were infected. The 
recombinant truncated VP1 protein developed and reported in this Chapter has 
provided an antigen able to detect antibody in MPV-1 infected mice by both ELISA 
and WIB. 
In these current experiments, VP1 was selected rather than NS1 for several reasons: 
the virion proteins (VP) are known to exhibit type-specific reactivity and the non-
structural (NS) proteins group-specific reactivity (Ball-Goodrich and Johnson, 
1994); the ELISA assays that use rVP2 expressed either with a baculovirus system 
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(Livingstone et al., 2002) or a bacterial system (Ball-Goodrich et al., 2002) were 
previously shown to be much more specific and to significantly outperform the rNS1 
MVM ELISA.  
The AD region of VP1 was selected as the antigen of choice rather than VP2, firstly 
because the PinPoint system failed to express the full length of VP2. As a result, 
truncated VP1 regions were generated. Of the 9 constructs based on various regions 
of the VP1 gene, protein products were expressed from 8. Secondly, because of the 
combination of yield and antigenicity shown by AD relative to a number of the other 
truncated VP1 proteins that were produced. Three of the proteins, B, E and AD, were 
expressed in low to moderate amount but demonstrated reasonably high antigenicity 
in terms of their ability to interact with MPV-1 antibody. Of the 3 proteins, the AD 
protein was the most antigenic by both ELISA and WIB, and as this protein was 
produced at levels that were considered sufficient to be able to purify a reasonable 
quantity of the protein from the E. coli lysate, this was the protein that was selected 
as the most appropriate.  Other VP1 polypeptides encompassing and overlapping the 
AD domain (proteins D, F and G) were not antigenic.  The reason for this is not 
known but it may be due to folding of the polypeptides and therefore altered 
presentation of antigenic epitopes associated with truncation of the proteins.   
A protein concentration of 1:10 was specifically chosen as by using a reasonable 
amount of the antigen, the middle point of the absorbances of the Std MPV-1 
positive control serum was obtained within the range of the concentrations of the 
antigen tested.  
The recombinant proteins were expressed intracellularly in an insoluble form, 
presumably as inclusion bodies. The temperature of 37ºC (Vasina and Baneyx, 
1996), which generally favours aggregation over folding, has most probably either 
alone and/or in a combination with other factors and perhaps including the T7 
promoter (Hoang et al., 1999) contributed to the formation of the inclusion bodies. It 
may have been possible to manipulate the growth temperature to increase the 
solubility of the protein, but this was not attempted as the high yield of protein at this 
temperature was favoured over solubility. 
The insolubility of the protein and location within inclusion bodies determined the 
approach to purification of the proteins.  To purify the insoluble proteins the method 
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of disruption of the bacterial cells employed both enzymatic and mechanical means: 
lysozyme to cleave the glucosidic linkages in the bacterial cell wall polysaccharide 
and disruption of the inner cytoplasmic membrane by sonication (Sambrook et al., 
1989). During these procedures, partial clearing of the suspension was observed 
indicating an increase in solubility, and when the cells were examined 
microscopically many were visibly disrupted. Minimal sonication, however, was 
performed in order to prevent increased solubilisation of host cell proteins.  To 
maintain the stability of the protein and minimise the inactivating conditions such as 
denaturation and/or proteolysis, once the intracellular protein was expressed in and 
released from the host cells, close attention was paid to pH, temperature, reducing 
agents, stirring, vortexing and centrifugation speeds (Burgess, 1996). To prevent pH-
induced denaturation, all buffers used were within a range of pH 6-8. Vigorous 
stirring and vortexing were avoided since these may lead to oxidation or surface 
denaturation. The reducing agent 2-mercaptoethanol was used to counteract 
oxidative effects, particularly of cysteine residues. Protease inhibitors such as 1mM 
DTT and 1mM PMSF were added to the extraction buffer when inclusion bodies 
were treated to minimise proteolysis (Vuillard et al., 1998). Most of the purification 
steps were conducted on ice or at 4ºC to maintain the biological activity of the 
protein (Bondos and Bicknell, 2003). Urea solutions were stored at 4ºC and used 
within one week of preparation, in order to reduce the formation of cyanate ions, 
which can react with protein amino groups forming carbamylated derivatives 
(Simpson, 2004). Generation of heat during sonication was also controlled by 
conducting this in an ice bath (Bondos and Bicknell, 2003).   
Prior to purification of the proteins, centrifugation was used to try to separate the 
protein-containing inclusion bodies from the remainder of the bacterial cells, as these 
may associate with the expressed protein and interfere with its refolding (Tsumoto et 
al., 2003). An additional step that significantly improved the purification process 
was to carefully separate the final centrifugation products resulting from the last 
wash with 0.1% deoxycholate in PBS, by separating and subsequently utilising the 
top layer only, which contained the required protein, while discarding the bottom 
layer believed to contain mainly impurities from the host proteins. Although this led 
to reduced protein yields, this step greatly improved the efficiency of the purification 
process.   
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For solubilisation of the protein, 8M urea, a water-soluble chaotropic agent, was 
used.  This binds to protein in a concentration-dependent manner (Muralidhara and 
Prakash, 2001) and this concentration was expected to be sufficient to unfold and 
solubilise the protein (Tsumoto et al., 2003). Dialysis was used to remove the urea 
for refolding of the proteins as this technique reduces the urea concentration 
gradually (Tsumoto et al., 2003).  
The PinPoint
TM system was selected for the production of the recombinant proteins 
as proteins encoded with this system are expressed as fusion proteins containing a 
biotinylated site that potentially enables the protein to be applied directly to 
streptavidin-coated ELISA trays. The strong binding affinity of the biotinylated 
proteins to streptavidin was exploited to effect the single-step purification of the 
antigen by attaching the target protein to the solid support. The E. coli JM109 strain 
was selected as a host cell for expression as these bacteria are easy to grow with high 
yields and can be transformed efficiently (Promega Technical Bulletin No. 234). 
Many sera from both experimentally and naturally MPV-1-infected animals 
produced a high level of background activity when the rAD protein was used as an 
antigen in the ELISA. This problem was partly overcome by utilising skim milk 
powder to block non-specific binding of immunoglobulins, and this effect was 
enhanced by also incorporating skim milk powder into the ELISA diluent.  The use 
of skim milk powder as a blocking agent in an ELISA has been reported previously 
(Riemekasten et al., 2002). While milk-based protein blockers have been described 
as not being well suited for avidin/biotin based procedures (Pierce Blocking and 
Washing Technical Bulletin) as they contain biotin and phosphoproteins and 
interfere with the biotin-containing systems, in this current study they were better 
than BSA and casein. Bovine serum albumin used as a blocking agent was reported 
to result in low background absorbance values (Pierce Biotechnology Technical 
Resources, 2002) in ELISA but in the current study when BSA was used both as 
blocking agent and diluent at the same time, only some reduction of the signal was 
observed. 
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Chapter 4. Seroprevalence of MPV-1 in a large laboratory 
mouse colony 
 
Summary 
The presence of MPV-1 infection in a colony of about 45,000 mice was determined 
to provide information on the seroprevalence and hence the sampling size needed to 
reliably detect the infection within such large colonies. The prevalence of infection 
was determined by an ELISA and WIB procedure based on a recombinant protein 
AD domain of the VP1 of the Australian strain of MPV-1. A total of 1187 sera from 
a variety of strains of mice were examined and an overall seroprevalence of 16.5% 
was detected. A variation in the seroprevalence in different mouse strains was 
determined, even though all mice were housed within the same air space, which 
provides evidence of genetic variation in the susceptibility of mice to MPV-1 and 
their antibody response to infection, as had been previously reported by others 
(Besselsen et al., 2000). 
 
Introduction 
The detection of mouse parvovirus (MPV-1) in mice within the Animal Resources 
Centre (ARC), a principal supplier of multiple strains of inbred and outbred mice to 
the Australian research community, and the recognition that the serological 
technology used previously for the detection of virus infection by serological testing 
had failed to detect the infection (Chapter 3), necessitated a new approach to 
detection of the virus infection.  Modified serological tests were developed, 
including ELISA and WIB, based on a recombinant truncated VP1 antigen and these 
were found to detect antibody in the infected mice (Chapter 3). 
The ELISA test sensitivity and specificity for the mouse population was evaluated 
using 2 approaches: first, using WIB as a “gold standard” (Smith, 1995) and second, 
in the absence of a “gold standard” by Bayesian modelling (Thomas et al., 2006; Hui 
and Walter, 1980). Use of Bayesian modelling of screening test accuracy has 
increased recently in veterinary medicine (Gardner, 2002), especially since the 
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Bayesian approach has enabled simultaneous inferences about the population 
prevalence and the sensitivity and specificity values of a diagnostic test possible in 
the absence of a standard reference test (Lawrence et al., 1995). 
The aim of the studies reported in this Chapter was to accumulate useful data on the 
prevalence of MPV within rooms and within different strains of mice, so that 
modifications in the testing program could be made accordingly where required and 
to make sure that the newly re-derived population of mice could be tested in a 
manner that ensured freedom from infection. 
  
Materials and methods 
Sampling design 
The key components of the sampling procedures used were based on those described 
by Dohoo et al. (2003) which consider the target population, the required sampling 
size, sampling method, and screening tests.   
In April 2003, when the study was commenced, the total mouse population (target 
population) at the ARC was approximately 45,000, mostly of 23 different strains, 
housed in 11 rooms in 2 production units.  The number of mice (sample size) tested 
was based on an assumption that the lowest prevalence of MPV-1 infection 
detectable in the ARC population was 5%.  As shown in Table 4.1, a sample size of 
approximately 100 mice per room was selected as appropriate for providing a 99% 
probability of detecting at least one seropositive mouse in the population if present at 
an expected prevalence of 5% (Cannon and Roe, 1982). Between April and July of 
2003 blood samples were collected from 1187 randomly selected heterozygous 
retired breeders and stock mice of 8 weeks of age or older from all mouse strains. 
Homozygous nude mice were excluded from the sample population. The source of 
mice (units, rooms, mouse strains) and number of sera tested are shown in Table 4.2. 
Sera were separated by centrifugation, as described in Chapter 3 and kept at -20ºC 
until analysed. 
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Table 4.1. Confidence limits for detecting MPV-1 infection using different sample sizes at 
assumed rates of infection (from 1 to 50%). The probability of detecting at least one MPV-1 
seropositive mouse is given in a range of 5 – 99%. From Cannon and Roe (1982). 
 
Infection rate (%)  Sample size  
1       2       3       4       5       10      15    20     25    30     40    50 
    5 
  10 
  15 
  20 
  25 
  30 
  35 
  40 
  45 
  50 
  60 
  70 
  80 
  90 
100 
120 
140 
160 
180 
200 
0.05    0.10    0.14    0.18    0.23    0.41    0.56    0.67   0.76   0.83   0.92   0.97 
0.10    0.18    0.26    0.34    0.40    0.65    0.80    0.89   0.94   0.97   0.99 
0.14    0.26    0.37    0.46    0.54    0.79    0.91    0.95   0.99 
0.18    0.33    0.46    0.56    0.64    0.88    0.95    0.99 
0.22    0.40    0.53    0.64    0.72    0.93    0.98 
0.25    0.45    0.60    0.71    0.79    0.96    0.99 
0.30    0.51    0.66    0.76    0.83    0.97 
0.33    0.55    0.70    0.80    0.87    0.99 
0.36    0.69    0.75    0.84    0.90    0.99 
0.39    0.64    0.78    0.87    0.92    0.99 
0.45    0.70    0.84    0.91    0.95 
0.51    0.76    0.88    0.94    0.97 
0.55    0.80    0.91    0.96    0.98 
0.60    0.84    0.94    0.97    0.99 
0.63    0.87    0.95    0.98    0.99 
0.70    0.91    0.97    0.99   
0.76    0.94    0.99 
0.80    0.96    0.99 
0.84    0.97 
0.87    0.98     
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Table 4.2. Source of mice (units, rooms, mouse strains) and number of sera tested during the 
period from April to July 2003. 
 
Production unit  Room  Mouse strain  No. of sera tested 
3 
 
 
 
2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total 
40 
40 
41 
 
43 
44 
44 
44 
44 
46 
46 
46 
47 
47 
47 
47 
54 
60 
60 
61 and 64 
62 and 64 
64 
 
 
DBA/2JArc 
B6D2F1 
Hsd:NIH 
 
BALB/cArc-Foxn1 nu/+ 
SJL/JArc 
B6.129P2-Apoe tm1 Unc (N 10) 
CBB6 
C57BL/10ScSn-Dmdmdx 
C57BL/6JArc-A2Kb 
C57BL/10ScSnArc 
?* 
Il5 CBA-TgN<Il5>1Glx 
B6; 129S – Gt (ROSA) 26Sor  
Vm/Dk 
FVB – TgN<K14mCD80>6lrw  
N2Sn, PtPrca, A/JArc 
FVB/NArc 
C3H/HeJ 
ARC(s) 
C57BL/6JArc 
Arc:Q(S) 
 
 
8 
92 
118 
 
99 
42 
26 
23 
6 
32 
14 
26 
66 
21 
19 
13 
117 
77 
25 
87 + 48 
104 + 47 
77 
 
1187 
 
*? denotes an undisclosed mouse strain 
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Serological tests 
Two serological tests, an ELISA and WIB, were performed as reported in Chapter 3 
to detect IgG antibodies to the AD region of the capsid VP1 protein of the Australian 
strain of MPV-1.  This was expressed using the PinPoint
TM system (Promega) (rAD) 
in Escherichia coli (Chapter 3).  
 
Estimation of seroprevalence in the presence of a gold standard serological test 
Sera were first tested for antibody by ELISA using 2 different cut-off levels: one 
utilising a positive cut-off absorbance level 3 standard deviations (SD) greater than 
the mean of the control negative; one a positive cut-off level 2 SD greater than the 
mean of the control negative. Serum samples that were ELISA positive were further 
tested by WIB. WIB was regarded as the definitive “gold standard” for the detection 
of antibody and a positive antibody result (“true positive” results; TP) was 
interpreted on one with a positive result on both assays (2 SD ELISA and WIB). 
Those sera found to be positive by either 2 SD or 3 SD ELISA and unconfirmed by 
WIB were regarded as “false positives” (FP). Those sera negative by the 3 SD 
ELISA but positive by the 2 SD ELISA and positive by WIB were regarded as “false 
negative” (FN). Sera negative by WIB were regarded as “true negatives” (TN). 
The values for all 4 possible serological test outcomes, true correct outcomes (TP 
and TN) and 2 incorrect outcomes (FP and FN) were used to estimate the test 
sensitivity, specificity, predictive value and accuracy, and the prevalence (P) of 
MPV-1 infection in the mouse population (Smith, 1995). These were calculated 
using the formulas below. 
Sensitivity = TP / TP + FN 
Specificity = TN / FP + TN 
Predictive value of a positive test (PV+) = TP / TP + FP 
Predictive value of a negative test (PV-) = TN / FN + TN 
Prevalence (P) = (TP + FN) / (TP + FN + FP + TN) 
Accuracy = (TP + TN) / (TP + FP + FN + TN) 
 
The overall relationship between the sensitivity and specificity of the serologic tests 
(Dohoo et al., 2003) is illustrated in Table 4.3. 
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Table 4.3 Sensitivity, specificity and predictive values of the serologic testing. From Dohoo 
et al. (2003). 
 
Health status   
Diseased Not  diseased  Total 
Positive  TP  FP  TP + FP 
Negative  FN  TN  FN + TN 
Test results 
Total  TP + FN  FP + TN  TP + FP + FN + TN = N 
 
TP denotes positive by WIB (true positives). 
FP denotes positive by either 2 SD or 3 SD ELISA and negative by WIB (false positives). 
FN denotes negative by 3 SD ELISA, positive by 2 SD ELISA, and WIB positive (false negatives). 
TN denotes negative by WIB (true negatives). 
N denotes total population. 
 
 
The seroprevalence (P) in different mouse strains regardless of the different housing 
(e.g. rooms/units), and in different rooms and units regardless of the mouse strain, 
were calculated using the formula of Dohoo et al. (2003) as shown below:  
 
P = TP/n 
Where P = prevalence, TP= number of MPV-1 infected mice in the population 
at a point of time, n = number of mice tested. 
 
Based on the proportion of antibody positive sera, the sample size required to 
provide 90%, 95% and 99% certainty of detecting at least one antibody positive 
mouse in a population where the infection is present at a defined prevalence 
somewhere between 10 and 100% was calculated using Table 4.4.  
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Table 4.4. Sample size required for the detection of antibody-positive mice at 90%, 
95% and 99% level of confidence. From Cannon and Roe (1982). 
 
90% confidence  95% confidence  99% confidence 
Percentage of 
infected animals in 
population 
Percentage of 
infected animals in 
population 
Percentage of 
infected animals in 
population 
Population 
size (n) 
10 15 20  10  15 20 10 15 20 
10    9    8    7  10  10    8  10  10  10 
100  20 14 10  25  17 13 36 25 19 
1,000  22 15 11  29  19 14 43 28 21 
10,000  22 15 11  29  19 14 44 29 21 
<10,000  22 15 11  29  19 14 44 29 21 
 
 
Estimation of seroprevalence in the absence of a gold standard test 
A Bayesian analysis framework was used to make inferences about the prevalence, 
and sensitivity (Se) and specificity (Sp) of ELISA and WIB and the level of 
conditional dependence between these 2 tests, using the results from testing 1,187 
mice. Two models were constructed and run in WinBUGS (http://www.r-
project.org/user-2006/Slides/Thomas.pdf (Thomas et al., 2006). Each model was run 
with a burn-in phase of 5,000 iterations and 20,000 iterations were run to obtain 
estimates.  
 
The first model used a code (Branscum et al., 2004) to determine the sensitivity and 
specificity of 2 diagnostic tests, ELISA and WIB, using data from 2 populations (the 
mice coming from the 2 mouse populations of Units 2 and 3 within the ARC) in the 
absence of a gold standard. A pair-wise comparison of each of the 2 tests was 
performed and estimates of the sensitivity and specificity covariance’s inferred to 
evaluate the level of dependence. 
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The second model used the Bayesian analysis based on the Hui and Walter model 
(Hui and Walter, 1980) which assumes the 2 tests are independent in a 2 test, 2 
population setting. The prior estimates for the analysis were a beta distribution 
parametised using: 
 
Se and Sp = mean of 90% and S.D. 10% 
Prevalence = mean 16.5% and S.D. 5% 
 
Results  
A total of 1187 serum samples were tested: antibodies were detected in 196 sera of 
the 1187 sera examined by both ELISA and WIB and were regarded as TP (16.5%); 
991 sera were WIB negative and regarded as TN (83%); 7 were positive by both 2 
and 3 SD ELISA and negative by WIB, and regarded as FP (0.58%); 10 were 
negative by 3 SD ELISA, positive by 2D ELISA and were WIB negative and 
regarded as FN (0.84%). The MPV-1 antibody detection in different mouse strains at 
the ARC in 2003 presented in percentage is given in Table 4.5.  
The seroprevalence varied in different strains of mice: the highest seroprevalence 
was detected in Hsd:NIH mice, followed by B6D2F1 and ARC(s). The 
seroprevalence varied within different rooms and production units depending on the 
mouse strain they housed: the highest seroprevalence rate was detected in room 41 
(Unit 3), and infection was not detected in rooms 62 and 64 (Unit 2); the 
seroprevalence was 5 times greater in Unit 3 than Unit 2 (Table 4.6). 
Data obtained from the 2 serologic assays indicated a seroprevalence (P) of 16.51%, 
with an accuracy of 0.98%. ELISA specificity was 99.3% and sensitivity was 
95.14% (Table 4.7). The sample sizes of 43 mice required to determine the detection 
of MPV-1 at 10% prevalence with 99% confidence in the main production area in 
the ARC among a target population of 1,000 mice is shown in Table 4.8. 
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Table 4.5. MPV-1 antibody detection in different mouse strains at the ARC in 2003. 
 
Unit  Room   Mouse strain  Sample 
size 
TP 
(%) 
FP  
(%) 
FN 
(%) 
TN 
(%) 
3 40  DBA/2JArc  8  12.5  0 0 87.5 
  40  B6D2F1  92  42.4  0 0 57.6 
  41  Hsd:NIH  118 53.4  2.5 2.5 41.6 
2 43  BALB/cArc-Foxn/nu/+  99  7.0 2.0 0  91.0 
  44  SJL/JArc  42  2.4  0 0 97.6 
 44  B6.  129P2-Apoe 
tmlUnc (N 10) 
26  0 0 0 100 
  44  CBB6  23  0 0 0 100 
 44  C57BL/10ScSn-
Dmdmdx 
6  0 0 0 100 
  46  C57BL/6JArc-A2Kb  32  0 0 0 100 
  46  C57BL/10ScSnArc  14  0 0 0 100 
  46  ?  26  30.7 0  11.5 57.8 
 47  Il5  CBA-TgN<Il5>1Glx  66  13.6  0  1.5  84.9 
 47  B6;  129S-Gt  (ROSA) 
26Sor 
21  0 0 0 100 
 47  Vm/Dk  19  15.7  0  5.2  79.1 
 47  FVB-
TgN<K14mCD80>6lrw 
13  0 0 0 100 
  54  N2Sn,  PtPrca,  A/JArc  117  0 0.3  0 100 
  60  FVB/NArc  77  35  0 0 65 
  60  C3H/HeJ  25  20  0 0 80 
 61    ARC(s)  87  35.6  2.4  0  62 
  62    C57BL/6JArc  104  0 0 0 100 
  64  ARC:Q(S)  77  1.3  0 0 98.7 
  64  ARC(s)  48  2.1  0 0 97.9 
  64  C57BL/6JArc  47  0 0 0 100 
Total      1187  16.5  0.6 0.8 82.0 
   
 
TP denotes WIB positive (true positives). 
FP denotes 2 SD or 3 SD ELISA positive and WIB negative (false positives).   
FN denotes 3 SD ELISA negative, 2 SD ELISA positive, and WIB positive (false negatives). 
TN denotes WIB negative (true negatives). 
N denotes total population. 
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Table 4.6. Seroprevalence rates within individual mouse strains, production units and rooms 
at the ARC in 2003. 
 
                                                                           Seroprevalence in             Seroprevalence in     
                                                                           different rooms                different units 
                                                                          _________________        _______________ 
Mouse strain                              Total               Room      Prevalence         Unit      Prevalence   
                                                   prevalence                      (%)                                  (%) 
                                                   (%) 
DBA/2JArc  
B6D2F1 
Hsd:NIH 
BALB/cArc-Foxn1nu/+ 
SJL/JArc 
B6. 129P2-Apoe tmlUnc (N 10) 
CBB6 
C57BL/10ScSn-Dmdmdx 
C57BL/6JArc-A2Kb 
C57BL/10ScSnArc 
? 
Il5 CBA-TgN<Il5>1Glx 
B6; 129S-Gt (ROSA) 26Sor 
Vm/Dk 
FVB-TgN<K14mCD80>6lrw  
N2Sn, PtPrca, A/JArc 
FVB/NArc                  
C3H/HeJ  
ARC(s) 
C57BL/6JArc 
Q(s) 
ARC(s) 
C57BL/6JArc 
12.5 
42.4 
53.4 
7.07 
50 
0 
0 
0 
0 
0 
30.8 
13.6 
0 
15.8 
0 
0 
0.1 
20 
35.6 
0 
1.3 
2.1 
0 
40 
41 
43 
44 
46 
47 
54 
60 
61 
62 
64 
40 
53.4 
7.0 
1.0 
11.1 
0 
0 
31.4 
35.6 
0 
1.1 
 
  2 
  3 
  9.6 
  47.2 
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Table 4.7. Data used for calculation of ELISA sensitivity and specificity. 
 
Health status   
Diseased Not  diseased  Total 
Positive  196 (TP)  7 (FP)  203 (TP + FP) 
Negative     10 (FN)  974 (TN)  984 (FN + TN) 
Test results 
Total 206 
(TP + FN)  
981 
(FP + TN) 
1187  
 (TP + FP + FN + TN = N) 
 
TP denotes positive by WIB (true positives). 
FP denotes positive by either 2 SD or 3 SD ELISA and negative by WIB (false positives). 
FN denotes negative by 3 SD ELISA, positive by 2 SD ELISA, and WIB positive (false negatives). 
TN denotes negative by WIB (true negatives). 
N denotes total population. 
 
 
Sensitivity = 95.14% with 95% CI (91.0%, 97.5%). 
[TP / (TP + FN) % = 196/206 = 95.14%]  
 
Specificity = 99.3% with 95% CI (98.5%, 99.7%). 
 [TN / (FP + TN) % = 974/981 = 99.3%] 
 
PV+ = 96.55% [TP/(TP + FP) = 196/203 = 96.55%]. 
PV- = 99 % [TN/(FN + TN) = 974/984 = 99 %].  
Where: 
PV+ is positive predictive value 
PV- is negative predictive value 
CI is confidence intervals based on the binomial distributions (Noordhuizen et al., 2001) 
 
 
 
Table 4.8. Sample size required to detect MPV-1 infection at 99% levels of confidence at 
10% infection rate. From Cannon and Roe (1982). 
 
Population size  Level of confidence  Sample size required 
1000  99% 43 
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Estimation of the prevalence, sensitivity and specificity using Bayesian analysis 
The pair-wise comparison of test dependence indicated low estimates for the 
sensitivity and specificity covariances with 95% confidence intervals that included 
zero, and were therefore considered to be independent for subsequent analysis. The 
mean estimate of the sensitivity and specificity of ELISA and WIB for each 
population resulting from the first Bayesian analysis is presented in Table 4.9. 
 
 
Table 4.9 Mean prevalence of sensitivity and specificity of ELISA and WIB from the first 
Bayesian analysis assuming conditional dependence between the tests. 
 
 Mean 
Se WB  0.974 (0.938, 0.998) 
Se ELISA  0.974 (0.932, 0.998) 
Prevalence in population 1  0.421 (0.363, 0.482) 
Prevalence in population 2  0.101 (0.082, 0.121) 
Se covariance  0.087 (0.029, 0.412) 
Sp covariance  0.159 (0.002, 0.531) 
Sp WB  0.990 (0.978, 0.998) 
Sp ELISA  0.995 (0.987, 0.999) 
 
Se WIB denotes WIB sensitivity 
Se ELISA denotes ELISA sensitivity 
Sp WIB denotes WIB specificity 
Sp ELISA denotes ELISA specificity 
 
 
The second Bayesian analysis, using the Hui and Walter model showed that although 
the 2 tests were virtually identical in their accuracy and both measured antibodies 
against MPV-1, they were independent. Results from second Bayesian analysis are 
presented in Table 4.10.  
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Table 4.10.  Mean prevalence of sensitivity and specificity of ELISA and WIB from the 
second Bayesian analysis assuming conditional independence between the tests. 
 
 Mean  % 
Prevalence in population 1  48.72 (42.08, 55.35) 
Prevalence in population 2  10.01 (8.14, 12.06) 
Se WIB  97.30 (94.06, 99.60) 
Se ELISA  97.11 (92.93, 99.78) 
Sp WIB  99.19 (98.31, 99.89) 
Sp ELISA  99.64 (99.02, 99.98) 
 
Se WIB denotes WIB sensitivity 
Se ELISA denotes ELISA sensitivity 
Sp WIB denotes WIB specificity 
Sp ELISA denotes ELISA specificity 
 
 
The comparison of the estimation of the sensitivity and specificity of the in-house 
ELISA in the presence and absence of a “gold standard” showed high similarity and 
is presented in Table 4.11. 
 
 
Table 4.11 Comparison of the estimation of the in-house ELISA sensitivity and specificity in 
the presence and absence of the gold standard. 
 
 
  Se ELISA  Sp ELISA 
In the presence of a gold 
standard 
95.14 %  99.3 % 
In the absence of a gold 
standard 
97 %  99.6 % 
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Discussion 
The serological survey conducted was designed to determine the seroprevalence rate 
of naturally infected mouse stocks within the ARC mouse colonies at the start of the 
eradication program. This information was to be used as a basis for determining the 
level of testing required to confidently detect MPV-1 infection using the serological 
tests that were developed. The survey data were stratified to identify the results in 
individual mouse strains and revealed variation in prevalence of antibody in different 
mouse strains, which if confirmed could have a significant effect on the numbers and 
strains of mice that should be used for future surveillance.  The variation in the 
prevalence of detectable antibody within different mouse strains, all housed within 
the same air space, suggests either a genetic basis of the ability to synthesise 
antibody in response to infection, or perhaps genetic variation in the susceptibility of 
different strains. An investigation of the effect of mouse strain and age on infection 
is reported in Chapter 5.  
The serological methods used were an ELISA as a primary test and WIB as a 
confirmatory and definitive test of the presence of antibody. The ELISA was 
assessed using 2 cut-off points, or levels of sensitivity, one using a cut-off 
absorbance as the mean of a series of negative results plus 3 SD of the mean, and 
another using 2 SD of the same mean.  Lowering the threshold to the lower level of 2 
SD of the mean rather than 3 SD did not affect sensitivity, and resulted in less false 
negatives than when a cut-off value of 3 SD was used.  These results indicated that a 
cut-off positive level of 2 SD was optimal for routine use.  
When the ELISA results were compared with those of WIB, the ELISA was highly 
specific with only 1% false negative results detected (with a negative predictive 
value of 99%) and a high percentage of true positive results (positive predictive 
value of 96.55%).  
In this study, the Bayesian method was used for estimation of the accuracy of the in-
house ELISA as a diagnostic test, hypothesising that an imperfect reference test 
(WIB) was used. The comparison of the 2 approaches, in the presence and absence 
of the gold standard, has revealed that the in-house ELISA performed very similarly 
to the WIB, and the Bayesian analysis confirmed the high sensitivity and specificity 
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of the tests used. Therefore, ELISA can be reliably utilised to in the routine diagnosis 
of MPV-1, providing the significance of mouse strain variation was considered.  
The primary purpose of the survey was to determine the overall presence of MPV-1 
in the entire ARC colony of about 45,000 mice.  The ARC operates more than one 
production unit, and multiple rooms within each production unit, and it was 
important to determine differences in these units and rooms, as this could have an 
important bearing on the surveillance methods that should be adopted to detect 
possible re-infection in the colony once an eradication program was commenced.  It 
was important to also consider variation within the same room (regardless of the 
mouse strain) and additionally the prevalence of MPV-1 infection within the same 
mouse strain population within different units and rooms. The testing program 
defined as the “population” referred to the total number of mice within each 
production unit, based on the fact that personnel, equipment and mice were moved 
between individual rooms regularly. This strategy did not, however, take into 
account individual strains or ages of mice. 
The initial sample size to be tested was determined by making an initial assumption 
about the rates of MPV-1 infection and the randomness in sampling. The initial 
sample size required to detect infection was based on the need to find at least one 
infected animal when the prevalence of MPV-1 antibody-positive mice was likely to 
be more than 5%. Homozygous nude mice were excluded as these animals are not 
immunocompetent. Age was not considered during the survey but all mice were 
more than 8 weeks of age and included retired breeders. The effect of age was 
evaluated in a separate experiment reported in Chapter 5. Mice of both sexes were 
sampled and it is possible there might be sex-based differences in the immune 
response, as reported for BALB/c mice by Huber and Pfaeffle (1994).  
The overall serological prevalence of 16.5% detected does not take into account 
strain differences in susceptibility, and the prevalence varied from 0 to 53.38 % in 
different strains of mice.  Further examination of strain differences will be required 
and were undertaken and are reported in Chapter 5.  The highest prevalence detected 
suggests that even though parvoviruses are well recognised as being extremely 
resistant to environmental effects that transmission between mouse cages by this 
virus was limited.  This is compatible with the report that parvoviruses were not 
transmitted between rats housed in opposing compartments of duplex cages (Yang et 
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al., 1995) and that MVM was not transmitted between mice caged 8 inches apart 
(Parker et al., 1970 b).  
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Chapter 5. Strain variation in the response of mice to 
infection by an Australian isolate of MPV-1 
 
Summary   
An enzyme linked immunosorbent assay (ELISA) supported by a Western 
immunoblotting (WIB) assay for the detection of MPV-1 antibody, and PCR for the 
detection of virus in spleen and intestinal content, were used to determine the effect 
of mouse strain and age on the response to the ARC strain of MPV-1 (MPV-1arc). 
The strain of mouse infected and the age at infection were found to be significant 
factors in the pathogenesis of MPV-1arc, indicating that these factors must be 
considered during routine surveillance of mouse colonies for evidence of infection.  
Viral replication was detected in tissues of all mouse strains (outbred ARC(s) and 
inbred C57BL/6JArc, BALB/c and BALB/c-Foxn1
nu/Arc) inoculated both as 
juveniles and adults, with the exception of C57BL/6JArc inoculated as adults. 
However, while seroconversion in mice inoculated as juveniles and adults was 
detected in ARC(s) and C57BL/6JArc mice, it was not detected in BALB/c mice. 
ARC(s) mice had the highest rate of seroconversion to MPV-1arc, the earliest and 
the longest immune response, and there were no age differences in their 
susceptibility, which would make ARC(s) mice reliable sentinels for the detection of 
MPV-1 in laboratory mouse colonies. The difficulty in detecting antibody in sera of 
BALB/c mice infected with MPV-1arc indicated this strain of mice was not suitable 
for routine surveillance of MPV-1arc infection.  
 
Introduction  
Mouse strain variation in the antibody response to MPV-1 has been reported and the 
degree of variation seems dependent on the assay (ELISA, IFA and HAI) and 
antigens (rNS1 ELISA, MVM ELISA, MPV IFA, MVM IFA, MPV HAI and MVM 
HAI) used (Besselsen et al., 2000). Seroconversion was not detected in C57BL/6 
mice, while seroconversion was observed in all C3H mice and in some but not all 
BALB/c, ICR, and DBA/2 mice inoculated with a similar dose of MPV. Mice with a 
BALB/c background were also reported to generate poor antibody responses to 
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MPV-1 infection (Khan et al., 2005). BALB/cJ failed to generate antibodies to 
MPV-1 after they were infected by using intranasal, gastric lavage and incorporation 
of virus into dirty bedding but did when they were inoculated by the intraperitoneal 
route on multiple occasions and when ELISA kits purchased from Charles River 
Laboratories based on a recombinant structural protein VP2 (rVP2) antigen from 
Research Animal Diagnostic Laboratory, University of Missouri (Livingston et al., 
2002) were used as a method of antibody detection (Khan et al., 2005). An antibody 
response was generated in response to infection in C57BL/6J but less successfully in 
BALB/cJ mice (Khan et al., 2005), although Besselsen et al. (2000) reported that 
C57BL/6J mice rarely seroconverted in response to MPV-1 infection.  
The aims of the studies reported in this chapter were to develop an improved 
understanding of the pathogenesis of infection by the Australian strain of MPV-1 
(MPV-1arc) detected in the Animal Resources Centre, and to verify those 
conclusions previously reported by others.  It was deemed particularly important to 
understand the kinetics of virus replication and the antibody response in different 
strains, so that routine surveillance data could be interpreted with confidence. 
Experiments were therefore conducted to determine strain and age variation in the 
response of mice to MPV-1arc infection in 4 strains of mice (ARC(s), C67BL/6J, 
BALB/c and BALB/c-Foxn1
nu/Arc) infected at 4 weeks (juveniles) or 8 weeks of age 
(adults). The antibody response was assessed over a 10 month period.   
 
Materials and methods 
Experimental design 
Approximately 650 female mice of ARC(s), C57BL/6JArc, BALB/c and BALB/c-
Foxn1
nu/Arc strains of 4 and 8 weeks of age, and 50 male  BALB/cArc of 4 weeks of 
age, were housed separately in an isolator and maintained as described in Chapter 2, 
and infected with MPV-1arc as described below.  The 50 male mice were killed 29 
days post-infection (PI) and sera collected for serological examination. The 650 
female mice were sampled at intervals after infection: once prior to infection, twice a 
week for the first 6 weeks PI, once a week for the next 4 weeks, then once a month 
for the remainder of the experiment which was conducted until 305 days PI.  On 
each sampling time, a minimum of 3 mice from each group were euthanased in 20% 
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oxygen in carbon dioxide gas mix. Blood for serum, and spleen tissue and the 
contents of the large intestine for virus detection, were removed aseptically from the 
dead mice. Sera were examined for antibody by rAD ELISA and WIB, and tissues 
by PCR as described in Chapter 3.  
The research was conducted under Animal Resources Authority AEC Approval, 
ARC2/2002 and Murdoch University AEC Approval R1110-04. 
Preparation of the infectious MPV-1arc inoculum 
The infectious inoculum for the experiments described above was prepared from 
spleen tissue and faecal samples derived from 50 ARC(s) female juvenile mice that 
had been infected experimentally with MPV-1arc.  Spleen tissue was aseptically 
collected from the 50 mice, suspended in PBS to a final volume of 50 ml, 
homogenised and then stored at -80ºC.  The homogenate was then thawed and the 
cellular debris was removed by centrifugation (4,500 x g for 30 min). The 
supernatant was removed, without disturbing the overlying fatty layer, re-centrifuged 
(4,500 x g for 15 min) and the supernatant collected.  
The intestinal contents from the mice were homogenised in 150 ml sterile PBS, left 
in a glass container overnight at 4º C, and the cellular debris removed by 
centrifugation (4,500 x g for 30 min).  
The supernatants from the tissue and faecal preparations were pooled and used as the 
inoculum; it was dispensed into small volumes and stored at - 80ºC until needed. 
The titre of infectious virus in the inoculum was determined by making 10-fold serial 
dilutions in PBS of the thawed suspension and orally inoculating 0.1 ml of each 
dilution into each of 5 juvenile ARC(s) mice. Mice inoculated with each dilution 
were then kept separately. The mice were euthanased 10 days after inoculation and 
the spleens collected.  The presence of virus in each mouse was determined from 
DNA extracted from each spleen by PCR as described in Chapter 3.  A 50% mouse 
infectious dose (MID50) was determined using the procedure described by Reed and 
Muench (1938). 
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Preparation of sera 
Blood was collected by cardiocentesis in sterile containers and allowed to clot at 
room temperature. The serum was separated from the clot by centrifugation (5,000 g 
for 5 min) and stored at –20ºC until required.  
Serological tests 
The ELISA and WIB assays were conducted as previously described in Chapter 3. 
Selected samples of the sera collected were sent to commercial laboratories 
(Cerberus Laboratory and Murine virus Monitoring Service of the Institute of 
Medical and Veterinary Science, both in Adelaide) for independent serological 
screening: 62 sera collected from  BALB/cArc mice infected as juveniles and adults 
on 14, 17, 21, 28, 35 and 52 days PI; 6 sera from BALB/c-Foxn1
nu/Arc sampled on 
28, 31, 35 and 52 days PI; 5 sera from ARC(s) sampled on 14 day PI; 4 sera from 
uninfected ARC(s) mice. These were tested against commercially available ELISA 
antigens, rNS1 Parvo and rVP2 MPV, as well as by an MVM/MPV IFA. The 
reagents for the rNS1 Parvo ELISA and rVP2 MPV ELISA were obtained from 
Research Animal Diagnostic Laboratory, University of Missouri.  The rNS1 Parvo 
ELISA antigen was produced from a highly conserved genomic sequence using a 
baculovirus expression system and is considered to be a generic ELISA for detection 
of all murine parvoviruses (MVM, MPV, TH-1, KRV, RPV, RMV) (Riley et al., 
1996).  The rVP2 MPV ELISA, based on VP2, was also expressed using a 
baculovirus expression system and was considered specific for differential 
serodiagnosis of MVM and MPV-1 in mice (Livingston et al., 2002). The 
MVM/MPV-1 immunofluorescence assay was obtained from the Charles River 
Laboratories.  
Detection of MPV-1arc DNA in tissues 
Presence of viral DNA in tissues was determined by an MPV-1- specific PCR (AD 
MPV-1) as described in Chapter 3. 
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Results 
Virus titre of inoculum  
The number of MPV-1arc infected mice inoculated with serial 10-fold dilutions of 
the virus inoculum is shown in Table 5.1. The MID50 was determined to be 10
3.32/ml, 
and this was the dose administered to all mice. 
 
Table 5.1. Detection of virus by PCR in spleen tissue of mice inoculated orally with 0.1 ml 
of different dilutions of the MPV-1arc inoculum. 
 
Dilution 10˚  10¯¹  10¯²  10¯³  10
¯4 10
¯5 10
¯6 10
¯7 10
¯8 10
¯9 10
¯10
No. positive/  
No. inoculated 
5/5  5/5  3/5  1/5  0/5  0/5  0/5  0/5  0/5  0/5  0/5 
 
 
Clinical signs in MPV-1arc infected mice 
Apart from some BALB/c-Foxn1
nu/Arc mice that developed periocular abscesses 
(common infections in this mouse strain) and rectal prolapses, which were excluded 
from any sampling, infected mice remained clinically normal and none of them died 
during the duration of the experiment. The macroscopic appearance of the spleens of 
the infected animals was similar to that of the negative controls, except in BALB/c-
Foxn1
nu/Arc mice where the spleens of the infected mice had a granular appearance 
and were larger than the control group. 
Effect of mouse strain and age on seroconversion to MPV-1arc 
The ELISA and WIB assay detected MPV-1arc-specific IgG in ARC(s) and 
C57BL/6JArc mice strains infected at 4 or 8 weeks of age, but not in  BALB/cArc 
mice infected at 4 or 8 weeks of age (Figure 5.1). Higher ELISA absorbance values 
were detected in ARC/c mice of both age groups than in C57BL/6JArc mice.  
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Figure 5.1 Comparison of the persistence of MPV-1arc antibody in sera of 4 mouse strains 
infected with MPV-1arc at 4 or 8 weeks of age and examined until 305 days PI.  
 
 
Antibody was detected by ELISA in ARC(s) inoculated as juveniles and adults, 
commencing 10 days PI and persisting until 305 days PI when the experiment was 
terminated. Antibody was detected by ELISA in C57BL/6JArc infected as juveniles 
commencing 17 days PI and persisting until 305 days PI when the experiment was 
terminated, and in C57BL/6JArc infected as adults commencing 14 days PI and 
persisting until 125 days PI. Antibody was not detected in  BALB/cArc and 
BALB/c-Foxn1
nu/Arc mice inoculated as juveniles or as adults. 
In ARC(s) mice there was no age difference in the time of first detection of 
seroconversion, which occurred 10 days PI in both juveniles and adults. The 
prevalence of seroconversion in ARC(s) reached 100% 4 days sooner when they 
were infected as juveniles than as adults and mice infected at both ages were all 
seropositive from day 65 to day 305 PI.  
In virus-infected C57BL/6JArc, antibody was first detected on day 17 and day 14 PI 
in juveniles and adults, respectively. In the C57BL/ inoculated as juveniles, the 
number of seropositive mice at each time interval gradually increased from 17 days 
PI until 52 days PI when all mice were antibody positive, but the prevalence of 
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seropositive C57BL/6JArc juveniles then started to decrease although some 
seropositive mice were detected until 305 days PI when the experiment was 
discontinued. Antibody was detected in some C57BL/6JArc infected as adults from 
days 17-125 PI but was not detected after day 125 PI.  
An antibody response was not detected by rAD ELISA in 50 male  BALB/cArc mice 
tested 29 days PI by the rAD MPV-1 ELISA.  
Comparison of rAD MPV ELISA with other assays conducted by commercial 
laboratories  
Variance between the rAD MPV-1 ELISA results was detected with those of rNS1 
Parvo ELISA, rVP2 MPV-1 ELISA and IFA MVM/MPV-1 (Table 5.2). Antibody 
was not detected in any of 62  BALB/cArc or BALB/c-Foxn1
nu/Arc sera from MPV-
infected mice using the rAD MPV ELISA, but a doubtful (±) result was obtained 
with the rNS1 Parvo ELISA, and 2 and 11 of the 62 sera gave a positive and a ± 
result respectively with the commercial rVP2 MPV-1 ELISA, and 57 and 3 of these 
62 sera gave positive and ± result, respectively, with the MVM/MPV IFA.  The 
MVM/MPV IFA also provided a positive result in 4 of 7 sera from the MPV-1-
infected BALB/c-Foxn1
nu/Arc mice. Five ARC(s) control positive sera were 
confirmed by both rVP2 MPV ELISA and MVM/MPV IFA, while rNS1 Parvo 
ELISA failed to confirm those positive control sera. 
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Table 5.2. Variation in results when BALB/cArc sera were evaluated by different serologic 
tests and different antigens in other laboratories using commercially available antigens and 
serological tests. 
 
Number of serum samples 
rAD ELISA  rNS1 Parvo 
ELISA 
rVP2 MPV1 
ELISA 
MVM/MPV 
IFA 
Mouse 
strain 
Days 
PI 
No. of 
sera 
tested 
+  ±  -  +  ±  -  +  ±  -  +  ±  - 
BALB/c  14  12  0 0 12  0 0 12  0 1  11  12  0 0 
Arc  17  26  0 0 26  0 1 25  1 0  25  26  0 0 
  21   6  0  0  6  0  0   6  0  1   5   6  0  0 
  28   6  0  0   6  0  0   6  1  2   3   6  0  0 
  35   6  0  0   6  0  0   6  0  4   2   4  1  1 
  52   6  0  0   6  0  0   6  0  3   3   3  2  1 
BALB/c   28   2  0  0   2  0  0   2  0  0   2   1  0  1 
Foxn1
nu 31   2  0  0   2  0  0   2  0  0  2   2  0  0 
/Arc  35   2  0  0  0  0  0   2  0  0  2   0  1  1 
ARC(s)  14    5  5 0 0 0 0 5 5 0  0   5 0 0 
ARC(s)  Non-
infected     4  0 0 4 0 0 4 0 0  4   0 0 4 
 
± denotes result in intermediate range  
+ MP-1arc positive 
- denotes MPV-1arc negative 
 
 
Detection of virus by PCR  
MPV-1arc was detected in the large intestine and spleen of all mouse strains of both 
age groups that were inoculated with MPV-ARC, with the exception of 
C57BL/6JArc mice inoculated as adults (Figure 5.2). In BALB/cArc and ARC(s), 
the virus was detected as early as 3 days PI in both age groups, not until 10-17 days 
PI in BALB/c-Foxn1
nu/Arc mice inoculated as juveniles or adults, and not until 21 
days PI in C57BL/6JArc inoculated as juveniles. 
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Figure 5.2. PCR detection of MPV-1arc DNA and its persistence in tissues of 4 mouse 
strains after oral inoculation with MPV-1arc at 2 different ages. MPV-1arc DNA was 
detected in tissues of all mouse strains and age groups with the exception of C57BL/6JArc 
mice inoculated as adults, but the virus persisted for variable periods of time in the different 
mouse strains.  
 
 
Virus was first detected in the spleen and the intestinal contents concurrently in all 
the each mouse strains at both ages of infection, with the exception of BALB/c-
Foxn1
nu/Arc infected as both juveniles and adults when virus was detected in the 
intestinal contents before it was detected in the spleen. Virus persisted for longer in 
the spleen than in the intestinal contents; it persisted in the spleen of BALB/cArc 
inoculated as juveniles for 242 days but only 24 days in C57BL/6JArc inoculated as 
juveniles. It was detected in intestinal contents of BALB/cArc inoculated as adults 
for 55 days, but for only 17 days in C57BL/6JArc inoculated as juveniles.  
A summary of the duration of virus in tissues, and the detection of antibody, in the 4 
strains of mice is provided Table 5.3. 
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Table 5.3 Summary of the persistence of MPV-1arc in tissue, and the period of detection of antibody, 
after oral inoculation with MPV-1arc in 4 strains of mice. 
 
Mouse  strain  ARC(s)   C57BL/6JArc   BALB/cArc   BALB/c-
Foxn1
nu/Arc 
Age  at  infection  Juvenile Adult  Juvenile Adult  Juvenile Adult  Juvenile Adult 
Intestine  3 3    21  ND    3 3    10  10  Initial 
detection 
of virus 
(days PI) 
Spleen 3 3    21  ND    3 3    17  17 
Intestine 35  35   38  ND   38  58   38  35  Final 
detection 
of MPV 
(days PI) 
Spleen  155 155   45  ND    215 185    125 185 
Intestine 32  32   17  ND   35  55   28  25  Duration 
of 
persistence 
of MPV 
(days) 
Spleen  152 152   24  ND    242 182    108 141 
Initial detection of 
antibody (days PI) 
10 10    17  14   ND  ND   ND  ND 
Final detection of 
antibody (days PI) 
305  305   305  125   ND  ND   ND  ND 
Duration of 
persistence of 
antibody (days) 
295  295   288  111   ND  ND   ND  ND 
 
ND denotes not detected or negative. 
 
Discussion 
The techniques developed for the detection of MPV-1arc infection, a PCR assay for 
the detection of virus DNA (Chapter 3), and an ELISA and WIB assay for detection 
of antibody, were invaluable in providing an improved understanding of the 
pathogenesis of infection by this Australian strain of virus.  Their use demonstrated 
that there is a significant difference in the pathogenesis of virus infection depending 
on the mouse strain and age of the mice infected. The variation involved both the 
persistence of virus and the duration of the immune response. This information will 
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be invaluable in providing a basis for the detection of virus infection in laboratory 
mouse colonies, and consequently in eradication of the infection. 
Of the 4 strains of mice inoculated with MPV-1arc, C57BL/6JArc appeared to be the 
most resistant to infection, but there was age variation in the response to infection in 
this strain and juvenile mice were more susceptible than adults. Adult C57BL/6JArc 
mice were the only group of mice in which virus replication was not detected.  
However, while the results of the detection of virus DNA suggested that the virus did 
not replicate in adult C57BL/6JArc, antibodies did develop in adults, albeit for a 
shorter period than in juvenile mice, suggesting they were infected at a level too low 
to detect virus in the tissues sampled. The reasons for the resistance of adult 
C57BL/6JArc to infection are unknown but there may be a mucosal barrier inhibiting 
replication, perhaps a depletion of mitotically active cells required for virus 
replication (Jacoby et al., 1979; Spalholz and Tattersall, 1983). Perhaps similar 
factors in combination with the immune response detected in C57BL/6JArc infected 
as juveniles was associated with the short duration of virus persistence (only 24 
days) in this group of mice.  
Although in BALB/cArc mice it was not possible to detect antibody by the rAD 
ELISA that had been developed, BALB/cArc were susceptible to infection and the 
virus persisted for longer in both spleen and intestinal content in this strain than in 
any other mouse strain tested, both when they were infected as juveniles and as 
adults. Interestingly, despite the known T-cell deficiency of nude BALB/cArc, it was 
detected in this strain for a shorter period than in the conventional BALB/cArc mice. 
The persistence of the virus in both the conventional and nude BALB/c strains 
indicates that the BALB genotype (the background of both immuno-competent and 
immuno-compromised nude and SCID BALB/c) was highly susceptible to MPV-1 
regardless of age and immune competency, as reported previously by Smith et al. 
(1993). As suggested by Siegl (1988), there does not seem to be a direct relationship 
between the antibody response and the duration of persistence of the virus at least in 
the BALB/c genotype. There was a shorter period of persistence of the virus in 
athymic than conventional BALB/c mice, possibly indicating that innate immunity 
might be more important than a T cell response in the clearance of MPV in this 
strain. 
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The reasons for the difficulty in detecting antibody in BALB/cArc mice despite 
prolonged virus replication in this strain are unclear.  To investigate the possibility 
that antibody could have been present in BALB/cArc mice but not detected by the 
rAD ELISA, the results of this assay were compared to those obtained by other 
commercial laboratories using different assays. Inter-laboratory variation was 
detected and this depended on the antigen and serological method used. The 
serologic method was a significant factor since while neither the rAD nor the rNS1 
antigens detected antibody by ELISA or WIB, there was a low level of antibody 
detected by the commercially available rVP2 ELISA, and a much higher level of 
antibody detected by the commercially available MVM/MPV IFA assay. One 
possible explanation for these differences is a low affinity of IgG antibody for the 
recombinant protein ELISA antigen used, compared to the MVM/MPV IFA assay 
that detected native virus proteins where cell culture-propagated MPV is used as 
antigen. Different methods of purifying and solubilisation of the recombinant 
proteins might improve the ability of the antibody present in BALB/c strains to 
recognise the presented epitopes.  This should be investigated further. 
One hypothesis for the inability to detect antibody in BALB/cArc mice in response 
to MPV-1 infection was that the experimental mice used were female, and that there 
could be sex differences in the response.  There is a precedent for such sex-related 
effects on virus replication in mice: Huber and Pfaeffle (1994) reported that male 
and female BALB/c mice differed in susceptibility to myocarditis resulting from 
coxsackievirus type B3 infection, BALB/c females being less susceptible. However, 
this hypothesis could not be substantiated as antibody was not detected in 
BALB/cArc mice of either sex in response to MPV-1 infection.  
The difficulty of detecting antibody in BALB/cArc mice in response to MPV-1 
infection might also be associated with MPV-1-associated immunological 
dysfunction, although this is unlikely to be the major or only reason.  It is known that 
MPV-1 can cause immune dysfunction particularly in adult BALB/c mice beginning 
soon after infection and persisting after seroconversion (McKisic et al., 1996).  
The autosomal recessive mutation of BALB/c nude mice has produced dysgenesis of 
the thymic epithelium, resulting in reduced number of T-cells and defect in helper T-
cell activity (Holub, 1989; Klein-Schneegans et al., 1990).  Therefore, the 
development of a weak antibody response detected in 33% of the BALB/c-
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Foxn1
nu/Arc mice tested by IFA MVM/MPV, was surprising but could be due to a 
small number of T-lymphocytes that the athymic mice could produce. Previous 
studies have detected antibody in the sera of immunodeficient mice and the immune 
response in the original CB17 SCID mice was sometimes incomplete, suggesting 
spontaneous development of partial immune reactivity (Nonoyama et al., 1993). A 
tendency to produce some functional B and T-cells has also been reported with 
Prkdc SCID mice as they age, designated as “leaky” mice (Lake, 2006); the 
leakiness was higher in mice housed under non-SPF conditions, and was high on the 
C57BL/6J and BALB/cByJ backgrounds (Lake, 2006). A low level (2 -23%) of 
leakiness in immunodeficient mice was reported by Bosma et al. (1988) and a much 
higher frequency was reported by Cappoll et al. (1989). Low levels of IgG have been 
detected in athymic rats infected with rat parvovirus by IFA, although the humoral 
responses in those rats have been severely diminished (Fossum et al., 1980; Vos, 
1980; Gaertener et al., 1989).  
Although BALB/cArc mice were the most susceptible to infection in terms of the 
persistence of virus infection, the low rate of detectable seroconversion made them 
unsuitable as sentinel animals if serological tests were used as a method of 
surveillance for MPV-1 infection, especially if ELISA utilising either rAD or  rVP2. 
If BALB/c mice are incorporated into any surveillance program, and other assays 
such as IFA and/or PCR would be required. The highest rate of detectable 
seroconversion to MPV-1arc and also the earliest and the longest immune response 
occurred in ARC(s) mice.  There were also no age differences in the susceptibility of 
ARC(s) mice.  The high rate of seroconversion and lack of detectable differences in 
age susceptibility of ARC(s) mice would make them reliable sentinels for MPV-1 
infection in mouse colonies, if serological assays were used for surveillance as is 
normal. Infection would, however, not be detectable by serological means until 10-
17 days after infection, consistent with the findings of Jacoby et al. (1995), but 
earlier than in C57BL/6JArc. The observation that there was variability in the 
antibody response and detection of viral DNA in spleen and faeces by PCR in adult 
ARC(s) after infection indicates an inherent biological variation in response to MPV-
ARC within the outbred strain. Some mouse to mouse variation was also observed 
within the 3 inbred mouse strains. This variation also needs to be factored into the 
sampling procedure for routine surveillance.  
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If detection was required earlier than the onset of the antibody response, normally 
10-17 days PI, as might be the case in association with the introduction of new 
strains of mice into a colony, PCR based assays would need to be performed.  These 
assays would detect infection as early as 3 days PI, before the onset of an antibody 
response.  Spleen and intestinal content would be suitable tissues for examination by 
PCR: spleen was selected in the current experiments because of the known 
lymphotropic property of MPV-1 (Jacoby et al., 1996), and gastrointestinal tract 
because this is the natural route of entry and excretion of the virus.  Faecal pellets 
could be used if the mice were not to be destroyed for sample collection.   
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Chapter 6. Genetic characterisation of an Australian isolate 
of MPV 
 
Summary 
A mouse parvovirus, designated MPV-1arc, was identified from naturally infected 
laboratory mice in the Animal Resources Centre (ARC). The genomic nucleotide (nt) 
sequence and the predicted amino acid sequences of the non-structural NS1 and the 
structural VP1 proteins but excluding the terminal palindromic regions was 
determined and compared with previously characterised MPV-1a, MPV-1b and 
MPV-1c. While all these MPV-1 strains were very similar (98-99% nt identity), the 
whole DNA and the NS1 protein sequence of the Australian strain was most closely 
related to the cell culture-derived MPV-1a and MPV-1b, while the capsid VP1 
protein sequence had closer similarity to the wild MPV-1c. The differences in the 
Australian strain seemed sufficiently different to the other strains that it could be 
considered a fourth genotype of MPV-1. 
 
Introduction 
Several rodent parvoviruses have been identified and characterised, including the 
virus originally designated as the minute virus of mice (MVM), (Crawford, 1966; 
Mayo and Horzinek, 1998) and mouse parvovirus (MPV) (Ball-Goodrich and 
Johnson, 1994). Currently, 3 genotypes (strains) of MPV are recognised: MPV-1a, 
MPV-1b and MPV-1c (Besselsen et al., 1996). MPV-1a and MPV-1b originated 
from a murine cytotoxic T-cell line, while MPV-1c was a wild strain detected in a 
naturally infected laboratory mouse (McKisic et al., 1993; Besselsen et al., 1996). It 
is thought that these 3 strains are probably variants of the same virus (Besselsen et 
al., 1996). MPV-1 is an important pathogen of laboratory mice, reported to cause 
dysfunction of T-lymphocytes and alter the pattern of graft and tumour rejection 
(McKisic et al., 1996), yet infection with the virus is typically asymptomatic (Smith 
et al., 1993). Rates of MPV-1 infection in animal facilities have been reported to be 
high (Baker, 1998). 
115 
The complete DNA sequences of MVM (Astell et al., 1983 a) and MPV-1 (Goodrich 
and Johnson, 1994) have been determined. While the molecular biology of MVM 
has been well characterised (Cotmore and Tattersall, 1987; Ball-Goodrich and 
Johnson, 1994), MPV-1 is less defined and understood. Restriction analysis of the 
MPV-1 genome indicated that it resembled MVM in size and organisation, with 
conservation of open reading frames (ORFs) and similar promoter sequences, splice 
sites, packaging of the 5-kb minus (V) strand, replication intermediates, and non-
structural proteins. However, there was little conservation in the capsid region of 
MVM and MVP-1, which account for the antigenic differences between MPV-1 and 
MVM, and indicate that MPV-1 is a distinct murine parvovirus (Ball-Goodrich and 
Johnson, 1994).  
The 3 genetic types or strains of MPV, designated as MPV-1a, MPV-1b and MPV-
1c, have a linear single-stranded DNA genome of 5 kb, 2 large and several smaller 
ORFs (Ball-Goodrich and Johnson, 1994), and upstream from each of the 2 large 
ORFs there are promoters designated as P4 and P38. The P4 transcripts, R1 and R2, 
encode 2 non-structural proteins NS1 and NS2, and the P38 transcripts encode 
structural VP1 and VP2 proteins (Ball-Goodrich and Johnson, 1994). 
Both MVM and MPV-1 genomes are bracketed by short terminal palindromes or 
hairpin structures with an essential role in viral replication. As with all autonomous 
parvoviruses, the right (3’) and the left (5’) hairpin structures differ both in sequence 
and in size. The right-end structures of 114 nucleotides are conserved in the various 
rodent parvoviruses (Rhode and Klaassen, 1982; Ball-Goodrich and Johnson, 1994). 
On the other hand, the left  hairpin structures are not conserved in the rodent 
parvoviruses (Astell et al., 1985; Goodrich and Johnson, 1994; Clement et al., 2001; 
Wan et al., 2002). Replication occurs through monomer-and dimer-DNA 
intermediates, during which monomer minus-strand single-stranded DNA is 
encapsidated (Astell et al., 1985; Ball-Goodrich and Johnson, 1994). 
In this Chapter, the MPV-1 detected in the laboratory mouse colony of the ARC in 
2001, and previously only partially characterised by analysis of specific PCR 
products, was sequenced and the predicted amino acid sequence was determined. 
116 
Materials and methods 
Virus DNA 
Spleen tissue was obtained from NIH mice in the ARC, previously identified as 
serologically positive to MPV-1 (Chapter 4). DNA was extracted using a QIAamp 
tissue kit (QIAGEN) according to the protocol provided by the manufacturer, and 
used as a template for the sequencing attempts. This isolate was designated MPV-
1arc. 
Oligonucleotide primers 
Oligonucleotide primers (Proligo) were based on the previously reported sequence of 
other known strains of MPV-1 and were selected to produce 5 overlapping segments 
of the whole virus genome. The oligonucleotide primers for direct sequence analysis 
of the 5 amplicons and the amplicon for the routine PCR used for detection of MPV-
1arc are shown in Table 6.1. 
 
Table 6.1. Primer pairs used in analysis of the MPV-1arc genome. 
 
Primer names  Primer sequence  Amplicon size (base 
pairs) 
Purpose 
MPV1_147F 
MPV1_688R 
aggcgcgaaaaggaagtg 
cttgagcttgactaaagtc 
541 Cloning 
MPV1_1818F 
MPV_2487R 
attgcctggtgactttggt 
gcagcggcgtcagatg 
669 Cloning 
MPV1_264F 
MPV1_2283R 
catggctggaaatgcttac 
ttagtccaagttcagcgg 
2019 Cloning 
MPV1_2271F 
MPV1_4581R 
gaacttggactaaggtacg 
gaaagaaagaacatggttgg
2310 Cloning 
MPV1_4468F 
MPV1_4886R 
atacatgagcattcacaaatg 
agattttattgtttttttggtc 
418 Cloning 
MPV1_3505F 
MPV1_4158R 
ggctaatgccagcgggctg 
cagttagtggtccttagc 
653 Viral  detection 
117 
DNA amplification and cloning 
All reactions were performed in a 20 µl reaction volume in a MyCycler Thermal 
Cycler (Bio-Rad). For detection of viral infection, reaction mixes consisted of 1X 
Platinum Taq reaction buffer(Invitrogen), 1.5 mM Mg
2+, 0.15 mM dNTPs, 0.15 µM 
MPV1_3505F, 0.15 µM MPV1_4158R and 0.046 U/µl Platinum Taq (Invitrogen).  
The PCR cycling consisted of one cycle of 94°C for 3 min followed by 30 cycles of 
94°C for 30 seconds, 54°C for 30 seconds, 72°C for 30 seconds, then one final cycle 
of 72°C for 7 min. The PCR reaction products were separated by electrophoresis on 
a 1% agarose gel stained with ethidium bromide and visualised using a UVP 
transilluminator.  Visual images were produced with Molecular Analyst software 
version 1.4 (Bio-Rad). 
Once the presence of virus DNA in the DNA extracted from the spleen tissue had 
been confirmed by PCR, amplification of the entire genome for cloning was 
performed using 5 sets of primers to produce 5 overlapping amplicons.  The reaction 
conditions were similar to those used for detection of viral infection.  Each product 
was separated using agarose gel electrophoresis and purified from the gel using the 
Wizard SV Gel and PCR Clean-up System (Promega).  These products were then 
cloned into the pGEM-T Easy vector (Promega) according to the manufacturer’s 
instructions. Plasmid DNA was then isolated using the QIAprep Spin Miniprep Kit 
(QIAGEN). 
DNA sequencing and analysis 
The cloned products were sequenced using either vector-specific primers or primers 
specific to the cloned virus DNA, with an ABI PRISM Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit (PerkinElmer) at the State Agricultural 
Biotechnology Centre, Murdoch University, using the Big Dye terminator version 
3.1 method. The thermal cycling conditions for DNA amplification of the 
sequencing reactions consisted of one cycle of 96ºC for 2 min followed by 25 cycles 
of 96ºC for 10 seconds, 50ºC for 5 seconds and 60ºC for 4 min.  
Each region of viral DNA was sequenced from 4 different plasmid clones, each 
obtained from separate PCR reactions. The resulting sequences were then modified 
to remove sequence arising from the vector and from the primers. These were then 
combined using CAP3 (Huang and Madan, 1999). Sequence alignments and 
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similarity plots were performed using ClustalW (Thompson et al., 1994). Sequences 
used for comparison were those of MPV-1a (Genbank accession number U12460), 
MPV-1b (Genbank accession number U34253) and MPV-1c (Genbank accession 
number U34254).  
Ethanol precipitation for Big Dye terminators version 3.1 
The DNA amplified from the sequencing reactions was precipitated by ethanol. Each 
10 μl half reaction was transferred to a 0.5 ml microcentrifuge tube (Eppendorf) 
containing the following: 25 μl of 100% (v/v) ethanol, 1 μl of 3 M sodium acetate 
pH 5.2, 1 μl of 125 mM EDTA (disodium salt dissolved in distilled water).  The 3 
solutions were pipetted into the tube for each reaction individually, as the EDTA 
precipitates in a master mix before it can be aliquotted out. For the precipitation of 
the DNA fragments, the samples were mixed by pipetting up and down, incubated on 
ice for 20 min, and then centrifuged (14,000 g for 30 min). The supernatant was 
discarded and the pellet rinsed by adding 125 μl of 80% ethanol (v/v) and 
centrifugation (14,000 g for 5 min at room temperature). The supernatant was 
removed and the final pellet dried in the Speed-Vac vacuum concentrator (Savant) 
for about 15 min at room temperature. 
Protein sequence analysis 
The protein coding regions of the DNA sequence were excised and translated to give 
the protein coding sequence for NS1 and VP1. These were then compared with those 
of MPV-1a, MPV-1b, and MPV-1c, using ClustalW. 
 
Results 
Identification of MPV-1 in spleen tissue 
The DNA extracted from 10 serologically positive Hsd:NIH mouse spleens was 
evaluated by AD MPV-specific PCR which amplified the AD domain of the 
structural VP1 gene region. The amplified DNA product was detected in spleen from 
each of the 10 mice that were seropositive (Figure 6.1).  
 
 
 
119 
         1     2    3      4     5    6    7     8     9   10  11  12  13  14   15  16 
 
Figure 6.1. Agarose gel electrophoresis of PCR products from the spleens of 10 antibody-
positive Hsd:NIH mice. Lanes 3-12, PCR products resulting from amplification of spleen 
DNA from 10 NIH MPV-1 seropositive mice; lanes 2 and 15, MPV positive control; lane 
13, negative control from a non-exposed mouse; lane 14, no template negative control; lanes 
1 and 16, molecular size markers. 
     653 bp 
 
DNA sequence analysis 
The nt sequence of the newly identified Australian MPV-1arc strain corresponding 
to nucleotides 148-4864 of MPV-1a, shown in Figure 6.2, determined from DNA 
prepared from 10 antibody and PCR positive Hsd:NIH mice from ARC, included all 
the protein coding regions as well as some of the 5’ and 3’ regions of MPV-1a, but 
excluded the terminal palindromic regions. 
The sequence of MVP-1arc was then aligned with the sequence of MPV-1a, -1b and 
-1c (Figure 6.3) and a dendrogram of their genetic relationship was produced to 
demonstrate the phylogenetic relationship between the strains (Figure 6.4). 
Comparison of the nt sequence alignment of the Australian MPV-1arc with the other 
MPV-1 strains revealed that the newly identified strain was more closely related to 
MPV-1a and MPV-1b than MPV-1c, the cell culture derived strains, than to MPV-1c 
(the wild strain), though overall they were all very similar (98-99% nt identity).   
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       1 TATCCTTTTT TTCATTCTGT GAGTCGAGAC GCACAGAAAG AGAGTAACCA ACTAACCATG GCTGGAAATG 
      71 CTTACTCTGA TGAAGTTTTG GGAACAACCA ACTGGTTAAA GGAAAAAAGT AACCAGGAAG TGTTCTCATT
  
     141 TGTTTTTAAA ACTGAGGATG TTCAACTAAA TGGAAAAGAT ATCGGATGGA ATAATTACAA AAAGGAGCTG
  
     211 CAGGAGGACG AGCTGAAATC TTTACAACGA GGAGCGGAAA CTACCTGGGA CCAAAGCGAG GACATGGAAT
  
     281 GGGAATCTAC AGTGGATGAA ATGACCAAAA AGCAAGTATT CATTTATGAC TCTTTAGTTA AAAAATGTTT
  
     351 GTTTGAAGTG CTTAGCACAA AGAATATAGC TCCTGGTGAT GTTACTTGGT TTGTGCAGCA TGAATGGGGG
  
     421 AAAGACCAAG GCTGGCACTG CCATGTACTA ATTGGAGGCA AGGACTTTAG TCAAGCTCAA GGAAAATGGT
  
     491 GGAGAAGGCA GCTAAATGTT TACTGGAGCA GATGGTTGGT AACAGCCTGT AATGTGCAGC TAACACCAGC
  
     561 TGAAAGAATT AAACTAAGAG AAATAGCAGA AGACAGTGAG TGGGTTACTT TACTCACTTA TAAACATAAG
  
     631 CAAACCAAAA AGGACTATAC TAAATGTGTT CTTTTTGGAA ATATGATTGC TTACTACTTT TTAACCAAAA
  
     701 AGAAAATAAG CACCAGTCCG CCAAGAGACG GAGGCTATTT TCTAAGCAGT GACTCTGGCT GGAAAACTAA
  
     771 CTTTTTAAAA GAAGGCGAAC GCCATCTAGT GAGCAAACTA TACACTGATG ACATGCGACC AGAAACGGTT
  
     841 GAAACCACAG TAACCACTGC GCAGGAAACT AAGCGCGGCA GAATTCAAAC TAAAAAAGAG GTTTCTATTA
  
     911 AAACCACACT TAAAGAGCTG GTGCATAAAA GAGTAACCTC ACCAGAAGAC TGGATGATGA TGCAGCCAGA
  
     981 CAGTTACATT GAAATGATGG CTCAACCAGG TGGAGAAAAC CTGCTAAAAA ATACGCTAGA GATCTGTACA
  
    1051 CTAACTCTAG CTAGAACCAA AACAGCATTT GACTTGATTT TAGAAAAAGC TGAAACCAGC AAACTAACCA
  
    1121 ACTTTTCACT GCCTGATACA AGAACCTGCA AGATCTTTGC TTTTCATGGC TGGAACTACA TTAAAGTTTG
  
    1191 CCATGCTATT TGCTGTGTTC TAAACAGACA AGGAGGCAAA AGAAATACTG TTTTATTTCA TGGACCAGCC
  
    1261 AGTACAGGCA AATCCATTAT TGCACAAGCC ATAGCACAGG CAGTTGGTAA TGTTGGTTGC TATAATGCAG
  
    1331 CAAATGTGAA CTTTCCATTC AATGACTGTA CCAACAAGAA CTTAATTTGG GTGGAAGAAG CTGGTAACTT
  
    1401 TGGACAACAA GTAAACCAGT TTAAAGCCAT TTGCTCTGGT CAAACAATTC GCATTGATCA AAAAGGAAAA
  
    1471 GGCAGCAAGC AGATTGAACC AACACCAGTC ATCATGACCA CAAATGAAAA CATTACAGTG GTCAAAATAG
  
    1541 GCTGCGAGGA AAGACCAGAA CACACTCAAC CAATCAGAGA CAGAATGCTT AACATTCATC TAACACATAC
  
    1611 ATTGCCTGGT GACTTTGGTT TGGTTGACAA AAATGAGTGG CCCATGATTT GTGCTTGGTT GGTAAAGAAT
  
    1681 GGTTACCAAT CTACCATGGC AAGCTACTGT GCTAAATGGG GCAAAGTTCC TGATTGGACG GAAAACTGGG
  
    1751 CGGAGCCGAA GGTGCCGACT CCTATAAATT CACTAGGTTC GGCACGCTCA CCATTCACGA CACCGAAAAG
  
    1821 TACACCTCTC AGCCAGAACT ATGCACTAAC TCCACTTGCA TCGGATCTCG AGGACCTGGC TTTAGAGCCT
  
    1891 TGGAGCACAC CAAATACTCC TGTTGCGGGC ACTGCAGAAA CCCAGAACAC TGGGGAAGCT GGTTCCAAAG
  
    1961 CCTGCCAAGA TGGTCAACTG AGCCCAACTT GGTCAGAGAT CGAGGAGGAT TTGAGAGCGT GCTTCGGTGC
  
    2031 GGAACCGTTG AAGAAAGACT TCAGCGAGCC GCTGAACTTG GACTAAGGTA CGATGGCGCC TCCAGCTAAA
  
    2101 AGAGCTAAAA GAGGTAAGGG TTTAAGGGAT GGTTGGTTGG TGGGGTATTA ATGTTTAACT ACCTGTTTTA
  
    2171 CAGGCCTGAA ATCACTTGGT TCTAGGTTGG GTACCTCCAG GCTACAAGTA CCTGGGACCA GGAAACAGCC
  
    2241 TTGACCAAGG AGAACCAACC AATCCATCTG ACGCCGCTGC CAAAGAGCAC GACGAGGCCT ACGACAAATA
  
    2311 CATCAAATCT GGAAAAAATC CTTACCTGTA CTTCTCTGCT GCTGATCAAC GCTTTATTGA CCAAACCAAG
  
    2381 GACGCTAAAG ACTGGGGAGG AAAGGTTGGT CATTACTTTT TTAGAACCAA GCGCGCTTTT GCACCTAAGC
  
    2451 TTGCTAGTAG CTCTGAGCCT GGAACTTCTG GTGTGAGCAT AGCTGGTAAA CGTACCAAAC CACCTGCTCA
  
    2521 CATCTTTATT AACCAAGCCA GAGCTAAAAA AAAACGTGCT TCTCTTGCTG CACAACAGAG AACTCAGACA
  
    2591 ATGAGTGATG GCGCCGAGCA ACATGACAGC GGAAGCGCTG TCCAGTCAGC TGCAAGAGTT GAGCGAGCGG
  
    2661 CTGACGGTCC TGGAGGTTCT GGGGGTGGGG GCTCTGGCGG GGGTGGGGTT GGCGTTTCTA CTGGGAGTTA
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    2731 TGATAATCAG ACGCATTATA GGTTTTTAAG TGATGGTTGG GTAGAAATTA CTGCTTACAG CACACGCATG
  
    2801 GTGCACTTAA ATATGCCCAA ATCAGAAAAT TACTGCAGAG TGCGCGTACA CAACACAAAT GACACACACA
  
    2871 CAGCAGGAAA CATGGCAAAA GATGATGCTC ATGAGCAAAT TTGGACACCA TGGAGCCTAA TTGATTCTAA
  
    2941 TGCTTGGGGA GTTTGGTTTC AGCCAAGTGA TTGGCAATTT ATTTGTAACA ACATGAGTCA TGTGAATTTA
  
    3011 CACTCACTTG ATCAAGAGCT GTTTAATGTA GTAATTAAAA CAGTTACTGA ACAAAACACA GGAGCTGAAG
  
    3081 CAGTTAAAAT ATACAACAAT GACCTTACTG CTTCAATGAT GGTTGCTCTT GATTCTAACA ACATATTGCC
  
    3151 TTACACACCA GCAACAGACA ACCAAGAAAC ACTTGGTTTT TATCCTTGGA AACCAACCAT GCCAAGTCCT
  
    3221 TACAGGTACT ACTTTAACTG TGACAGATCT TTGTCAGTGA CTTACGCAGA CCAAACAGGA AACATTGTTG
  
    3291 ACACAATGGC TAATGCCAGC GGGCTGAGTT CTCAGTTTTT TACCATTGAG AACACTCAAC GCATTCAACT
  
    3361 GCTTAGAACT GGTGATGAAT TTGCTACTGG AACTTACTAC TTCGAAACAG AACCAATCAA ACTTTCTCAC
  
    3431 ACATGGCAAT CAAACAGGCA GCTGGGTCAG CCTCCACAAA TTACTGACCT ACCAACTGCT GACAACGAAA
  
    3501 ATGCTACTTT AGTAGCTAGA GGTGACAGAT CAGGCATAAC CCAGATTTTT GGCAGCAATG ATGTGACTGA
  
    3571 AGCTACTAGA GTAAGGCCTG CACAAGTTGG ATTTTGTCAA CCTCATGACA ATTTTGAAAC CAGCAGAGCA
  
    3641 GGACCTTTTA AAGTTCCAGT AGTGCCAGCA AATGTTACAC AAGGCAATGA ACATGACGCC AATGGCAGCC
  
    3711 TAAGATACAC ATATGACAAA CAACATGGTC AAGACTGGGG CAGTAACAAC AGCAAAGAGC GGTTTACTTG
  
    3781 GGATGCTATT AGCTATGATT CAGGCAGATG GGCTGACAGA TGCTTTATTA ATGCAACACC ATTTACATCA
  
    3851 ACACCAGCTC TTAACAACAT ACTGGCAAAC TCTGACCACA TTGGAAACAA GACTGGTATA CATTATCAGA
  
    3921 ATGTATTTAA CAGCTATGGA CCACTAACTG CTTTTCCACA TCCTGCGCCA ATTTATCCAC AAGGGCAAAT
  
    3991 TTGGGACAAA GAACTTGATC TTGAACACAA ACCAAGACTG CACGCACAAG CTCCCTTTGT TTGCAAGAAC
  
    4061 AATGCTCCAG GTCAACTTCT TGTTAGACTT GCACCAAACC TTACTGATCA GTATGATCCT AACAGTAGCA
  
    4131 CTCTTTCTAG AATTGTAACT TATGGCACAT TTTTTTGGAA GGGCAAACTA ACACTAAAAG CAAAACTTAG
  
    4201 ACCTAATGCT ACTTGGAACC CAGTTTACCA AGTAAGTGCT CAATACCAAA ATGAAAATGA ATACATGAGC
  
    4271 ATTCACAAAT GGCTGCCAAC TGCTACTGGC AACATGCAAA ATATACCTTT GCTTTCTAGA CCTGTTGCTA
  
    4341 GAAATACTTA CTAACCAACC ATGTTCTTTC TTTCTGTACT TCATATATTA TTAAAACTAA TAAAAATACA
  
    4411 ACATAGAAAT ATAATATTAC ATATAGATTT AAGAAATAGA ATAATATGGT ACTCACTAAC TGTTAGAAAT
  
    4481 AATAGAACTT TTGGAATAAC AAGATAGTTA GTTAATTAAT GTTAGATAAA ATAAGAAGAT GATGTACAAT
  
    4551 GGGTAAATAG TTAGTTGGTT AATGTTAAGT AGAATAAGAA GATTATGTAT AATGGGTAAA AGGGTGGAAG
  
    4621 GGTGGTTGGT TGGTATTCCC TTAGACTTGA TGTTAAG   
 
Figure 6.2. Genome DNA sequence of the newly identified Australian MPV-1arc strain, 
corresponding to nucleotides 148-4864 of MPV-1a. The sequence was determined from 
DNA prepared from serologically and PCR positive Hsd:NIH mice from the ARC laboratory 
mouse colonies. 
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MPV-1arc        ------------------------------------------------------------ 
MPV-1a          ATCATTTTTAGAACTGACCAACCATGTTCACGTAAGTGACGTGATGACGCGCGCTTCGCG 
MPV-1b          ------------------------------------------------------------ 
MPV-1c          ------------------------------------------------------------ 
                                                                            
MPV-1arc        ------------------------------------------------------------ 
MPV-1a          CGCTGCCTGCGGCAGTCACACGTCACTTACGTCTCACATGGTTGGTCAGTTCTAAAAATG 
MPV-1b          ------------------------------------------------------------ 
MPV-1c          ------------------------------------------------------------ 
                                                                             
MPV-1arc        ---------------------------GGCGCGAAAAGGAAGTGGGCGTGGTTTAAAGTA 
MPV-1a          ATAAGCGGTTCAGAGAGTTTAGACCAAGGCGCGAAAAGGAAGTGGGCGTGGTTTAAAGTA 
MPV-1b          -----------------------CCAAGGCGCGAAAAGGAAGTGGGCGTGGTTTAAAGTA 
MPV-1c          -----------------------CCCAGGCGCGAAAAGGAAGTGGGCGTGGTTTAAAGTA 
                                           ********************************* 
MPV-1arc        TATAAGCAAATGCTGAAGTCAGTTACTTATCCTTTTTTTCATTCTGTGAGTCGAGACGCA 
MPV-1a          TATAAGCAAATGCTGAAGTCAGTTACTTATCCTTTCTTTCATTCTGTGAGTCGAGACGCG 
MPV-1b          TATAAGCAAATGCTGAAGTCAGTTACTTATCCTTTCTTTCATTCTGTGAGTCGAGACGCG 
MPV-1c          TATAAGCAACTACTGAAATCAGTTACTTATCTTTTCTTTCATTCTGTGAGTCGAGACACA 
                ********* * ***** ************* *** ********************* *  
 
MPV-1arc       CAGAAAGAGAGTAACCAACTAACCATGGCTGGAAATGCTTACTCTGATGAAGTTTTGGGA 
MPV-1a         CAGAAAGAGAGTAACCAACTAACCATGGCTGGAAATGCTTACTCTGATGAAGTTTTGGGA 
MPV-1b         CAGAAAGAGAGTAACCAACTAACCATGGCTGGAAATGCTTACTCTGATGAAGTTTTGGGA 
MPV-1c         CAGAAAGAGAGCAACCAACTAACCATGGCTGGAAATGCTTACTCTGATGAAGTTTTGGGA 
               *********** ************************************************ 
 
MPV-1arc       ACAACCAACTGGTTAAAGGAAAAAAGTAACCAGGAAGTGTTCTCATTTGTTTTTAAAACT 
MPV-1a         ACAACCAACTGGTTAAAGGAAAAAAGTAACCAGGAAGTGTTCTCATTTGTTTTTAAAACT 
MPV-1b         ACAACCAACTGGTTAAAGGAAAAAAGTAACCAGGAAGTGTTCTCATTTGTTTTTAAAACT 
MPV-1c         ACAACCAACTGGTTAAAGGAAAAAAGTAACCAGGAAGTGTTCTCATTTGTTTTTAAAACT 
               ************************************************************ 
 
MPV-1arc       GAGGATGTTCAACTAAATGGAAAAGATATCGGATGGAATAATTACAAAAAGGAGCTGCAG 
MPV-1a         GAGGATGTTCAACTAAATGGAAAAGATATCGGATGGAATAATTACAAAAAGGAGCTGCAG 
MPV-1b         GAGGATGTTCAACTAAATGGAAAAGATATCGGATGGAATAATTACAAAAAGGAGCTGCAG 
MPV-1c         GAAGATGTTCAACTAAATGGAAAAGATATTGGATGGAATAATTACAGAAAGGAGCTGCAA 
               ** ************************** **************** ************  
 
MPV-1arc       GAGGACGAGCTGAAATCTTTACAACGAGGAGCGGAAACTACCTGGGACCAAAGCGAGGAC 
MPV-1a         GAGGACGAGCTGAAATCTTTACAACGAGGAGCGGAAACTACCTGGGACCAAAGCGAGGAC 
MPV-1b         GAGGACGAGCTGAAATCTTTACAACGAGGAGCGGAAACTACCTGGGACCAAAGCGAGGAC 
MPV-1c         GAGGACGAGCTAAAATCTTTACAACGAGGAGCGGAAACTACCTGGGACCAAAGCGAGGAC 
               *********** ************************************************ 
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MPV-1arc      ATGGAATGGGAATCTACAGTGGATGAAATGACCAAAAAGCAAGTATTCATTTATGACTCT 
MPV-1a        ATGGAATGGGAATCTACAGTGGATGAAATGACCAAAAAGCAAGTATTCATTTATGACTCT 
MPV-1b        ATGGAATGGGAATCTACAGTGGATGAAATGACCAAAAAGCAAGTATTCATTTATGACTCT 
MPV-1c        ATGGAATGGGAATCTACAGTGGATGAAGTGACCAAAAAGCAAGTATTCATTTATGACTCT 
              *************************** ******************************** 
 
MPV-1arc       TTAGTTAAAAAATGTTTGTTTGAAGTGCTTAGCACAAAGAATATAGCTCCTGGTGATGTT 
MPV-1a         TTAGTTAAAAAATGTTTGTTTGAAGTGCTTAGCACAAAGAATATAGCTCCTGCTGATGTT 
MPV-1b         TTAGTTAAAAAATGTTTGTTTGAAGTGCTTAGCACAAAGAATATAGCTCCTGCTGATGTT 
MPV-1c         TTAGTTAAAAAATGTTTGTTTGAAGTGCTTAACACAAAGAACATATCTCCTGGTGATGTT 
               ******************************* ********* *** ****** ******* 
 
MPV-1arc        ACTTGGTTTGTGCAGCATGAATGGGGGAAAGACCAAGGCTGGCACTGCCATGTACTAATT 
MPV-1a          ACTTGGTTTGTGCAGCATGAATGGGGGAAAGACCAAGGCTGGCACTGCCATGTACTAATT 
MPV-1b          ACTTGGTTTGTGCAGCATGAATGGGGGAAAGACCAAGGCTGGCACTGCCATGTACTAATT 
MPV-1c          AATTGGTTTGTGCAGCATGAATGGGGAAGAGACCAAGGCTGGCATTGCCATGTACTAATT 
                * ************************ * *************** *************** 
 
MPV-1arc        GGAGGCAAGGACTTTAGTCAAGCTCAAGGAAAATGGTGGAGAAGGCAGCTAAATGTTTAC 
MPV-1a          GGAGGCAAGGACTTTAGTCAAGCTCAAGGAAAATGGTGGAGAAGGCAGCTAAATGTTTAC 
MPV-1b          GGAGGCAAGGACTTTAGTCAAGCTCAAGGAAAATGGTGGAGAAGGCAGCTAAATGTTTAC 
MPV-1c          GGAGGCAAAGACTTTAGTCAAGCTCAAGGAAAGTGGTGGAGAAGGCAGCTAAGTGTTTAC 
                ******** *********************** ******************* ******* 
 
MPV-1arc        TGGAGCAGATGGTTGGTAACAGCCTGTAATGTGCAGCTAACACCAGCTGAAAGAATTAAA 
MPV-1a          TGGAGCAGATGGTTGGTAACAGCCTGTAATGTGCAGCTAACACCAGCTGAAAGAATTAAA 
MPV-1b          TGGAGCAGATGGTTGGTAACAGCCTGTAATGTGCAGCTAACACCAGCTGAAAGAATTAAA 
MPV 1c          TGGAGCAGATGGTTGGTAACAGCCTGTAATGTACAGCTAACACCAGCTGAAAGAATTAAA 
                ******************************** *************************** 
 
MPV-1arc        CTAAGAGAAATAGCAGAAGACAGTGAGTGGGTTACTTTACTCACTTATAAACATAAGCAA 
MPV-1a          CTAAGAGAAATAGCAGAAGACAGTGAGTGGGTTACTTTACTTACTTATAAACATAAGCAA 
MPV-1b          CTAAGAGAAATAGCAGAAGACAGTGAGTGGGTTACTTTGCTCACTTATAAGCATAAGCAA 
MPV-1c          CTAAGAGAAATAGCAGAAGACAGTGAATGGGTTACCTTGCTCACTTATAAGCATAAGCAA 
                ************************** ******** ** ** ******** ********* 
 
MPV-1arc        ACCAAAAAGGACTATACTAAATGTGTTCTTTTTGGAAATATGATTGCTTACTACTTTTTA 
MPV-1a          ACCAAAAAGGACTATACTAAATGTGTTCTTTTTGGAAATATGATTGCTTACTACTTTTTA 
MPV-1b          ACCAAAAAGGACTATACCAAGTGTGTTCTTTTTGGAAACATGATTGCTTACTACTTTTTA 
MPV-1c          ACCAAAAAGGACTATACCAAGTGTGTTCTTTTNGGCAACATAATTGCTTACTACTTTTTA 
                ***************** ** *********** ** ** ** ****************** 
 
MPV-1arc        ACCAAAAAGAAAATAAGCACCAGTCCGCCAAGAGACGGAGGCTATTTTCTAAGCAGTGAC 
MPV-1a          ACCAAAAAAAAAATAAGCACCAGTCCGCCAAGAGACGGAGGCTATTTTCTAAGCAGTGAC 
MPV-1b          ACCAAGAAGAAAATAAGCACTAGTCCGCCAAGGGACGGAGGCTATTTTCTGAGCAGTGAC 
MPV-1c          ACCAAGAAGAAAATAAGCACCAGTCCGCCAAGGGACGGAGGCTATTTTCTTAGTAGTGAC 
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                ***** ** *********** *********** ***************** ** ****** 
MPV-1arc        TCTGGCTGGAAAACTAACTTTTTAAAAGAAGGCGAACGCCATCTAGTGAGCAAACTATAC 
MPV-1a          TCTGGCTGGAAAACTAACTTTTTAAAAGAAGGCGAACGCCATCTAGTGAGCAAACTATAC 
MPV-1b          TCTGGCTGGAAAACTAACTTTTTAAAAGAGGGCGAACGCCATCTAGTGAGCAAACTATAC 
MPV-1c          TCTGGCTGGAAAACTAACTTTTTAAAAGAGGGCGAACGCCATCTAGTGAGCAAACTATAC 
                ***************************** ****************************** 
MPV-1arc        ACTGATGACATGCGACCAGAAACGGTTGAAACCACAGTAACCACTGCGCAGGAAACTAAG 
MPV-1a          ACTGATGACATGCGACCAGAAACGGTTGAAACCACAGTAACCACTGCGCAGGAAACTAAG 
MPV-1b          ACTGATGACATGCGGCCAGAAACGGTTGAAACCACAGTAACCACTGCGCAGGAAACTAAG 
MPV-1c          ACTGATGACATGCGGCCAGAAACGGTTGAAACCACAGTAACCACTGCGCAGGAAACTAAG 
                ************** ********************************************* 
 
MPV-1arc        CGCGGCAGAATTCAAACTAAAAAAGAGGTTTCTATTAAAACCACACTTAAAGAGCTGGTG 
MPV-1a          CGCGGCAGAATTCAAACTAAAAAAGAGGTTTCTATTAAAACCACACTTAAAGAGCTGGTG 
MPV-1b          CGCGGCAGAATTCAAACTAAAAAAGAGGTTTCTATTAAAACCACACTTAAAGAGCTGGTG 
MPV-1c          CGCGGCAGAATTCAAACTAAAAAAGAGGTTTCTATTAAAACCACACTTAAAGAGCTAGTG 
                ******************************************************** *** 
 
MPV-1arc        CATAAAAGAGTAACCTCACCAGAAGACTGGATGATGATGCAGCCAGACAGTTACATTGAA 
MPV-1a          CATAAAAGAGTAACCTCACCAGAAGACTGGATGATGATGCAGCCAGACAGTTACATTGAA 
MPV-1b          CATAAAAGAGTAACCTCACCAGAAGACTGGATGATGATGCAGCCAGACAGTTACATTGAA 
MPV-1c          CATAAGAGAGTAACCTCACCAGAAGACTGGATGATGATGCAGCCAGACAGTTATATTGAA 
                ***** *********************************************** ****** 
 
MPV-1arc        ATGATGGCTCAACCAGGTGGAGAAAACCTGCTAAAAAATACGCTAGAGATCTGTACACTA 
MPV-1a          ATGATGGCTCAACCAGGTGGAGAAAACCTGCTGAAAAATACGCTAGAGATCTGTACACTA 
MPV-1b          ATGATGGCTCAACCAGGTGGAGAAAACCTGCTGAAAAATACGCTAGAGATCTGTACACTA 
MPV-1c          ATGATGGCTCAACCAGGTGGAGAAAACCTGCTGAAAAATACGCTAGAGATCTGTACACTA 
                ******************************** *************************** 
 
MPV-1arc        ACTCTAGCTAGAACCAAAACAGCATTTGACTTGATTTTAGAAAAAGCTGAAACCAGCAAA 
MPV-1a          ACTCTAGCTAGAACCAAAACAGCATTTGACTTGATTTTAGAAAAAGCTGAAACCAGCAAA 
MPV-1b          ACTCTAGCTAGAACCAAAACAGCATTTGACTTGATTTTAGAAAAAGCTGAAACCAGCAAA 
MPV1-c          ACTCTAGCTAGAACCAAAACAGCATTTGACTTGATTTTAGAAAAAGCTGAAACCAGCAAA 
                ************************************************************ 
 
MPV-1arc        CTAACCAACTTTTCACTGCCTGATACAAGAACCTGCAAGATCTTTGCTTTTCATGGCTGG 
MPV-1a          CTAACCAACTTTTCACTGCCTGACACAAGAACCTGCAAGATCTTTGCTTTTCATGGCTGG 
MPV-1b          CTAACCAACTTTTCACTGCCTGACACAAGAACCTGCAAGATCTTTGCTTTTCATGGCTGG 
MPV-1c          CTAACCAACTTTTCACTGCCTGACACAAGAACCTGCAAGATCTTTGCTTTTCATGGCTGG 
                *********************** ************************************ 
 
MPV-1arc        AACTACATTAAAGTTTGCCATGCTATTTGCTGTGTTCTAAACAGACAAGGAGGCAAAAGA 
MPV-1a          AACTACATTAAAGTTTGCCATGCTATTTGCTGTGTTCTAAACAGACAAGGAGGCAAAAGA 
MPV-1b          AACTACATTAAAGTTTGCCATGCTATTTGCTGTGTTCTAAACAGACAAGGAGGCAAAAGA 
MPV-1c          AACTACATTAAAGTTTGCCATGCTATTTGCTGTGTTCTAAACAGACAAGGAGGCAAAAGA 
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                ************************************************************ 
MPV-1arc        AATACTGTTTTATTTCATGGACCAGCCAGTACAGGCAAATCCATTATTGCACAAGCCATA 
MPV-1a          AATACTGTTTTATTTCATGGACCAGCCAGTACAGGCAAATCCATTATTGCACAAGCCATA 
MPV-1b          AATACTGTTTTATTTCATGGACCAGCCAGTACAGGCAAATCCATTATTGCACAAGCCATA 
MPV-1c          AATACTGTTTTATTTCATGGACCAGCCAGTACAGGCAAATCCATTATTGCACAAGCCATA 
                ************************************************************ 
 
MPV-1arc        GCACAGGCAGTTGGTAATGTTGGTTGCTATAATGCAGCAAATGTGAACTTTCCATTCAAT 
MPV-1a          GCACAGGCAGTTGGTAATGTTGGTTGCTATAATGCAGCAAATGTGAACTTTCCATTCAAT 
MPV-1b          GCACAGGCAGTTGGTAATGTTGGTTGCTATAATGCAGCAAATGTGAACTTTCCATTCAAT 
MPV-1c          GCACAGGCAGTTGGTAATGTTGGTTGTTATAATGCAGCAAATGTGAACTTTCCATTCAAT 
                ************************** ********************************* 
 
MPV-1arc        GACTGTACCAACAAGAACTTAATTTGGGTGGAAGAAGCTGGTAACTTTGGACAACAAGTA 
MPV-1a          GACTGTACCAACAAGAACTTAATTTGGGTGGAAGAAGCTGGTAACTTTGGACAACAAGTA 
MPV-1b          GACTGTACCAACAAGAACTTGATTTGGGTGGAAGAAGCTGGTAACTTTGGACAGCAAGTA 
MPV-1c          GACTGTACCAACAAGAACTTAATTTGGGTGGAAGAAGCTGGTAACTTTGGACAACAAGTA 
                ******************** ******************************** ****** 
 
MPV-1arc        AACCAGTTTAAAGCCATTTGCTCTGGTCAAACAATTCGCATTGATCAAAAAGGAAAAGGC 
MPV-1a          AACCAGTTTAAAGCCATTTGCTCTGGTCAAACAATTCGCATTGATCAAAAAGGAAAAGGC 
MPV-1b          AACCAGTTTAAAGCCATTTGCTCTGGTCAAACAATTCGCATTGATCAAAAAGGAAAAGGC 
MPV-1c          AACCAGTTTAAAGCCATTTGCTCTGGTCAAACAATTCGCATTGATCAAAAAGGAAAAGGC 
                ************************************************************ 
 
MPV-1arc        AGCAAGCAGATTGAACCAACACCAGTCATCATGACCACAAATGAAAACATTACAGTGGTC 
MPV-1a          AGCAAGCAGATTGAACCAACACCAGTCATCATGACCACAAATGAAAACATTACAGTGGTC 
MPV-1b          AGCAAGCAGATTGAACCAACACCAGTCATCATGACCACAAATGAGAACATTACAGTGGTC 
MPV-1c          AGCAAGCAGATTGAACCAACACCAGTCATCATGACCACAAATGAAAACATTACAGTGGTC 
                ******************************************** *************** 
MPV-1arc        AAAATAGGCTGCGAGGAAAGACCAGAACACACTCAACCAATCAGAGACAGAATGCTTAAC 
MPV-1a          AAAATAGGCTGCGAGGAAAGACCAGAACACACTCAACCAATCAGAGACAGAATGCTTAAC 
MPV-1b          AAAATAGGCTGCGAGGAGAGACCAGAACACACTCAACCAATCAGAGACAGAATGCTTAAC 
MPV-1c          AAAATAGGCTGCGAGGAAAGACCAGAACACACTCAACCAATCAGAGACAGAATGCTTAAC 
                ***************** ****************************************** 
 
MPV-1arc        ATTCATCTAACACATACATTGCCTGGTGACTTTGGTTTGGTTGACAAAAATGAGTGGCCC 
MPV-1a          ATTCATCTAACACATACATTGCCTGGTGACTTTGGTTTGGTTGACAAAAATGAGTGGCCC 
MPV-1b          ATTCATCTAACACATACATTGCCTGGTGACTTTGGTTTGGTTGACAAAAGTGAGTGGCCC 
MPV-1c          ATTCATCTAACACATACATTGCCTGGTGACTTTGGTTTGGTTGACAAACATGANTGGCCC 
                ************************************************  *** ****** 
 
MPV-1arc        ATGATTTGTGCTTGGTTGGTAAAGAATGGTTACCAATCTACCATGGCAAGCTACTGTGCT 
MPV-1a          ATGATTTGTGCTTGGTTGGTAAAGAATGGTTACCAATCTACCATGGCAAGCTACTGTGCT 
MPV-1b          ATGATCTGTGCTTGGTTGGTAAAGAATGGTTACCAATCTACCATGGCAAGCTACTGTGCT 
MPV-1c          ATGATTTGTGCTTGGTTGGTAAAGAATGGTTACCAATCTACCATGGCAAGCTACTGTGCT 
126 
                ***** ****************************************************** 
MPV-1arc        AAATGGGGCAAAGTTCCTGATTGGACGGAAAACTGGGCGGAGCCGAAGGTGCCGACTCCT 
MPV-1a          AAATGGGGCAAAGTTCCTGATTGGACGGAAAACTGGGCGGAGCCGAAGGTGCCGACTCCT 
MPV-1b          AAATGGGGCAAAGTTCCTGATTGGACAGAAAACTGGGCGGAGCCGAAGGTGCCGACTCCT 
MPV-1c          AAATGGGGCAAAGTTCCTGATTGGACGGAAAACTGGGCGGAGCCGAAGGTGCCGACTCCT 
                ************************** ********************************* 
 
MPV-1arc        ATAAATTCACTAGGTTCGGCACGCTCACCATTCACGACACCGAAAAGTACACCTCTCAGC 
MPV-1a          ATAAATTCACTAGGTTCGGCACGCTCACCATTCACGACACCGAAAAGTACGCCTCTCAGC 
MPV-1b          ATAAATTCACTAGGTTCGGCACGCTCACCATTCACGACACCGAAAAGTACGCCTCTCAGC 
MPV-1c          ATAAATTCACTAGGTTCGGCACGCTCACCATTCACGACACCGAAAAGTACGCCTCTCAGC 
                ************************************************** ********* 
 
MPV-1arc        CAGAACTATGCACTAACTCCACTTGCATCGGATCTCGAGGACCTGGCTTTAGAGCCTTGG 
MPV-1a          CAGAACTATGCACTAACTCCACTTGCATCGGATCTCGAGGACCTGGCTTTAGAGCCTTGG 
MPV-1b          CAGAACTATGCACTAACTCCACTTGCATCGGATCTCGAGGACCTGGCTTTAGAGCCTTGG 
MPV-1c          CAGAACTATGCACTAACTCCACTTGCATCGGATCTCGAGGACCTGGCTTTAGAGCCTTGG 
                ************************************************************ 
 
MPV-1arc        AGCACACCAAATACTCCTGTTGCGGGCACTGCAGAAACCCAGAACACTGGGGAAGCTGGT 
MPV-1           AGCACACCAAATACTCCTGTTGCGGGCACTGCAGAAACCCAGAACACTGGGGAAGCTGGT 
MPV-1b          AGCACACCAAATACTCCTGTTGCGGGCACTGCAGAAACCCAGAACACTGGGGAAGCTGGT 
MPV-1c          AGCACACCAAATACTCCTGTTGCGGGCACTGCAGAAACCCAGAACACTGGGGAAGCTGGT 
                ************************************************************ 
 
MPV-1arc        TCCAAAGCCTGCCAAGATGGTCAACTGAGCCCAACTTGGTCAGAGATCGAGGAGGATTTG 
MPV-1a          TCCAAAGCCTGCCAAGATGGTCAACTGAGCCCAACTTGGTCAGAGATCGAGGAGGATTTG 
MPV-1           TCCAAAGCCTGCCAAGATGGTCAACTGAGCCCAACTTGGTCAGAGATCGAGGAGGATTTG 
MPV-1           TCCAAAGCCTGCCAAGATGGTCAACTGAGCCCAACTTGGTCAGAGATCGAGGAGGATTTG 
                ************************************************************ 
 
MPV-1arc        AGAGCGTGCTTCGGTGCGGAACCGTTGAAGAAAGACTTCAGCGAGCCGCTGAACTTGGAC 
MPV-1a          AGAGCGTGCTTCGGTGCGGAACCGTTGAAGAAAGACTTCAGCGAGCCGCTGAACTTGGAC 
MPV-1b          AGAGCGTGCTTCGGTGCGGAACCGTTGAAGAGAGACTTCAGCGAGCCGCTGAACTTGGAC 
MPV-1           AAAGCGTGCTTCGGTGCGGAACCGTTGAAGAGAGACTTCAGCGAGCCGCTGAACTTGGAC 
                * ***************************** **************************** 
 
MPV-1arc        TAAGGTACGATGGCGCCTCCAGCTAAAAGAGCTAAAAGAGGTAAGGGTTTAAGGGATGGT 
MPV-1a          TAAGGTACGATGGCGCCTCCAGCTAAAAGAGCTAAAAGAGGTAAGGGTTTAAGGGATGGT 
MPV-1b          TAAGGTACGATGGCGCCTCCAGCTAAAAGAGCTAAAAGAGGTAAGGGTTTAAGGGATGGT 
MPV-1c          TAAGGTACGATGGCGCCTCCAGCTAAAAGAGTCAAAAGAGGTAAGGGTTTAAGGGATGGT 
                *******************************  *************************** 
 
 
 
 
127 
 
MPV-1arc        TGGTTGGTGGGGTATTAATGTTTAACTACCTGTTTTACAGGCCTGAAATCACTTGGTTCT 
MPV-1           TGGTTGGTGGGGTATTAATGTTTAACTACCTGTTTTACAGGCCTGAAATCACTTGGTTCT 
MPV-1           TGGTTGGTGGGGTATTAATGTTTAACTACCTGTTTTACAGGCCTGAAATCACTTGGTTCT 
MPV-1           TGGTCGGTGGGGTATTAATGTTTAACTACCTGTTTTACAGGCCTGAAATCACTTGGTTCT 
                **** ******************************************************* 
 
MPV-1arc        AGGTTGGGTACCTCCAGGCTACAAGTACCTGGGACCAGGAAACAGCCTTGACCAAGGAGA 
MPV-1           AGGTTGGGTACCTCCAGGCTACAAGTACCTGGGACCAGGAAACAGCCTTGACCAAGGAGA 
MPV-1           AGGTTGGGTACCTCCAGGCTACAAGTACCTGGGACCAGGAAACAGCCTTGACCAAGGAGA 
MPV-1           AGGTTGGGTACCTCCAGGCTACAAGTACCTGGGACCAGGGAACAGCCTTGACCAAGGAGA 
                *************************************** ******************** 
 
MPV-1arc        ACCAACCAATCCATCTGACGCCGCTGCCAAAGAGCACGACGAGGCCTACGACAAATACAT 
MPV-1a          ACCAACCAATCCATCTGACGCCGCTGCCAAAGAGCACGACGAGGCCTACGACAAATACAT 
MPV-1b          ACCAACCAATCCATCTGACGCCGCTGCCAAAGAGCACGACGAGGCCTACGACAAATACAT 
MPV-1c          ACCAACCAATCCATCTGACGCCGCTGCCAAAGAGCACGACGAGGCCTACGACAAATACAT 
                ************************************************************ 
 
MPV-1arc        CAAATCTGGAAAAAATCCTTACCTGTACTTCTCTGCTGCTGATCAACGCTTTATTGACCA 
MPV-1a          CAAATCTGGAAAAAATCCTTACCTGTACTTCTCTGCTGCTGATCAACGCTTTATTGACCA 
MPV-1b          CAAATCTGGAAAAAATCCTTACCTGTACTTCTCTGCTGCTGATCAACGCTTTATTGACCA 
MPV-1c          CAAATCTGGAAAAAATCCTTACCTGTACTTCTCTGCTGCTGATCAACGCTTTATTGACCA 
                ************************************************************ 
 
MPV-1arc        AACCAAGGACGCTAAAGACTGGGGAGGAAAGGTTGGTCATTACTTTTTTAGAACCAAGCG 
MPV-1a          AACCAAGGACGCTAAAGACTGGGGAGGAAAGGTTGGTCACTACTTTTTTAGAACCAAGCG 
MPV-1b          AACCAAGGACGCTAAAGACTGGGGAGGAAAGGTTGGTCACTACTTTTTTAGAACCAAGCG 
MPV-1c          AACCAAGGACGCTAAAGACTGGGGAGGAAAGGTTGGTCACTACTTTTTTAGAACCAAGCG 
                *************************************** ******************** 
 
MPV-1arc        CGCTTTTGCACCTAAGCTTGCTAGTAGCTCTGAGCCTGGAACTTCTGGTGTGAGCATAGC 
MPV-1a          CGCTTTTGCACCTAGGCTTGCTAGTAGCTCTGAGCCTGGAACTTCTGGTGTGAGCATAGC 
MPV-1b          CGCTTTTGGACCTAGGCTTGCTAGTAGCTCTGAGCCTGGAACTTCTGGTGTGAGCATAGC 
MPV-1c          CGCTTTTGCACCTAGGCTTGCTAGTAGCTCTGAGCCTGGAACTTCTGGTGTGAGCATAGC 
                ******** ***** ********************************************* 
 
MPV-1arc        TGGTAAACGTACCAAACCACCTGCTCACATCTTTATTAACCAAGCCAGAGCTAAAAAAAA 
MPV-1a          TGGTAAACGTACCAAACCACCTGCTCACATCTTTATTAACCAAGCCAGAGCTAAAAAAAA 
MPV-1b          TGGTAAACGTACCAAACCACCTGCTCACATCTTTATTAACCAAGCCAGAGCTAAAAAAAA 
MPV1c           TGGTAAACGTACCAAACCACCTGCTCACATCTTTATTAACCAAGCCAGAGCTAAAAAAAA 
                ************************************************************ 
 
 
 
 
128 
 
MPV-1arc        ACGTGCTTCTCTTGCTGCACAACAGAGAACTCAGACAATGAGTGATGGCGCCGAGCAACA 
MPV-1a          ACGTGCTTCTCTTGCTGCACAGCAAAGAACTCAGACAATGAGTGATGGCGCCGAGCAACC 
MPV-1b          ACGTGCTTCTCTTGCTGCACAGCAAAGAACTCAGACAATGAGTGATGGCGCCGAGCAACC 
MPV-1c          ACGTGCTTCTCTTGCTGCACAACAGAGAACTCAGACAATGAGTGATGGCACCGAGCAACC 
                ********************* ** ************************ *********  
 
 
MPV-1arc        TGACAGCGGAAGCGCTGTCCAGTCAGCTGCAAGAGTTGAGCGAGCGGCTGACGGTCCTGG 
MPV-1a          TGACAGCGGAAGCGCTGTCCAGTCAGCTGCAAGAGTTGAGCGAGCGGCTGACGGTCCTGG 
MPV-1b          TGACAGCGGAAGCGCTGTCCAGTCAGCTGCAAGAGTTGAGCGAGCGGCTGACGGTCCTGG 
MPV1c           TGACAGCGGAAGCGCTGTCCAGTCAGCTGCAAGAGTTGAGCGAGCGACTGACGGTCCTGG 
                ********************************************** ************* 
 
MPV-1arc        AGGTTCTGGGGGTGGGGGCTCTGGCGGGGGTGGGGTTGGCGTTTCTACTGGGAGTTATGA 
MPV-1a          AGGTTCTGGGGGTGGGGGCTCTGGCGGGGGTGGGGTTGGCGTTTCTACTGGGAGTTATGA 
MPV-1b          AGGTTCTGGGGGTGGGGGCTCTGGCGGGGGTGGGGTTGGCGTTTCTACTGGGAGTTATGA 
MPV1-c          AGGTTCTGGGGGTGGGGGCTCTGGCGGGGGTGGGGTTGGCGTTTCTACTGGGAGTTATGA 
                ************************************************************ 
 
MPV-1arc        TAATCAGACGCATTATAGGTTTTTAAGTGATGGTTGGGTAGAAATTACTGCTTACAGCAC 
MPV-1           TAATCAGACGCATTATAGGTTTTTAAGTGATGGTTGGGTAGAAATTACTGCTTACAGCAC 
MPV-1           TAATCAGACGCATTATAGGTTTTTAAGTGATGGTTGGGTAGAAATTACTGCTTACAGCAC 
MPV-1c          TAATCAGACGCATTATAGGTTTTTAAGTGATGGTTGGGTAGAAATTACTGCTTACAGCAC 
                ************************************************************ 
  
MPV-1arc        ACGCATGGTGCACTTAAATATGCCCAAATCAGAAAATTACTGCAGAGTGCGCGTACACAA 
MPV-1a          ACGCATGGTGCACTTAAATATGCCCAAATCAGAAAATTACTGCAGAGTGCGCGTACACAA 
MPV-1b          ACGCATGGTGCACTTAAATATGCCCAAATCAGAAAATTACTGCAGAGTGCGCGTACACAA 
MPV-1c          ACGCATGGTGCACTTAAATATGCCCAAATCAGAAAATTACTGCAGAGTGCGCGTACACAA 
                ************************************************************ 
 
MPV-1arc        CACAAATGACACACACACAGCAGGAAACATGGCAAAAGATGATGCTCATGAGCAAATTTG 
MPV-1a          CACAAATGACACACGCACAGCAGGAAACATGGCAAAAGATGATGCTCATGAGCAAATTTG 
MPV-1b          CACAAATGACACACGCACAGCAGGAAACATGGCAAAAGATGATGCTCATGAGCAAATTTG 
MPV-1c          CACAAATGACACACACACAGCAGGAAACATGGCAAAAGATGATGCTCATGAGCAAATTTG 
                ************** ********************************************* 
 
MPV-1arc        GACACCATGGAGCCTAATTGATTCTAATGCTTGGGGAGTTTGGTTTCAGCCAAGTGATTG 
MPV1-a          GACACCATGGAGCCTAATTGATTCTAATGCTTGGGGAGTTTGGTTTCAGCCAAGTGATTG 
MPV-1b          GACACCATGGAGCCTAATTGATTCTAATGCTTGGGGAGTTTGGTTTCAGCCAAGTGATTG 
MPV-1c          GACACCATGGAGCCTAATTGATTCTAATGCTTGGGGAGTTTGGTTTCAGCCAAGTGATTG 
                ************************************************************ 
 
 
 
129 
 
MPV-1arc        GCAATTTATTTGTAACAACATGAGTCATGTGAATTTACACTCACTTGATCAAGAGCTGTT 
MPV-1a          GCAATTTATTTGTAACAACATGAGTCATGTGAATCTACACTCACTTGATCAAGAGCTGTT 
MPV-1b          GCAATTTATTTGTAACAACATGAGTCATGTGAATCTACACTCACTTGATCAAGAGCTGTT 
MPV-1c          GCAATTTATTTGTAACAACATGAGTCATGTAAATTTACACTCACTTGATCAAGAGCTGTT 
                ****************************** *** ************************* 
 
MPV-1arc        TAATGTAGTAATTAAAACAGTTACTGAACAAAACACAGGAGCTGAAGCAGTTAAAATATA 
MPV-1a          TAATGTAGTAATTAAAACAGTTACTGAACAAAACACAGGAGCTGAAGCAGTTAAAATATA 
MPV-1b          TAATGTAGTAATTAAAACAGTTACTGAACAAAACACAGGAGCTGAAGCAGTTAAAATATA 
MPV-1c          TAATGTAGTAATTAAAACAGTTACTGAACAAAACACAGGAGCTGAAGCAGTTAAAGTATA 
                ******************************************************* **** 
 
MPV-1arc        CAACAATGACCTTACTGCTTCAATGATGGTTGCTCTTGATTCTAACAACATATTGCCTTA 
MPV-1a          CAACAATGACCTTACTGCTTCAATGATGGTTGCTCTTGATTCTAACAACATATTGCCTTA 
MPV-1b          CAACAATGACCTTACTGCTTCAATGATGGTTGCTCTTGATTCTAACAACATATTGCCTTA 
MPV-1c          CAACAATGACCTCACTGCTTCAATGATGGTTGCTCTTGATTCTAACAACATATTACCTTA 
                ************ ***************************************** ***** 
 
MPV-1arc        CACACCAGCAACAGACAACCAAGAAACACTTGGTTTTTATCCTTGGAAACCAACCATGCC 
MPV-1a          CACACCAGCAACAGACAACCAAGAAACACTTGGTTTTTATCCTTGGAAACCAACCATGCC 
MPV-1b          CACACCAGCAACAGACAACCAAGAAACACTTGGTTTTTATCCTTGGAAACCAACCATGCC 
MPV-1c          CACACCAGCAACAGACAACCAAGAAACACTTGGTTTTTATCCTTGGAAACCAACCATGCC 
                ************************************************************ 
 
MPV-1arc        AAGTCCTTACAGGTACTACTTTAACTGTGACAGATCTTTGTCAGTGACTTACGCAGACCA 
MPV-1a          AAGTCCTTACAGGTACTACTTTAACTGTGACAGATCTTTGTCAGTGACTTACACAGACCA 
MPV-1b          AAGTCCTTACAGGTACTACTTTAACTGTGACAGATCTTTGTCAGTGACTTACACAGACCA 
MPV-1c          AAGTCCTTACAGGTACTACTTTAACTGTGACAGATCTTTGTCAGTAACTTACGCAGACCA 
                ********************************************* ****** ******* 
 
MPV-1arc        AACAGGAAACATTGTTGACACAATGGCTAATGCCAGCGGGCTGAGTTCTCAGTTTTTTAC 
MPV-1a          AACAGGAAGCATTGTTGACACAATGGCTAATGCCAGCGGGCTGAGTTCTCAGTTTTTTAC 
MPV-1b          AACAGGAAGCATTGTTGACACAATGGCTAATGCCAGCGGGGTGAGTTCTCAGTTTTTTAC 
MPV-1c          AACAGGAAACATTGTTGACACAATGGCTAATGCCAGCGGGCTGAGTTCTCAGTTTTTTAC 
                ******** ******************************* ******************* 
 
MPV-1arc        CATTGAGAACACTCAACGCATTCAACTGCTTAGAACTGGTGATGAATTTGCTACTGGAAC 
MPV-1a          CATTGAGAACACTCAACGCATTCAACTGCTTAGAACTGGTGATGAATTTGCTACTGGAAC 
MPV-1b          CATTGAGAACACTCAACGCATTCAACTGCTTAGAACTGGTGATGAATTTGCTACTGGAAC 
MPV-1c           CATTGAGAACACTCAACGCATTCAGCTGCTTAGAACTGGTGATGAATTTGCTACTGGAAC 
                ************************ *********************************** 
MPV-1arc        TTACTACTTCGAAACAGAACCAATCAAACTTTCTCACACATGGCAATCAAACAGGCAGCT 
MPV-1a          TTACTACTTCGAAACAGAACCAATCAAACTTTCTCACACATGGCAATCAAACAGGCAGCT 
MPV-1b          TTACTACTTCGAAACAGAACCAATCAAACTTTCTCACACATGGCAATCAAACAGGCAGCT 
MPV-1c          TTACTACTTTGAAACAGAACCAATCAAACTTTCTCACACATGGCAATCAAACAGGCAGCT 
130 
                ********* ************************************************** 
 
MPV-1arc        GGGTCAGCCTCCACAAATTACTGACCTACCAACTGCTGACAACGAAAATGCTACTTTAGT 
MPV-1a          GGGTCAGCCTCCACAAATTACTGACCTACCAACTGCTGACAACGAAAATGCTACTTTAGT 
MPV-1b          GGGTCAGCCTCCACAAATTACTGACCTACCAACTGCTGACAACGAAAATGCTACTTTAGT 
MPV-1c          GGGTCAGCCTCCACAAATTACTGACCTGCCAACTGCTGACAACGAAAATGCTACTTTAGT 
                *************************** ******************************** 
 
MPV-1arc        AGCTAGAGGTGACAGATCAGGCATAACCCAGATTTTTGGCAGCAATGATGTGACTGAAGC 
MPV-1a          AACTAGAGGTGACAGATCAGGCATAACCCAAATTTCTGGCAGCAATGATGTGACTGAAGC 
MPV-1b          AACTAGAGGTGACAGATCAGGCATAACCCAAATTTCTGGCAGCAATGATGTGACTGAAGC 
MPV-1c          AGCTAGAGGTGACAGATCAGGCATAACCCAAATTTTTGGCAGCAATGATGTGACTGAAGC 
                * **************************** **** ************************ 
 
MPV-1arc        TACTAGAGTAAGGCCTGCACAAGTTGGATTTTGTCAACCTCATGACAATTTTGAAACCAG 
MPV-1a          TACTAGAGTAAGGCCTGCACAAGTTGGATTTTGTCAACCTCATGACAATTTTGAAACCAG 
MPV-1b          TACTAGAGTAAGGCCTGCACAAGTTGGATTTTGTCAACCTCATGACAATTTTGAAACCAG 
MPV-1c          TACTAGAGTAAGGCCTGCACAAGTTGGATTTTGTCAACCTCATGACAATTTTGAAACCAG 
                ************************************************************ 
 
MPV-1arc        CAGAGCAGGACCTTTTAAAGTTCCAGTAGTGCCAGCAAATGTTACACAAGGCAATGAACA 
MPV-1a          CAGAGCAGGACCTTTTAAAGTTCCAGTAGTGCCAGCAAATGTTACACAAGGCAATGAACA 
MPV-1b          CAGAGCAGGACCTTTTAAAGTTCCAGTAGTGCCAGCAAATGTTACACAAGGCAATGAACA 
MPV-1c          CAGAGCAGGACCTTTTAAAGTTCCAGTAGTGCCAGCAAATGTTACACAAGGCAATGAACA 
                ************************************************************ 
 
MPV-1arc        TGACGCCAATGGCAGCCTAAGATACACATATGACAAACAACATGGTCAAGACTGGGGCAG 
MPV-1a          TGACGCCAATGGCAGCCTAAGATACACATATGACAAACAACATGGTCAAGACTGGGGCAG 
MPV-1b          TGACGCCAATGGCAGCCTAAGATACACATATGACAAACAACATGGTCAAGACTGGGGCAG 
MPV1c           TGACGCCAATGGCAGCCTAAGATACACATATGACAAACAACATGGTCAAGACTGGGGCAG 
                ************************************************************ 
 
MPV-1arc        TAACAACAGCAAAGAGCGGTTTACTTGGGATGCTATTAGCTATGATTCAGGCAGATGGGC 
MPV-1a          TAACAACAGCAAAGAACGGTTTACTTGGGATGCTATTAGCTATGATTCAGGCAGATGGGC 
MPV-1b          TAACAACAGCAAAGAACGGTTTACTTGGGATGCTATTAGCTATGATTCAGGCAGATGGGC 
MPV-1c          TAACAACAGCAAAGAAAGGTTTACTTGGGATGCTATTAGCTATGATTCAGGCAGATGGGC 
                ***************  ******************************************* 
MPV-1arc        TGACAGATGCTTTATTAATGCAACACCATTTACATCAACACCAGCTCTTAACAACATACT 
MPV-1a          TGACAGATGCTTTATTAATGCAACACCATTTACATCACCACCAGCTCTTAACAACATACT 
MPV-1b          TGACAGATGCTTTATTAATGCAACACCATTTACATCACCACCAGCTCTTAACAACATACT 
MPV-1c          TGACAGATGCTTTATTAATGCAACACCATTTACATCACCACCAGCTCTTAACAACATACT 
                ************************************* ********************** 
 
 
 
 
131 
 
MPV-1arc        GGCAAACTCTGACCACATTGGAAACAAGACTGGTATACATTATCAGAATGTATTTAACAG 
MPV-1a          GACAAACTCTGACCCCATTGGAAACAAGACTGCTATACATTATCAGAATGTATTTAACAG 
MPV-1b          GACAAACTCTGACCCCATTGGAAACAAGACTGCTATACATTATCAGAATGTATTTAACAG 
MPV-1c          AACAAACTCTGACCCCATTGGAAACAAGACTGGTATACATTATCAGAATGTATTTAACAG 
                  ************ ***************** *************************** 
 
MPV-1arc        CTATGGACCACTAACTGCTTTTCCACATCCTGCGCCAATTTATCCACAAGGGCAAATTTG 
MPV-1a          CTATGGACCACTAACTGCTTTTCCACATCCTGCGCCAATTTATCCACAAGGGCAAATTTG 
MPV-1b          CTATGGACCACTAACTGCTTTTCCACATCCTGCGCCAATTTATCCACAAGGGCAAATTTG 
MPV-1c          CTATGGACCACTAACTGCTTTTCCACATCCTGCGCCAATTTATCCACAAGGGCAAATTTG 
                ************************************************************ 
 
MPV-1arc        GGACAAAGAACTTGATCTTGAACACAAACCAAGACTGCACGCACAAGCTCCCTTTGTTTG 
MPV-1a          GGACAAAGAACTTGATCTTGAACACAAACCAAGACTGCACGCACAAGCTCCCTTTGTTTG 
MPV-1b          GGACAAAGAACTTGATCTTGAACACAAACCAAGACTGCACGCACAAGCTCCCTTTGTTTG 
MPV-1c          GGACAAAGAACTTGATCTTGAACACAAACCAAGACTGCACGCACAAGCTCCCTTTGTTTG 
                ************************************************************ 
 
MPV-1arc        CAAGAACAATGCTCCAGGTCAACTTCTTGTTAGACTTGCACCAAACCTTACTGATCAGTA 
MPV-1a          CAAGAACAATGCTCCAGGTCAACTTCTTGTTAGACTTGCACCAAACCTTACTGATCAGTA 
MPV-1b          CAAGAACAATGCTCCAGGTCAACTTCTTGTTAGACTTGCACCAAACCTTACTGATCAGTA 
MPV-1c          CAAGAACAATGCTCCAGGTCAACTTCTTGTTAGACTTGCACCAAACCTTACTGATCAGTA 
                ************************************************************ 
 
MPV-1arc        TGATCCTAACAGTAGCACTCTTTCTAGAATTGTAACTTATGGCACATTTTTTTGGAAGGG 
MPV-1a          TGATCCTAACAGTAGCACTCTTTCTAGAATTGTAACTTATGGCACATTTTTTTGGAAGGG 
MPV-1b          TGATCCTAACAGTAGCACTCTTTCTAGAATTGTAACTTATGGCACATTTTTTTGGAAGGG 
MPV1c           TGATCCTAACAGTAGCACTCTTTCTAGAATTGTAACTTATGGCACATTTTTTTGGAAGGG 
                ************************************************************ 
 
MPV-1arc        CAAACTAACACTAAAAGCAAAACTTAGACCTAATGCTACTTGGAACCCAGTTTACCAAGT 
MPV-1a          CAAACTAACACTAAAAGCAAAACTTAGACCTAATGCTACTTGGAACCCAGTTTACCAAGT 
MPV-1b          CAAACTAACACTAAAAGCAAAACTTAGACCTAATGCTACTTGGAACCCAGTTTACCAAGT 
MPV1c           CAAACTAACACTAAAAGCAAAACTTAGACCTAATGCTACTTGGAACCCAGTTTACCAAGT 
                ************************************************************ 
 
MPV-1arc        AAGTGCTCAATACCAAAATGAAAATGAATACATGAGCATTCACAAATGGCTGCCAACTGC 
MPV-1a          AAGTGCTCAATACCAAAATGAAAATGAATACATGAGCATTCACAAATGGCTGCCAACTGC 
MPV-1b          AAGTGCTCAATACCAAAATGAAAATGAATACATGAGCATTCACAAATGGCTGCCAACTGC 
MPV-1c          AAGTGCTCAATACCAAAATGAAAATGAATACATGAGCATTCACAAATGGCTGCCAACTGC 
                ************************************************************ 
 
 
 
 
132 
 
MPV-1arc        TACTGGCAACATGCAAAATATACCTTTGCTTTCTAGACCTGTTGCTAGAAATACTTACTA 
MPV-1a          TACTGGCAACATGCAAAGTATACCTTTGCTTTCTAGACCTGTTGCTAGAAATACTTACTA 
MPV-1b          TACTGGCAACATGCAAAGTATACCTTTGCTTTCTAGACCTGTTGCTAGAAATACTTACTA 
MPV-1c          TACTGGCAACATGCAAAGTATACCTTTGCTTTCTAGACCTGTTGCTAGAAATACTTACTA 
                ***************** ****************************************** 
 
MPV-1arc        ACCAACCATGTTCTTTCTTTCTGTACTTCATATATTATTAAAACTAATAAAAATACAACA 
MPV-1a          ACCAACCATGTTCTTTCTTTCTGTACTTCATATATTATTAAAACTAATAAAAATACAACA 
MPV-1b          ACCAACCATGTTCTTTCTTTCTGTACTTCATATATTATTAAAACTAATAAAAATACAACA 
MPV-1c          ACCAACCATGTTCTTTCTTTCTGTACTTCATATATTATTAAGACTAATAAAAATACAACA 
                ***************************************** ****************** 
 
MPV-1arc        TAGAAATATAATATTACATATAGATTTAAGAAATAGAATAATATGGTACTCACTAACTGT 
MPV-1a          TAGAAATATAATATTACATATAGATTTAAGAAATAGAATAATATGGTACTCACTAACTGT 
MPV-1b          TAGAAATATAATATTACATATAGATTTAAGAAATAGAATAATATGGTACTCACTAACTGT 
MPV-1c          TAGAAATATAATATTACATATAGATTTAAGAAATAGAATAATATGGTACTCACTAACTGT 
                ************************************************************ 
 
MPV-1arc        TAGAAATAATAGAACTTTTGGAATAACAAGATAGTTAGTTAATTAATGTTAGATAAAATA 
MPV-1a          TAGAAATAATAGAACTTTTGGAATAACAAGATAGTTAGTTAATTAATGTTAGATAAAATA 
MPV-1b          TAGAAATAATAGAACTTTTGGAATAACAAGATAGTTAGTTAATTAATGTTAGATAAAATA 
MPV-1c          TAGAAATAATAGAACTTTTGGAATAACAAGATAGTTAGTTAATTAATGTTAGATAGAATA 
                ******************************************************* **** 
 
MPV-1arc        AGAAGATGATGTACAATGGGTAAATAGTTAGTTGGTTAATGTTAAGTAGAATAAGAAGAT 
MPV-1a          AGAAGATGATGTACAATGGGTAAATAGTTAGTTGGTTAATGTTAAGTAGAATAAGAAGAT 
MPV-1b          AGAAGATGATGTACAATGGGTAAATAGTTAGTTGGTTAATGTTAAGTAGAATAAGAAGAT 
MPV-1c          AGAAGATGATGTACAATGGGTAAATAGTTAGTTGGTTAATGTTAAGTAGAATAAGAAGAT 
                ************************************************************ 
 
MPV-1arc        TATGTATAATGGGTAAAAGGGTGGAAGGGTGGTTGGTTGGTATTCCCTTAGACTTGATGT 
MPV-1a          TATGTATAATGGGTAAAAGGGTGGAAGGGTGGTTGGTTGGTATTCCCTTAGACTTGATGT 
MPV-1b          TATGTATAATGGGTAAAAGGGTGGAAGGGTGGTTGGTTGGTATTCCCTTAGACTTGATGT 
MPV-1c          TATGTATAATGGGTAAAAGGGTGGAAGGGTGGTTGGTTGGTATTCCCTTAGACTTGATGT 
                ************************************************************ 
 
MPV-1arc        TAAG-------------------------------------------------------- 
MPV-1a          TAAGGACCAAAAAAACAATAAAATCTTTTTAAAACCTAACCAAGACTACTGTCTATTCAG 
MPV-1b          TAAGGACCAAAAAAACAATAAAATCTTTTTAAAACTAAACCAAGACT------------- 
MPV-1c          TAAGGNCCAAAAAAACAATAAAATCTTTTTGAAACCTAACCAAGACT------------- 
                ****                                                         
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MPV-1arc        ------------------------------------------------------------ 
MPV-1a          TTGAACCAACTGAACCATAAATATCAATATGTTTTTAGGGTGGGAGGGTGGGAGATACAT 
MPV-1b          ------------------------------------------------------------ 
MPV-1c          ------------------------------------------------------------ 
                                                                             
 
MPV-1arc        ------------------------------------------------------------ 
MPV-1a          GTGTTCGCTATGAGCGAACTGGTACTGGTTGGTTGCTCTGCTCAACCAACCAGACCGGCA 
MPV-1b          ------------------------------------------------------------ 
MPV-1c          ------------------------------------------------------------ 
                                                                             
 
MPV-1arc        ------------------------------------------------------------ 
MPV-1a          AAGCCGGTCTGGTTGGTTGAGCGCAACCAACCAGTACCAGTTCGCTCATAGCGAACACAT 
MPV-1b          ------------------------------------------------------------ 
MPV-1c          ------------------------------------------------------------ 
                                                                             
 
MPV-1arc        -------------------------------------------- 
MPV-1a          GTATCTCCCACCCTCCCACCCTAAAAACATATTGATATTTATGG 
MPV-1b          -------------------------------------------- 
MPV-1c          -------------------------------------------- 
 
Figure 6.3. Multiple nt sequence alignment of the genomes of the newly identified MPV- 
1arc strain with the 3 previously recognised strains MPV-1a, MPV-1b and MPV-1c. The 
alignment generated with the ClustalW program revealed that MPV- 1arc was more closely 
related to the cell culture derived MPV-1a and MPV-1b (nt identity 99%), than to the wild 
type MPV-1c (98% nt identity). Asterisks indicate nt identity.  
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Figure 6.4.The genetic relationship of the newly identified Australian strain MPV-1arc with 
the previously characterised strains MPV-1a, MPV-1b and MPV-1c. The alignment was 
generated with the ClustalW program and demonstrated that the Australian strain was more 
closely related to the cell culture-derived MPV strains MPV-1a and MPV-1b (nt identity 
99%), than to the wild MPV-1c strain (98% nt identity).  
MPV-1arc 
MPV-1a 
MPV-1b 
MPV-1c 
 
 
Amino acid sequence analysis 
The protein-coding regions NS1 and VP1 were deduced from the determined nt 
sequences and compared among the newly identified Australian MPV strain and the 
3 known MPV-1 variants. The NS1 proteins were very similar between strains, but 
the new strain had greater similarity to MPV-1a and MPV-1b (99% homologous, 1 
amino acid difference), than MPV-1c (98% homologous, 13 amino acids difference). 
The NS1 protein alignments and the dendrogram based on NS1 protein sequence are 
shown in Figure 6.5 and 6.6, respectively.   
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MPV-1arc        MAGNAYSDEVLGTTNWLKEKSNQEVFSFVFKTEDVQLNGKDIGWNNYKKELQEDELKSLQ 
MPV-1a          MAGNAYSDEVLGTTNWLKEKSNQEVFSFVFKTEDVQLNGKDIGWNNYKKELQEDELKSLQ 
MPV-1b          MAGNAYSDEVLGTTNWLKEKSNQEVFSFVFKTEDVQLNGKDIGWNNYKKELQEDELKSLQ 
MPV-1c          MAGNAYSDEVLGTTNWLKEKSNQEVFSFVFKTEDVQLNGKDIGWNNYRKELQEDELKSLQ 
                ***********************************************:************ 
 
MPV-1arc        RGAETTWDQSEDMEWESTVDEMTKKQVFIYDSLVKKCLFEVLSTKNIAPGDVTWFVQHEW 
MPV-1a          RGAETTWDQSEDMEWESTVDEMTKKQVFIYDSLVKKCLFEVLSTKNIAPADVTWFVQHEW 
MPV-1b          RGAETTWDQSEDMEWESTVDEMTKKQVFIYDSLVKKCLFEVLSTKNIAPADVTWFVQHEW 
MPV-1c          RGAETTWDQSEDMEWESTVDEVTKKQVFIYDSLVKKCLFEVLNTKNISPGDVNWFVQHEW 
                *********************:********************.****:*.**.******* 
 
MPV-1arc        GKDQGWHCHVLIGGKDFSQAQGKWWRRQLNVYWSRWLVTACNVQLTPAERIKLREIAEDS 
MPV-1a          GKDQGWHCHVLIGGKDFSQAQGKWWRRQLNVYWSRWLVTACNVQLTPAERIKLREIAEDS 
MPV-1b          GKDQGWHCHVLIGGKDFSQAQGKWWRRQLNVYWSRWLVTACNVQLTPAERIKLREIAEDS 
MPV1c           GRDQGWHCHVLIGGKDFSQAQGKWWRRQLSVYWSRWLVTACNVQLTPAERIKLREIAEDS 
                *:***************************.****************************** 
 
MPV-1arc        EWVTLLTYKHKQTKKDYTKCVLFGNMIAYYFLTKKKISTSPPRDGGYFLSSDSGWKTNFL 
MPV-1a          EWVTLLTYKHKQTKKDYTKCVLFGNMIAYYFLTKKKISTSPPRDGGYFLSSDSGWKTNFL 
MPV-1b          EWVTLLTYKHKQTKKDYTKCVLFGNMIAYYFLTKKKISTSPPRDGGYFLSSDSGWKTNFL 
MPV-1c          EWVTLLTYKHKQTKKDYTKCVLXGNIIAYYFLTKKKISTSPPRDGGYFLSSDSGWKTNFL 
                ********************** **:********************************** 
 
MPV-1arc        KEGERHLVSKLYTDDMRPETVETTVTTAQETKRGRIQTKKEVSIKTTLKELVHKRVTSPE 
MPV-1a          KEGERHLVSKLYTDDMRPETVETTVTTAQETKRGRIQTKKEVSIKTTLKELVHKRVTSPE 
MPV-1b          KEGERHLVSKLYTDDMRPETVETTVTTAQETKRGRIQTKKEVSIKTTLKELVHKRVTSPE 
MPV-1c          KEGERHLVSKLYTDDMRPETVETTVTTAQETKRGRIQTKKEVSIKTTLKELVHKRVTSPE 
                ************************************************************ 
 
MPV-1arc        DWMMMQPDSYIEMMAQPGGENLLKNTLEICTLTLARTKTAFDLILEKAETSKLTNFSLPD 
MPV-1a          DWMMMQPDSYIEMMAQPGGENLLKNTLEICTLTLARTKTAFDLILEKAETSKLTNFSLPD 
MPV-1b          DWMMMQPDSYIEMMAQPGGENLLKNTLEICTLTLARTKTAFDLILEKAETSKLTNFSLPD 
MPV-1c          DWMMMQPDSYIEMMAQPGGENLLKNTLEICTLTLARTKTAFDLILEKAETSKLTNFSLPD 
                ************************************************************ 
 
MPV-1arc        TRTCKIFAFHGWNYIKVCHAICCVLNRQGGKRNTVLFHGPASTGKSIIAQAIAQAVGNVG 
MPV-1a          TRTCKIFAFHGWNYIKVCHAICCVLNRQGGKRNTVLFHGPASTGKSIIAQAIAQAVGNVG 
MPV-1b          TRTCKIFAFHGWNYIKVCHAICCVLNRQGGKRNTVLFHGPASTGKSIIAQAIAQAVGNVG 
MPV-1c          TRTCKIFAFHGWNYIKVCHAICCVLNRQGGKRNTVLFHGPASTGKSIIAQAIAQAVGNVG 
                ************************************************************ 
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MPV-1arc        CYNAANVNFPFNDCTNKNLIWVEEAGNFGQQVNQFKAICSGQTIRIDQKGKGSKQIEPTP 
MPV-1a          CYNAANVNFPFNDCTNKNLIWVEEAGNFGQQVNQFKAICSGQTIRIDQKGKGSKQIEPTP 
MPV-1b          CYNAANVNFPFNDCTNKNLIWVEEAGNFGQQVNQFKAICSGQTIRIDQKGKGSKQIEPTP 
MPV-1c          CYNAANVNFPFNDCTNKNLIWVEEAGNFGQQVNQFKAICSGQTIRIDQKGKGSKQIEPTP 
                ************************************************************ 
 
MPV-1arc        VIMTTNENITVVKIGCEERPEHTQPIRDRMLNIHLTHTLPGDFGLVDKNEWPMICAWLVK 
MPV-1a          VIMTTNENITVVKIGCEERPEHTQPIRDRMLNIHLTHTLPGDFGLVDKNEWPMICAWLVK 
MPV-1b          VIMTTNENITVVKIGCEERPEHTQPIRDRMLNIHLTHTLPGDFGLVDKSEWPMICAWLVK 
MPV-1c          VIMTTNENITVVKIGCEERPEHTQPIRDRMLNIHLTHTLPGDFGLVDKHXWPMICAWLVK 
                ************************************************  ********** 
 
MPV-1arc        NGYQSTMASYCAKWGKVPDWTENWAEPKVPTPINSLGSARSPFTTPKSTPLSQNYALTPL 
MPV-1a          NGYQSTMASYCAKWGKVPDWTENWAEPKVPTPINSLGSARSPFTTPKSTPLSQNYALTPL 
MPV-1b          NGYQSTMASYCAKWGKVPDWTENWAEPKVPTPINSLGSARSPFTTPKSTPLSQNYALTPL 
MPV-1c          NGYQSTMASYCAKWGKVPDWTENWAEPKVPTPINSLGSARSPFTTPKSTPLSQNYALTPL 
                ************************************************************ 
 
MPV-1arc       ASDLEDLALEPWSTPNTPVAGTAETQNTGEAGSKACQDGQLSPTWSEIEEDLRACFGAEP 
MPV-1a         ASDLEDLALEPWSTPNTPVAGTAETQNTGEAGSKACQDGQLSPTWSEIEEDLRACFGAEP 
MPV-1b         ASDLEDLALEPWSTPNTPVAGTAETQNTGEAGSKACQDGQLSPTWSEIEEDLRACFGAEP 
MPV1-c         ASDLEDLALEPWSTPNTPVAGTAETQNTGEAGSKACQDGQLSPTWSEIEEDLKACFGAEP 
               ****************************************************:******* 
 
MPV-1arc       LKKDFSEPLNLD 
MPV-1a         LKKDFSEPLNLD 
MPV-1b         LKRDFSEPLNLD 
MPV-1c         LKRDFSEPLNLD 
                        **:********* 
Figure 6.5. Amino acid sequence alignment of the NS1 proteins for the Australian MPV-
1arc strain and the previously characterised strains MPV-1a, MPV-1b, and MPV-1c 
generated with the ClustalW program which indicated that the Australian strain was more 
closely related to the cell culture derived MPV-1 variants MPV-1a and MPV-1b (99% 
amino-acid identity) than to the wild type MPV-1c (98% amino-acid identity). Asterisks 
indicate amino acid identity.  
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Figure 6.6. The genetic relationship of the newly identified Australian MPV-1arc strain and 
the 3 already characterised MPV-1 types based on the amino-acid sequence of the non-
structural NS1 protein; it revealed that the Australian strain was more closely related to the 
tissue culture derived MPV-1 strains MPV-1a and MPV-1b (99% amino-acid identity) than 
to the wild type MPV-1c (98% amino-acid identity).  
MPV-1arc 
MPV-1a 
MPV-1b 
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The VP1 proteins of the 3 MPV-1 variants and the newly identified Australian MPV-
1arc strain have shown a high level of homology, though not as much as with NS1. 
Unlike NS1 and the genomic nt sequence, the Australian MPV-1arc strain was more 
closely related to the wild MPV-1c variant (98.63 % identical, 10 amino acids 
difference) than to the cell culture derived strain MPV-1a (98.49 % identical with 12 
amino acid differences). Figure 6.7 shows the alignment of the VP1 proteins and 
Figure 6.8 show s a dendrogram comparing the VP2 protein of the MPV-1 variants.  
 
MPV-1arc_VP1    MAPPAKRAKRGWVPPGYKYLGPGNSLDQGEPTNPSDAAAKEHDEAYDKYIKSGKNPYLYF 
MPV-1a_VP1      MAPPAKRAKRGWVPPGYKYLGPGNSLDQGEPTNPSDAAAKEHDEAYDKYIKSGKNPYLYF 
MPV-1b_VP1      MAPPAKRAKRGWVPPGYKYLGPGNSLDQGEPTNPSDAAAKEHDEAYDKYIKSGKNPYLYF 
MPV-1c_VP1      MAPPAKRVKRGWVPPGYKYLGPGNSLDQGEPTNPSDAAAKEHDEAYDKYIKSGKNPYLYF 
                *******.**************************************************** 
 
MPV-1arc_VP1    SAADQRFIDQTKDAKDWGGKVGHYFFRTKRAFAPKLASSSEPGTSGVSIAGKRTKPPAHI 
MPV-1a_VP1      SAADQRFIDQTKDAKDWGGKVGHYFFRTKRAFAPRLASSSEPGTSGVSIAGKRTKPPAHI 
MPV-1b_VP1      SAADQRFIDQTKDAKDWGGKVGHYFFRTKRAFGPRLASSSEPGTSGVSIAGKRTKPPAHI 
MPV-1c_VP1      SAADQRFIDQTKDAKDWGGKVGHYFFRTKRAFAPRLASSSEPGTSGVSIAGKRTKPPAHI 
                ********************************.*:************************* 
 
MPV-1arc_VP1    FINQARAKKKRASLAAQQRTQTMSDGAEQHDSGSAVQSAARVERAADGPGGSGGGGSGGG 
MPV-1a_VP1      FINQARAKKKRASLAAQQRTQTMSDGAEQPDSGSAVQSAARVERAADGPGGSGGGGSGGG 
MPV-1b_VP1      FINQARAKKKRASLAAQQRTQTMSDGAEQPDSGSAVQSAARVERAADGPGGSGGGGSGGG 
MPV-1c_VP1      FINQARAKKKRASLAAQQRTQTMSDGTEQPDSGSAVQSAARVERATDGPGGSGGGGSGGG 
                **************************:** ***************:************** 
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MPV-1arc_VP1    GVGVSTGSYDNQTHYRFLSDGWVEITAYSTRMVHLNMPKSENYCRVRVHNTNDTHTAGNM 
MPV-1a_VP1      GVGVSTGSYDNQTHYRFLSDGWVEITAYSTRMVHLNMPKSENYCRVRVHNTNDTRTAGNM 
MPV-1b_VP1      GVGVSTGSYDNQTHYRFLSDGWVEITAYSTRMVHLNMPKSENYCRVRVHNTNDTRTAGNM 
MPV-1c_VP1      GVGVSTGSYDNQTHYRFLSDGWVEITAYSTRMVHLNMPKSENYCRVRVHNTNDTHTAGNM 
                ******************************************************:***** 
 
MPV-1arc_VP1    AKDDAHEQIWTPWSLIDSNAWGVWFQPSDWQFICNNMSHVNLHSLDQELFNVVIKTVTEQ 
MPV-1a_VP1      AKDDAHEQIWTPWSLIDSNAWGVWFQPSDWQFICNNMSHVNLHSLDQELFNVVIKTVTEQ 
MPV-1b_VP1      AKDDAHEQIWTPWSLIDSNAWGVWFQPSDWQFICNNMSHVNLHSLDQELFNVVIKTVTEQ 
MPV-1c_VP1      AKDDAHEQIWTPWSLIDSNAWGVWFQPSDWQFICNNMSHVNLHSLDQELFNVVIKTVTEQ 
                ************************************************************ 
 
MPV-1arc_VP1    NTGAEAVKIYNNDLTASMMVALDSNNILPYTPATDNQETLGFYPWKPTMPSPYRYYFNCD 
MPV1-a_VP1      NTGAEAVKIYNNDLTASMMVALDSNNILPYTPATDNQETLGFYPWKPTMPSPYRYYFNCD 
MPV-1b_VP1      NTGAEAVKIYNNDLTASMMVALDSNNILPYTPATDNQETLGFYPWKPTMPSPYRYYFNCD 
MPV1-c_VP1      NTGAEAVKVYNNDLTASMMVALDSNNILPYTPATDNQETLGFYPWKPTMPSPYRYYFNCD 
                ********:*************************************************** 
 
MPV-1arc_VP1    RSLSVTYADQTGNIVDTMANASGLSSQFFTIENTQRIQLLRTGDEFATGTYYFETEPIKL 
MPV-1a_VP1      RSLSVTYTDQTGSIVDTMANASGLSSQFFTIENTQRIQLLRTGDEFATGTYYFETEPIKL 
MPV-1b_VP1      RSLSVTYTDQTGSIVDTMANASGVSSQFFTIENTQRIQLLRTGDEFATGTYYFETEPIKL 
MPV-1c_VP1      RSLSVTYADQTGNIVDTMANASGLSSQFFTIENTQRIQLLRTGDEFATGTYYFETEPIKL 
                *******:****.**********:************************************ 
 
MPV-1arc_VP1    SHTWQSNRQLGQPPQITDLPTADNENATLVARGDRSGITQIFGSNDVTEATRVRPAQVGF 
MPV-1a_VP1      SHTWQSNRQLGQPPQITDLPTADNENATLVTRGDRSGITQISGSNDVTEATRVRPAQVGF 
MPV-1b_VP1      SHTWQSNRQLGQPPQITDLPTADNENATLVTRGDRSGITQISGSNDVTEATRVRPAQVGF 
MPV-1c_VP1      SHTWQSNRQLGQPPQITDLPTADNENATLVARGDRSGITQIFGSNDVTEATRVRPAQVGF 
                ******************************:********** ****************** 
 
MPV-1arc_VP1    CQPHDNFETSRAGPFKVPVVPANVTQGNEHDANGSLRYTYDKQHGQDWGSNNSKERFTWD 
MPV-1a_VP1      CQPHDNFETSRAGPFKVPVVPANVTQGNEHDANGSLRYTYDKQHGQDWGSNNSKERFTWD 
MPV-1b_VP1      CQPHDNFETSRAGPFKVPVVPANVTQGNEHDANGSLRYTYDKQHGQDWGSNNSKERFTWD 
MPV-1c_VP1      CQPHDNFETSRAGPFKVPVVPANVTQGNEHDANGSLRYTYDKQHGQDWGSNNSKERFTWD 
                ************************************************************ 
 
MPV-1arc_VP1    AISYDSGRWADRCFINATPFTSTPALNNILANSDHIGNKTGIHYQNVFNSYGPLTAFPHP 
MPV-1a_VP1      AISYDSGRWADRCFINATPFTSPPALNNILTNSDPIGNKTAIHYQNVFNSYGPLTAFPHP 
MPV-1b_VP1      AISYDSGRWADRCFINATPFTSPPALNNILTNSDPIGNKTAIHYQNVFNSYGPLTAFPHP 
MPV-1c_VP1      AISYDSGRWADRCFINATPFTSPPALNNILTNSDPIGNKTGIHYQNVFNSYGPLTAFPHP 
                **********************.*******:*** *****.******************* 
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MPV-1arc_VP1    APIYPQGQIWDKELDLEHKPRLHAQAPFVCKNNAPGQLLVRLAPNLTDQYDPNSSTLSRI 
MPV-1a_VP1      APIYPQGQIWDKELDLEHKPRLHAQAPFVCKNNAPGQLLVRLAPNLTDQYDPNSSTLSRI 
MPV-1b_VP1      APIYPQGQIWDKELDLEHKPRLHAQAPFVCKNNAPGQLLVRLAPNLTDQYDPNSSTLSRI 
MPV-1c_VP1      APIYPQGQIWDKELDLEHKPRLHAQAPFVCKNNAPGQLLVRLAPNLTDQYDPNSSTLSRI 
                ************************************************************ 
 
MPV-1arc_VP1    VTYGTFFWKGKLTLKAKLRPNATWNPVYQVSAQYQNENEYMSIHKWLPTATGNMQNIPLL 
MPV-1a_VP1      VTYGTFFWKGKLTLKAKLRPNATWNPVYQVSAQYQNENEYMSIHKWLPTATGNMQSIPLL 
MPV-1b_VP1      VTYGTFFWKGKLTLKAKLRPNATWNPVYQVSAQYQNENEYMSIHKWLPTATGNMQSIPLL 
MPV-1c_VP1      VTYGTFFWKGKLTLKAKLRPNATWNPVYQVSAQYQNENEYMSIHKWLPTATGNMQSIPLL 
                *******************************************************.**** 
 
MPV-1arc_VP1    SRPVARNTY 
MPV-1a_VP1      SRPVARNTY 
MPV-1b_VP1      SRPVARNTY 
MPV-1c_VP1      SRPVARNTY 
                ********* 
Figure 6.7. Amino acid sequence alignments of the VP1 proteins for the newly identified 
Australian MPV-1arc and MPV-1a, MPV-1b and MPV1-c, generated with the ClustalW 
program indicated that Australian MPV-1arc strain was more closely related to the wild 
MPV-1c variant (98.63 % identical, 10 amino acids difference) than to the cell culture 
derived strain MPV-1a (98.49 % identical with 12 amino acid difference). Asterisks indicate 
identity. 
 
 
 
 
Figure 6.8. The genetic relationship between the newly identified Australian MPV-1arc and 
MPV-1a MPV-1b and MPV1-c based on the amino acid sequence of the VP1 proteins; 
which indicated that the Australian MPV-1arc strain had greater similarity to the wild type 
MPV-1c variant (98.63 % identity, 10 amino acids difference) than to the cell culture 
derived strains MPV-1a and MPV-1b (98.49 % identical with 11 amino acid difference).  
MPV-1a 
MPV-1b 
MPV-1c 
MPV-1arc 
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Discussion  
The presence of a new strain of virus in laboratory mice colonies in Australia, 
antibody to which was not detected by the use of a commercially available 
recombinant parvovirus NS1 protein antigen, was a cause of concern. The sequence 
analysis of the Australian strain that has evaded the previously used serological test 
has an NS1 region that is very similar to the tissue derived MPV-1a and -1b variants, 
while the structural VP1/2 region of the Australian strain appeared to have a closer 
relationship to the wild MPV-1c strain.  The Australian MPV-1arc strain might have 
originated by a recombination event between the laboratory strains and the wild 
strain; such an event has been observed with canine parvovirus, and thought to be 
important in the evolution of this virus in cell culture (Badgett et al., 2002). 
Alternatively, the Australian strain may have arisen by a series of individual nt 
mutations, consistent with observations that canine parvovirus isolates mutate by a 
series of individual nt changes rather than by recombinant events (Parrish et al., 
1991). 
The close nt and amino acid similarity of the Australian strain with the other strains 
characterised previously suggest there should be minimal or no antigenic differences 
between these strains.  However, even single nt and amino acid changes can effect a 
significant antigenic change in some virus systems so it is not possible to state with 
certainty that the Australian strain is antigenically identical with other strains that 
have been identified. 
The terminal palindromic regions were not sequenced, as there were technical 
problems which made it difficult and insufficient time was available to complete this 
aspect of the sequence analysis. PCR primers based on the palindromic regions of 
the previously identified MPV types failed to amplify any product.  While this may 
have been due to diversity of the viruses in these regions, it is more likely that 
primers that will bind to a repeat sequence will have multiple sites to bind as 
opposed to just one, resulting in multiple products varying in length and no single 
identifiable amplicon.  An alternative approach would be as described by Ball-
Goodrich and Johnson (1994), to sequence the hairpins generated during replication.  
These authors examined the replicative forms in MPV-infected cells by Southern 
blotting and were able to recover some intact termini. They still, however, found it 
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difficult to obtain the complete sequence of the right terminus.   
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Chapter 7.  General discussion  
 
 
The effective use of laboratory animals as models for disease investigation by the 
research industry relies on the availability of animals maintained in an environment 
with highly stringent controls that ensure stability of the microbiological and health 
status of the animals.  The presence of infectious pathogens in laboratory mice is of 
major concern and to be accepted for research purposes mice need to be free of 
specified pathogens suspected or known to cause problems (specific-pathogen-free, 
SPF), including the mouse parvovirus (MPV-1).  Rodents, particularly, are 
frequently used for investigation of a range of medical problems that requires an 
accurate representation of their immune system, and MPV-1 is known to affect 
immunological function. 
The Animal Resources Centre (ARC) is the major supplier of laboratory rodents to 
scientific research establishments in Australia.  The centre has a track record of 
maintaining a high quality control program to maintain the health of their animals 
and the SPF status.  The discovery in early 2001 that MPV-1 was present in mouse 
stocks was unexpected and potentially disastrous for the health sciences research 
community and the ARC.  
An eradication program was successfully undertaken and required the development 
of methods to monitor for the presence of virus and ensure continued freedom from 
infection.  As MPV-1 does not produce a cytopathic effect in any known cell culture 
system, reliance was placed on the use of molecular biological procedures for 
detection of infection: a polymerase chain reaction (PCR) assay for the detection of 
the virus in lymphoid tissues (spleen and lymph node) and faeces (Chapter 3); 
recombinant DNA technology for the production of a capsid protein that was used as 
an antigen for the development of sensitive and cost effective ELISA and Western 
immunoblotting (WIB) assay (Chapter 3).  
Of paramount importance for the development of the serological tests was the need 
to produce a recombinant virus protein for use as an antigen, with high specificity 
and sensitivity.  The capsid protein was selected rather than the non-structural (NS) 
proteins, as NS1 antibody was produced only transiently in infected mice (Besselsen 
et al., 2000), as recombinant NS1 protein was demonstrated to lack antigenic 
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specificity (Riley et al., 1996) and as it was reported to not detect MPV-1 antibodies 
in some strains of adult mice (Besselsen et al., 2000).  Several truncated VP1 
proteins were produced and trialled and one, based on the AD region of VP1, was 
selected based on a combination of yield and antigenicity.  This was produced using 
the PinPoint
TM Xa-1 vector and was expressed as an insoluble product in the JM109 
strain of Escherichia coli.  Since the production of this protein and its use for the 
development of sensitive and specific ELISA and WIB assays, another commercial 
ELISA antigen has become available, a recombinant VP2 MPV-1 ELISA supplied 
by the Research Animal Diagnostic Laboratory, University of Missouri.  
Comparison of results obtained with the VP1 antigen developed during this current 
study with those obtained with the recombinant VP2 MPV-1 ELISA were very 
similar (Chapter 5). 
A serological survey was conducted to determine the prevalence of MPV-1 infection 
in the entire ARC colony of about 45,000 mice, over a 3 month period during 2003  
(Chapter 4).  It was hypothesised that that this would provide information on the 
sampling size needed to detect infection using the serological tests that had been 
developed.  Differences in the prevalence of infection in different rooms and within 
the production units and variation in prevalence in the same mouse strain population 
within different units and rooms were noted. The variation in numbers of 
serologically positive animals between different rooms can be explained at least in 
part by variation in the response of different mouse strains to virus infection.  Strain 
variation had previously been reported (Besselsen et al., 2000; Livingston et al., 
2002; Khan et al., 2005) and so this was further investigated with the ARC strain.  
When 4 different mouse strains were infected to determine if there were differences 
in the response to the virus (Chapter 5), the results confirmed there was strain 
variation: not all strains and particularly those of the BALB/c genotype did not 
develop antibody even BALB/c mice were the most susceptible to infection in terms 
of the persistence of virus infection; there was also considerable strain variation in 
the duration and persistence of virus in infected mice.  There was also age variation 
in susceptibility to infection, particularly evident in C57BL/6JArc.   
It is clear that random sampling without consideration of mouse strain is an 
inadequate approach to the detection of antibody to MPV-1 and that the strain 
differences must be considered in the design of future immunosurveillance 
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programs.  The highest rate of detectable seroconversion to the MPV-1 strain in the 
ARC, and also the earliest and the longest immune response occurred in ARC(s) 
mice.  There were also no age differences in the susceptibility of ARC(s) mice.  The 
high rate of seroconversion and lack of detectable differences in age susceptibility of 
ARC(s) mice would make them reliable sentinels for MPV-1arc infection in mouse 
colonies, if serological assays were used for surveillance as is normal.  Similarly, the 
lack of an antibody response in BALB/c would make them an unsuitable strain for 
detection of virus infection if serological assays were used for surveillance. 
The relationship of the ARC strain of MPV-1 that was detected to previously 
identified strains of MPV-1 was addressed by the sequence analysis of the genome 
that was reported in Chapter 6.  As the virus had not been detected by serological 
tests previously used for this virus, it was originally thought it may be quite different 
genetically and antigenically.  However, the sequence analysis indicated it was very 
similar to other strains reported previously.  Some variation was reported but the 
variation was minor and was unlikely to affect antigenicity.  The genome of the ARC 
strain encoding the NS proteins was very similar to the MPV-1a and -1b variants 
detected in cell cultures, while the structural VP1 and VP2 regions had very high 
identity to the MPV-1c strain detected in mice. Whether these differences reflect a 
recombination event or are associated with point mutations is unknown.  
The methods developed during the course of this study, and the pathogenesis studies 
undertaken, were invaluable during a successful program to eradicate MPV-1 from 
the ARC, completed in 2005.  This eradication program involved Caesarean section 
rederivation of all mouse strains, establishing virus-free nuclear breeding colonies, 
and then eventually using these re-established colonies to replace the previous 
breeding stock.  Constant monitoring by a combination of PCR for the detection of 
the virus and serological tests (ELISA and WIB using the recombinant capsid protein 
described in Chapter 3) for antibody was invaluable to ensure freedom from 
infection.  The use of ARC(s) as sentinel animals was also invaluable in those strains 
suspected or known to not produce antibody or to resist MPV-1arc infection.   
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